Genetic 0 
mapping 0 
of 0 
the 0 
copper 1
toxicosis 1
locus 0 
in 0 
Bedlington 0 
terriers 0 
to 0 
dog 0 
chromosome 0 
_NUM2 0 
, 0 
in 0 
a 0 
region 0 
syntenic 0 
to 0 
human 0 
chromosome 0 
region 0 
2p13-p16 0 
. 0 

Abnormal 0 
hepatic 1
copper 1
accumulation 1
is 0 
recognized 0 
as 0 
an 0 
inherited 1
disorder 1
in 0 
man 0 
, 0 
mouse 0 
, 0 
rat 0 
and 0 
dog 0 
. 0 

The 0 
major 0 
cause 0 
of 0 
hepatic 1
copper 1
accumulation 1
in 0 
man 0 
is 0 
a 0 
dysfunctional 0 
ATP7B 0 
gene 0 
, 0 
causing 0 
Wilson 1
disease 1
-LRB- 0 
WD 1
-RRB- 0 
. 0 

Mutations 0 
in 0 
the 0 
ATP7B 0 
genes 0 
have 0 
also 0 
been 0 
demonstrated 0 
in 0 
mouse 0 
and 0 
rat 0 
. 0 

The 0 
ATP7B 0 
gene 0 
has 0 
been 0 
excluded 0 
in 0 
the 0 
much 0 
rarer 0 
human 0 
copper 1
overload 1
disease 0 
non-Indian 1
childhood 1
cirrhosis 1
, 0 
indicating 0 
genetic 0 
heterogeneity 0 
. 0 

By 0 
investigating 0 
the 0 
common 0 
autosomal 0 
recessive 0 
copper 1
toxicosis 1
-LRB- 0 
_DS 1
-RRB- 0 
in 0 
Bedlington 0 
terriers 0 
, 0 
we 0 
have 0 
identified 0 
a 0 
new 0 
locus 0 
involved 0 
in 0 
progressive 0 
liver 1
disease 1
. 0 

We 0 
examined 0 
whether 0 
the 0 
WD 1
gene 0 
ATP7B 0 
was 0 
also 0 
causative 0 
for 0 
_DS 1
by 0 
investigating 0 
the 0 
chromosomal 0 
co-localization 0 
of 0 
ATP7B 0 
and 0 
_AN 0 
, 0 
using 0 
fluorescence 0 
in 0 
situ 0 
hybridization 0 
-LRB- 0 
FISH 0 
-RRB- 0 
. 0 

_AN 0 
is 0 
an 0 
anonymous 0 
microsatellite 0 
marker 0 
closely 0 
linked 0 
to 0 
_DS 1
. 0 
. 0 

However 0 
, 0 
BAC 0 
clones 0 
containing 0 
ATP7B 0 
and 0 
_AN 0 
mapped 0 
to 0 
the 0 
canine 0 
chromosome 0 
regions 0 
CFA22q11 0 
and 0 
CFA10q26 0 
, 0 
respectively 0 
, 0 
demonstrating 0 
that 0 
WD 1
can 0 
not 0 
be 0 
homologous 0 
to 0 
_DS 1
. 0 
. 0 

The 0 
copper 0 
transport 0 
genes 0 
CTR1 0 
and 0 
CTR2 0 
were 0 
also 0 
excluded 0 
as 0 
candidate 0 
genes 0 
for 0 
_DS 1
since 0 
they 0 
both 0 
mapped 0 
to 0 
canine 0 
chromosome 0 
region 0 
CFA11q22 0 
. 0 

2-22 0 
. 0 

_NUM1 0 
. 0 

A 0 
transcribed 0 
sequence 0 
identified 0 
from 0 
the 0 
C04107-containing 0 
BAC 0 
was 0 
found 0 
to 0 
be 0 
homologous 0 
to 0 
a 0 
gene 0 
expressed 0 
from 0 
human 0 
chromosome 0 
2p13-p16 0 
, 0 
a 0 
region 0 
devoid 0 
of 0 
any 0 
positional 0 
candidate 0 
genes 0 
. 0 

Molecular 0 
analysis 0 
of 0 
the 0 
APC 1
gene 0 
in 0 
_NUM3 0 
families 0 
: 0 
extended 0 
genotype-phenotype 0 
correlations 0 
in 0 
FAP 1
and 0 
evidence 0 
for 0 
the 0 
role 0 
of 0 
APC 1
amino 0 
acid 0 
changes 0 
in 0 
colorectal 1
cancer 1
predisposition 0 
. 0 

BACKGROUND 0 
/ 0 
AIMS 0 
The 0 
development 0 
of 0 
colorectal 1
cancer 1
and 0 
a 0 
variable 0 
range 0 
of 0 
extracolonic 0 
manifestations 0 
in 0 
familial 1
adenomatous 1
polyposis 1
-LRB- 0 
FAP 1
-RRB- 0 
is 0 
the 0 
result 0 
of 0 
the 0 
dominant 0 
inheritance 0 
of 0 
adenomatous 1
polyposis 1
coli 1
-LRB- 0 
APC 1
-RRB- 0 
gene 0 
mutations 0 
. 0 

In 0 
this 0 
study 0 
, 0 
direct 0 
mutation 0 
analysis 0 
of 0 
the 0 
APC 1
gene 0 
was 0 
performed 0 
to 0 
determine 0 
genotype-phenotype 0 
correlations 0 
for 0 
nine 0 
extracolonic 0 
manifestations 0 
and 0 
to 0 
investigate 0 
the 0 
incidence 0 
of 0 
APC 1
mutations 0 
in 0 
non-FAP 0 
colorectal 1
cancer 1
. 0 

METHODS 0 
The 0 
APC 1
gene 0 
was 0 
analysed 0 
in 0 
_NUM3 0 
unrelated 0 
FAP 1
and 0 
_NUM2 0 
non-FAP 0 
colorectal 1
cancer 1
patients 0 
using 0 
denaturing 0 
gradient 0 
gel 0 
electrophoresis 0 
, 0 
the 0 
protein 0 
truncation 0 
test 0 
, 0 
and 0 
direct 0 
sequencing 0 
. 0 

RESULTS 0 
Chain 0 
terminating 0 
signals 0 
were 0 
only 0 
identified 0 
in 0 
patients 0 
belonging 0 
to 0 
the 0 
FAP 1
group 0 
-LRB- 0 
_NUM3 0 
patients 0 
-RRB- 0 
. 0 

Amino 0 
acid 0 
changes 0 
were 0 
identified 0 
in 0 
four 0 
patients 0 
, 0 
three 0 
of 0 
whom 0 
belonged 0 
to 0 
the 0 
non-FAP 0 
group 0 
of 0 
colorectal 1
cancer 1
patients 0 
. 0 

Genotype-phenotype 0 
correlations 0 
identified 0 
significant 0 
differences 0 
in 0 
the 0 
nature 0 
of 0 
certain 0 
extracolonic 0 
manifestations 0 
in 0 
FAP 1
patients 0 
belonging 0 
to 0 
three 0 
mutation 0 
subgroups 0 
. 0 

CONCLUSIONS 0 
Extended 0 
genotype-phenotype 0 
correlations 0 
made 0 
in 0 
this 0 
study 0 
may 0 
have 0 
the 0 
potential 0 
to 0 
determine 0 
the 0 
most 0 
appropriate 0 
surveillance 0 
and 0 
prophylactic 0 
treatment 0 
regimens 0 
for 0 
those 0 
patients 0 
with 0 
mutations 0 
associated 0 
with 0 
life 0 
threatening 0 
conditions 0 
. 0 

This 0 
study 0 
also 0 
provided 0 
evidence 0 
for 0 
the 0 
pathological 0 
nature 0 
of 0 
amino 0 
acid 0 
changes 0 
in 0 
APC 0 
associated 0 
with 0 
both 0 
FAP 1
and 0 
non-FAP 0 
colorectal 1
cancer 1
patients 0 
. 0 
. 0 

A 0 
European 0 
multicenter 0 
study 0 
of 0 
phenylalanine 1
hydroxylase 1
deficiency 1
: 0 
classification 0 
of 0 
_NUM3 0 
mutations 0 
and 0 
a 0 
general 0 
system 0 
for 0 
genotype-based 0 
prediction 0 
of 0 
metabolic 0 
phenotype 0 
. 0 

Phenylketonuria 1
-LRB- 0 
PKU 1
-RRB- 0 
and 0 
mild 1
hyperphenylalaninemia 1
-LRB- 0 
MHP 1
-RRB- 0 
are 0 
allelic 1
disorders 1
caused 0 
by 0 
mutations 0 
in 0 
the 0 
gene 0 
encoding 0 
phenylalanine 0 
hydroxylase 0 
-LRB- 0 
PAH 0
-RRB- 0 
. 0 

Previous 0 
studies 0 
have 0 
suggested 0 
that 0 
the 0 
highly 0 
variable 0 
metabolic 0 
phenotypes 0 
of 0 
PAH 1
deficiency 1
correlate 0 
with 0 
PAH 0
genotypes 0 
. 0 

We 0 
identified 0 
both 0 
causative 0 
mutations 0 
in 0 
_NUM3 0 
patients 0 
from 0 
seven 0 
European 0 
centers 0 
. 0 

On 0 
the 0 
basis 0 
of 0 
the 0 
phenotypic 0 
characteristics 0 
of 0 
_NUM3 0 
functionally 0 
hemizygous 0 
patients 0 
, 0 
_NUM3 0 
of 0 
the 0 
mutations 0 
were 0 
assigned 0 
to 0 
one 0 
of 0 
four 0 
arbitrary 0 
phenotype 0 
categories 0 
. 0 

We 0 
proposed 0 
and 0 
tested 0 
a 0 
simple 0 
model 0 
for 0 
correlation 0 
between 0 
genotype 0 
and 0 
phenotypic 0 
outcome 0 
. 0 

The 0 
observed 0 
phenotype 0 
matched 0 
the 0 
predicted 0 
phenotype 0 
in 0 
_NUM2 0 
% 0 
of 0 
the 0 
cases 0 
, 0 
and 0 
in 0 
only 0 
_NUM1 0 
of 0 
_NUM3 0 
patients 0 
was 0 
the 0 
observed 0 
phenotype 0 
more 0 
than 0 
one 0 
category 0 
away 0 
from 0 
that 0 
expected 0 
. 0 

Among 0 
the 0 
seven 0 
contributing 0 
centers 0 
, 0 
the 0 
proportion 0 
of 0 
patients 0 
for 0 
whom 0 
the 0 
observed 0 
phenotype 0 
did 0 
not 0 
match 0 
the 0 
predicted 0 
phenotype 0 
was 0 
_NUM1 0 
% 0 
-23 0 
% 0 
-LRB- 0 
P 0 
< 0 
. 0 

_NUM4 0 
-RRB- 0 
, 0 
suggesting 0 
that 0 
differences 0 
in 0 
methods 0 
used 0 
for 0 
mutation 0 
detection 0 
or 0 
phenotype 0 
classification 0 
may 0 
account 0 
for 0 
a 0 
considerable 0 
proportion 0 
of 0 
genotype-phenotype 0 
inconsistencies 0 
. 0 

Our 0 
data 0 
indicate 0 
that 0 
the 0 
PAH-mutation 0 
genotype 0 
is 0 
the 0 
main 0 
determinant 0 
of 0 
metabolic 0 
phenotype 0 
in 0 
most 0 
patients 0 
with 0 
PAH 1
deficiency 1
. 0 

In 0 
the 0 
present 0 
study 0 
, 0 
the 0 
classification 0 
of 0 
_NUM3 0 
PAH 0 
mutations 0 
may 0 
allow 0 
the 0 
prediction 0 
of 0 
the 0 
biochemical 0 
phenotype 0 
in 0 
> 0 
_NUM2 0 
, 0 
_NUM3 0 
genotypes 0 
, 0 
which 0 
may 0 
be 0 
useful 0 
for 0 
the 0 
management 0 
of 0 
hyperphenylalaninemia 1
in 0 
newborns 0 
. 0 

Disruption 0 
of 0 
splicing 0 
regulated 0 
by 0 
a 0 
CUG-binding 0 
protein 0 
in 0 
myotonic 1
dystrophy 1
. 0 

Myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
is 0 
caused 0 
by 0 
a 0 
_DS 0 
expansion 0 
in 0 
the 0 
_NUM1 0 
untranslated 0 
region 0 
of 0 
the 0 
DM 1
gene 0 
. 0 

One 0 
model 0 
of 0 
DM 1
pathogenesis 0 
suggests 0 
that 0 
RNAs 0 
from 0 
the 0 
expanded 0 
allele 0 
create 0 
a 0 
gain-of-function 0 
mutation 0 
by 0 
the 0 
inappropriate 0 
binding 0 
of 0 
proteins 0 
to 0 
the 0 
CUG 0 
repeats 0 
. 0 

Data 0 
presented 0 
here 0 
indicate 0 
that 0 
the 0 
conserved 0 
heterogeneous 0 
nuclear 0 
ribonucleoprotein 0 
, 0 
CUG-binding 0 
protein 0 
-LRB- 0 
CUG-BP 0 
-RRB- 0 
, 0 
may 0 
mediate 0 
the 0 
trans-dominant 0 
effect 0 
of 0 
the 0 
RNA 0 
. 0 

CUG-BP 0 
was 0 
found 0 
to 0 
bind 0 
to 0 
the 0 
human 0 
cardiac 0 
troponin 0 
T 0 
-LRB- 0 
cTNT 0 
-RRB- 0 
pre-messenger 0 
RNA 0 
and 0 
regulate 0 
its 0 
alternative 0 
splicing 0 
. 0 

Splicing 0 
of 0 
cTNT 0 
was 0 
disrupted 0 
in 0 
DM 1
striated 0 
muscle 0 
and 0 
in 0 
normal 0 
cells 0 
expressing 0 
transcripts 0 
that 0 
contain 0 
CUG 0 
repeats 0 
. 0 

Altered 0 
expression 0 
of 0 
genes 0 
regulated 0 
posttranscriptionally 0 
by 0 
CUG-BP 0 
therefore 0 
may 0 
contribute 0 
to 0 
DM 1
pathogenesis 0 
. 0 
. 0 

Maternal 1
disomy 1
and 0 
Prader-Willi 1
syndrome 1
consistent 0 
with 0 
gamete 0 
complementation 0 
in 0 
a 0 
case 0 
of 0 
familial 0 
translocation 0 
-LRB- 0 
_NUM1 0 
; 0 
_NUM2 0 
-RRB- 0 
-LRB- 0 
_AN 0 
; 0 
_AN 0 
.2 0 
-RRB- 0 
. 0 

Maternal 1
uniparental 1
disomy 1
-LRB- 1
UPD 1
-RRB- 1
for 1
chromosome 1
_NUM2 1
is 0 
responsible 0 
for 0 
an 0 
estimated 0 
_NUM2 0 
% 0 
of 0 
cases 0 
of 0 
Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
. 0 

We 0 
report 0 
on 0 
an 0 
unusual 0 
case 0 
of 0 
maternal 1
disomy 1
_NUM2 1
in 0 
PWS 1
that 0 
is 0 
most 0 
consistent 0 
with 0 
adjacent-1 0 
segregation 0 
of 0 
a 0 
paternal 0 
t 0 
-LRB- 0 
_NUM1 0 
; 0 
_NUM2 0 
-RRB- 0 
-LRB- 0 
_AN 0 
; 0 
_AN 0 
. 0 

_NUM1 0 
-RRB- 0 
with 0 
simultaneous 0 
maternal 0 
meiotic 0 
nondisjunction 0 
for 0 
chromosome 0 
_NUM2 0 
. 0 

The 0 
patient 0 
-LRB- 0 
J. 0 
B. 0 
-RRB- 0 
, 0 
a 0 
17-year-old 0 
white 0 
male 0 
with 0 
PWS 1
, 0 
was 0 
found 0 
to 0 
have 0 
_NUM2 0 
chromosomes 0 
with 0 
a 0 
supernumerary 0 
, 0 
paternal 0 
der 0 
-LRB- 0 
_NUM2 0 
-RRB- 0 
consisting 0 
of 0 
the 0 
short 0 
arm 0 
and 0 
the 0 
proximal 0 
long 0 
arm 0 
of 0 
chromosome 0 
_NUM2 0 
, 0 
and 0 
distal 0 
chromosome 0 
arm 0 
3p 0 
. 0 

The 0 
t 0 
-LRB- 0 
_NUM1 0 
; 0 
_NUM2 0 
-RRB- 0 
was 0 
present 0 
in 0 
the 0 
balanced 0 
state 0 
in 0 
the 0 
patients 0 
father 0 
and 0 
a 0 
sister 0 
. 0 

Fluorescent 0 
in 0 
situ 0 
hybridization 0 
analysis 0 
demonstrated 0 
that 0 
the 0 
PWS 1
critical 0 
region 0 
resided 0 
on 0 
the 0 
derivative 0 
chromosome 0 
_NUM1 0 
and 0 
that 0 
there 0 
was 0 
no 0 
deletion 0 
of 0 
the 0 
PWS 1
region 0 
on 0 
the 0 
normal 0 
pair 0 
of 0 
15s 0 
present 0 
in 0 
J. 0 
B. 0 
Methylation 0 
analysis 0 
at 0 
exon 0 
alpha 0 
of 0 
the 0 
small 0 
nuclear 0 
ribonucleoprotein-associated 0 
polypeptide 0 
N 0 
-LRB- 0 
SNRPN 0 
-RRB- 0 
gene 0 
showed 0 
a 0 
pattern 0 
characteristic 0 
of 0 
only 0 
the 0 
maternal 0 
chromosome 0 
_NUM2 0 
in 0 
J. 0 
B. 0 
Maternal 1
disomy 1
was 0 
confirmed 0 
by 0 
polymerase 0 
chain 0 
reaction 0 
analysis 0 
of 0 
microsatellite 0 
repeats 0 
at 0 
the 0 
gamma-aminobutyric 0 
acid 0 
receptor 0 
beta3 0 
subunit 0 
-LRB- 0 
GABRB3 0 
-RRB- 0 
locus 0 
. 0 

A 0 
niece 0 
-LRB- 0 
B. 0 
B. 0 
-RRB- 0 
with 0 
_NUM2 0 
chromosomes 0 
and 0 
the 0 
derivative 0 
_NUM1 0 
but 0 
without 0 
the 0 
der 0 
-LRB- 0 
_NUM2 0 
-RRB- 0 
demonstrated 0 
a 0 
phenotype 0 
consistent 0 
with 0 
that 0 
reported 0 
for 0 
haploinsufficiency 0 
of 0 
distal 0 
_NUM1 0 
p. 0 
Uniparental 1
disomy 1
associated 0 
with 0 
unbalanced 0 
segregation 0 
of 0 
non-Robertsonian 0 
translocations 0 
has 0 
been 0 
reported 0 
previously 0 
but 0 
has 0 
not 0 
, 0 
to 0 
our 0 
knowledge 0 
, 0 
been 0 
observed 0 
in 0 
a 0 
case 0 
of 0 
PWS 1
. 0 

Furthermore 0 
, 0 
our 0 
findings 0 
are 0 
best 0 
interpreted 0 
as 0 
true 0 
gamete 0 
complementation 0 
resulting 0 
in 0 
maternal 1
UPD 1
_NUM2 1
and 0 
PWS 1
Segregation 0 
distortion 0 
in 0 
myotonic 1
dystrophy 1
. 0 

Myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
is 0 
an 0 
autosomal 1
dominant 1
disease 1
which 0 
, 0 
in 0 
the 0 
typical 0 
pedigree 0 
, 0 
shows 0 
a 0 
three 0 
generation 0 
anticipation 0 
cascade 0 
. 0 

This 0 
results 0 
in 0 
infertility 1
and 0 
congenital 1
myotonic 1
dystrophy 1
-LRB- 0 
CDM 1
-RRB- 0 
with 0 
the 0 
disappearance 0 
of 0 
DM 1
in 0 
that 0 
pedigree 0 
. 0 

The 0 
concept 0 
of 0 
segregation 0 
distortion 0 
, 0 
where 0 
there 0 
is 0 
preferential 0 
transmission 0 
of 0 
the 0 
larger 0 
allele 0 
at 0 
the 0 
DM 1
locus 0 
, 0 
has 0 
been 0 
put 0 
forward 0 
to 0 
explain 0 
partially 0 
the 0 
maintenance 0 
of 0 
DM 1
in 0 
the 0 
population 0 
. 0 

In 0 
a 0 
survey 0 
of 0 
DM 1
in 0 
Northern 0 
Ireland 0 
, 0 
_NUM2 0 
pedigrees 0 
were 0 
ascertained 0 
. 0 

Sibships 0 
where 0 
the 0 
status 0 
of 0 
all 0 
the 0 
members 0 
had 0 
been 0 
identified 0 
were 0 
examined 0 
to 0 
determine 0 
the 0 
transmission 0 
of 0 
the 0 
DM 1
expansion 0 
from 0 
affected 0 
parents 0 
to 0 
their 0 
offspring 0 
. 0 

Where 0 
the 0 
transmitting 0 
parent 0 
was 0 
male 0 
, 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
of 0 
the 0 
offspring 0 
were 0 
affected 0 
, 0 
and 0 
in 0 
the 0 
case 0 
of 0 
a 0 
female 0 
transmitting 0 
parent 0 
, 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
were 0 
affected 0 
. 0 

Studies 0 
on 0 
meiotic 0 
drive 0 
in 0 
DM 1
have 0 
shown 0 
increased 0 
transmission 0 
of 0 
the 0 
larger 0 
allele 0 
at 0 
the 0 
DM 1
locus 0 
in 0 
non-DM 0 
heterozygotes 0 
for 0 
CTGn 0 
. 0 

This 0 
study 0 
provides 0 
further 0 
evidence 0 
that 0 
the 0 
DM 1
expansion 0 
tends 0 
to 0 
be 0 
transmitted 0 
preferentially 0 
. 0 

Ataxia-telangiectasia 1
: 0 
identification 0 
and 0 
detection 0 
of 0 
founder-effect 0 
mutations 0 
in 0 
the 0 
ATM 0 
gene 0 
in 0 
ethnic 0 
populations 0 
. 0 

To 0 
facilitate 0 
the 0 
evaluation 0 
of 0 
ATM 0 
heterozygotes 0 
for 0 
susceptibility 0 
to 0 
other 0 
diseases 0 
, 0 
such 0 
as 0 
breast 1
cancer 1
, 0 
we 0 
have 0 
attempted 0 
to 0 
define 0 
the 0 
most 0 
common 0 
mutations 0 
and 0 
their 0 
frequencies 0 
in 0 
ataxia-telangiectasia 1
-LRB- 0 
A-T 1
-RRB- 0 
homozygotes 0 
from 0 
_NUM2 0 
ethnic 0 
populations 0 
. 0 

Both 0 
genomic 0 
mutations 0 
and 0 
their 0 
effects 0 
on 0 
cDNA 0 
were 0 
characterized 0 
. 0 

Protein-truncation 0 
testing 0 
of 0 
the 0 
entire 0 
ATM 0 
cDNA 0 
detected 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
truncating 0 
mutations 0 
in 0 
_NUM3 0 
mutant 0 
alleles 0 
screened 0 
. 0 

The 0 
haplotyping 0 
of 0 
patients 0 
with 0 
identical 0 
mutations 0 
indicates 0 
that 0 
almost 0 
all 0 
of 0 
these 0 
represent 0 
common 0 
ancestry 0 
and 0 
that 0 
very 0 
few 0 
spontaneously 0 
recurring 0 
ATM 0 
mutations 0 
exist 0 
. 0 

Assays 0 
requiring 0 
minimal 0 
amounts 0 
of 0 
genomic 0 
DNA 0 
were 0 
designed 0 
to 0 
allow 0 
rapid 0 
screening 0 
for 0 
common 0 
ethnic 0 
mutations 0 
. 0 

These 0 
rapid 0 
assays 0 
detected 0 
mutations 0 
in 0 
_NUM2 0 
% 0 
of 0 
Costa 0 
Rican 0 
patients 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
, 0 
_NUM2 0 
% 0 
of 0 
Norwegian 0 
patients 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
, 0 
_NUM2 0 
% 0 
of 0 
Polish 0 
patients 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
, 0 
and 0 
_NUM2 0 
% 0 
of 0 
Italian 0 
patients 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
, 0 
as 0 
well 0 
as 0 
in 0 
patients 0 
of 0 
Amish 0 
/ 0 
Mennonite 0 
and 0 
Irish 0 
English 0 
backgrounds 0 
. 0 

Additional 0 
mutations 0 
were 0 
observed 0 
in 0 
Japanese 0 
, 0 
Utah 0 
Mormon 0 
, 0 
and 0 
African 0 
American 0 
patients 0 
. 0 

These 0 
assays 0 
should 0 
facilitate 0 
screening 0 
for 0 
A-T 1
heterozygotes 0 
in 0 
the 0 
populations 0 
studied 0 
. 0 
. 0 

Constitutional 0 
RB1-gene 0 
mutations 0 
in 0 
patients 0 
with 0 
isolated 0 
unilateral 1
retinoblastoma 1
. 0 

In 0 
most 0 
patients 0 
with 0 
isolated 0 
unilateral 1
retinoblastoma 1
, 0 
tumor 1
development 0 
is 0 
initiated 0 
by 0 
somatic 0 
inactivation 0 
of 0 
both 0 
alleles 0 
of 0 
the 0 
RB1 0 
gene 0 
. 0 

However 0 
, 0 
some 0 
of 0 
these 0 
patients 0 
can 0 
transmit 0 
retinoblastoma 1
predisposition 0 
to 0 
their 0 
offspring 0 
. 0 

To 0 
determine 0 
the 0 
frequency 0 
and 0 
nature 0 
of 0 
constitutional 0 
RB1-gene 0 
mutations 0 
in 0 
patients 0 
with 0 
isolated 0 
unilateral 1
retinoblastoma 1
, 0 
we 0 
analyzed 0 
DNA 0 
from 0 
peripheral 0 
blood 0 
and 0 
from 0 
tumor 1
tissue 0 
. 0 

The 0 
analysis 0 
of 0 
tumors 1
from 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
of 0 
_NUM2 0 
informative 0 
patients 0 
showed 0 
loss 0 
of 0 
constitutional 0 
heterozygosity 0 
-LRB- 0 
LOH 0 
-RRB- 0 
at 0 
intragenic 0 
loci 0 
. 0 

Three 0 
of 0 
_NUM2 0 
uninformative 0 
patients 0 
had 0 
constitutional 0 
deletions 0 
. 0 

For 0 
_NUM2 0 
randomly 0 
selected 0 
tumors 1
, 0 
SSCP 0 
, 0 
hetero-duplex 0 
analysis 0 
, 0 
sequencing 0 
, 0 
and 0 
Southern 0 
blot 0 
analysis 0 
were 0 
used 0 
to 0 
identify 0 
mutations 0 
. 0 

Mutations 0 
were 0 
detected 0 
in 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
of 0 
_NUM2 0 
tumors 1
with 0 
LOH 0 
. 0 

In 0 
_NUM1 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
of 0 
_NUM2 0 
tumors 1
without 0 
LOH 0 
, 0 
one 0 
mutation 0 
was 0 
detected 0 
, 0 
and 0 
in 0 
_NUM1 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
of 0 
the 0 
tumors 1
without 0 
LOH 0 
, 0 
both 0 
mutations 0 
were 0 
found 0 
. 0 

Thus 0 
, 0 
a 0 
total 0 
of 0 
_NUM2 0 
mutations 0 
were 0 
identified 0 
in 0 
tumors 1
of 0 
_NUM2 0 
patients 0 
. 0 

Thirty-nine 0 
of 0 
the 0 
mutations-including 0 
_NUM2 0 
small 0 
mutations 0 
, 0 
_NUM1 0 
large 0 
structural 0 
alterations 0 
, 0 
and 0 
hypermethylation 0 
in 0 
_NUM1 0 
tumors-were 0 
not 0 
detected 0 
in 0 
the 0 
corresponding 0 
peripheral 0 
blood 0 
DNA 0 
. 0 

In 0 
_NUM1 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
of 0 
the 0 
_NUM2 0 
patients 0 
, 0 
a 0 
mutation 0 
was 0 
detected 0 
in 0 
constitutional 0 
DNA 0 
, 0 
and 0 
_NUM1 0 
of 0 
these 0 
mutations 0 
is 0 
known 0 
to 0 
be 0 
associated 0 
with 0 
reduced 0 
expressivity 0 
. 0 

The 0 
presence 0 
of 0 
a 0 
constitutional 0 
mutation 0 
was 0 
not 0 
associated 0 
with 0 
an 0 
early 0 
age 0 
at 0 
treatment 0 
. 0 

In 0 
_NUM1 0 
patient 0 
, 0 
somatic 0 
mosaicism 0 
was 0 
demonstrated 0 
by 0 
molecular 0 
analysis 0 
of 0 
DNA 0 
and 0 
RNA 0 
from 0 
peripheral 0 
blood 0 
. 0 

In 0 
_NUM1 0 
patients 0 
without 0 
a 0 
detectable 0 
mutation 0 
in 0 
peripheral 0 
blood 0 
, 0 
mosaicism 0 
was 0 
suggested 0 
because 0 
_NUM1 0 
of 0 
the 0 
patients 0 
showed 0 
multifocal 0 
tumors 1
and 0 
the 0 
other 0 
later 0 
developed 0 
bilateral 1
retinoblastoma 1
. 0 

In 0 
conclusion 0 
, 0 
our 0 
results 0 
emphasize 0 
that 0 
the 0 
manifestation 0 
and 0 
transmissibility 0 
of 0 
retinoblastoma 1
depend 0 
on 0 
the 0 
nature 0 
of 0 
the 0 
first 0 
mutation 0 
, 0 
its 0 
time 0 
in 0 
development 0 
, 0 
and 0 
the 0 
number 0 
and 0 
types 0 
of 0 
cells 0 
that 0 
are 0 
affected 0 
. 0 
. 0 

Missense 0 
mutations 0 
in 0 
the 0 
most 0 
ancient 0 
residues 0 
of 0 
the 0 
PAX6 0 
paired 0 
domain 0 
underlie 0 
a 0 
spectrum 0 
of 0 
human 0 
congenital 1
eye 1
malformations 1
. 0 

Mutations 0 
of 0 
the 0 
human 0 
PAX6 0 
gene 0 
underlie 0 
aniridia 1
-LRB- 0 
congenital 1
absence 1
of 1
the 1
iris 1
-RRB- 0 
, 0 
a 0 
rare 0 
dominant 0 
malformation 1
of 1
the 1
eye 1
. 0 

The 0 
spectrum 0 
of 0 
PAX6 0 
mutations 0 
in 0 
aniridia 1
patients 0 
is 0 
highly 0 
biased 0 
, 0 
with 0 
_NUM2 0 
% 0 
of 0 
all 0 
reported 0 
mutations 0 
leading 0 
to 0 
premature 0 
truncation 0 
of 0 
the 0 
protein 0 
-LRB- 0 
nonsense 0 
, 0 
splicing 0 
, 0 
insertions 0 
and 0 
deletions 0 
-RRB- 0 
and 0 
just 0 
_NUM1 0 
% 0 
leading 0 
to 0 
substitution 0 
of 0 
one 0 
amino 0 
acid 0 
by 0 
another 0 
-LRB- 0 
missense 0 
-RRB- 0 
. 0 

The 0 
extraordinary 0 
conservation 0 
of 0 
the 0 
PAX6 0 
protein 0 
at 0 
the 0 
amino 0 
acid 0 
level 0 
amongst 0 
vertebrates 0 
predicts 0 
that 0 
pathological 0 
missense 0 
mutations 0 
should 0 
in 0 
fact 0 
be 0 
common 0 
even 0 
though 0 
they 0 
are 0 
hardly 0 
ever 0 
seen 0 
in 0 
aniridia 1
patients 0 
. 0 

This 0 
indicates 0 
that 0 
there 0 
is 0 
a 0 
heavy 0 
ascertainment 0 
bias 0 
in 0 
the 0 
selection 0 
of 0 
patients 0 
for 0 
PAX6 0 
mutation 0 
analysis 0 
and 0 
that 0 
the 0 
missing 0 
PAX6 0 
missense 0 
mutations 0 
frequently 0 
may 0 
underlie 0 
phenotypes 0 
distinct 0 
from 0 
textbook 0 
aniridia 1
. 0 

Here 0 
we 0 
present 0 
four 0 
novel 0 
PAX6 0 
missense 0 
mutations 0 
, 0 
two 0 
in 0 
association 0 
with 0 
atypical 0 
phenotypes 0 
ectopia 1
pupillae 1
-LRB- 0 
displaced 1
pupils 1
-RRB- 0 
and 0 
congenital 1
nystagmus 1
-LRB- 0 
searching 1
gaze 1
-RRB- 0 
, 0 
and 0 
two 0 
in 0 
association 0 
with 0 
more 0 
recognizable 0 
aniridia 1
phenotypes 0 
. 0 

Strikingly 0 
, 0 
all 0 
four 0 
mutations 0 
are 0 
located 0 
within 0 
the 0 
PAX6 0
paired 0 
domain 0 
and 0 
affect 0 
amino 0 
acids 0 
which 0 
are 0 
highly 0 
conserved 0 
in 0 
all 0 
known 0 
paired 0 
domain 0 
proteins 0 
. 0 

Our 0 
results 0 
support 0 
the 0 
hypothesis 0 
that 0 
the 0 
under-representation 0 
of 0 
missense 0 
mutations 0 
is 0 
caused 0 
by 0 
ascertainment 0 
bias 0 
and 0 
suggest 0 
that 0 
a 0 
substantial 0 
burden 0 
of 0 
PAX6 1
related 1
disease 1
remains 0 
to 0 
be 0 
uncovered 0 
. 0 
. 0 

Somatic 0 
instability 0 
of 0 
the 0 
_DS 0 
repeat 0 
in 0 
mice 0 
transgenic 0 
for 0 
the 0 
myotonic 1
dystrophy 1
region 0 
is 0 
age 0 
dependent 0 
but 0 
not 0 
correlated 0 
to 0 
the 0 
relative 0 
intertissue 0 
transcription 0 
levels 0 
and 0 
proliferative 0 
capacities 0 
. 0 

A 0 
-LRB- 0 
_DS 0 
-RRB- 0 
nexpansion 0 
in 0 
the 0 
3-untranslated 0 
region 0 
-LRB- 0 
UTR 0 
-RRB- 0 
of 0 
the 0 
DM 0 
protein 0 
kinase 0 
gene 0 
-LRB- 0 
DMPK 0 
-RRB- 0 
is 0 
responsible 0 
for 0 
causing 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
. 0 

Major 0 
instability 0 
, 0 
with 0 
very 0 
large 0 
expansions 0 
between 0 
generations 0 
and 0 
high 0 
levels 0 
of 0 
somatic 0 
mosaicism 0 
, 0 
is 0 
observed 0 
in 0 
patients 0 
. 0 

There 0 
is 0 
a 0 
good 0 
correlation 0 
between 0 
repeat 0 
size 0 
-LRB- 0 
at 0 
least 0 
in 0 
leucocytes 0 
-RRB- 0 
, 0 
clinical 0 
severity 0 
and 0 
age 0 
of 0 
onset 0 
. 0 

The 0 
trinucleotide 0 
repeat 0 
instability 0 
mechanisms 0 
involved 0 
in 0 
DM 1
and 0 
other 0 
human 0 
genetic 1
diseases 1
are 0 
unknown 0 
. 0 

We 0 
studied 0 
somatic 0 
instability 0 
by 0 
measuring 0 
the 0 
_DS 0 
repeat 0 
length 0 
at 0 
several 0 
ages 0 
in 0 
various 0 
tissues 0 
of 0 
transgenic 0 
mice 0 
carrying 0 
a 0 
-LRB- 0 
_DS 0 
-RRB- 0 
55expansion 0 
surrounded 0 
by 0 
_NUM2 0 
kb 0 
of 0 
the 0 
human 0 
DM 1
region 0 
, 0 
using 0 
small-pool 0 
PCR 0 
. 0 

These 0 
mice 0 
have 0 
been 0 
shown 0 
to 0 
reproduce 0 
the 0 
intergenerational 0 
and 0 
somatic 0 
instability 0 
of 0 
the 0 
_NUM2 0 
_DS 0 
repeat 0 
suggesting 0 
that 0 
surrounding 0 
sequences 0 
and 0 
the 0 
chromatin 0 
environment 0 
are 0 
involved 0 
in 0 
instability 0 
mechanisms 0 
. 0 

As 0 
observed 0 
in 0 
some 0 
of 0 
the 0 
tissues 0 
of 0 
DM 1
patients 0 
, 0 
there 0 
is 0 
a 0 
tendency 0 
for 0 
repeat 0 
length 0 
and 0 
somatic 0 
mosaicism 0 
to 0 
increase 0 
with 0 
the 0 
age 0 
of 0 
the 0 
mouse 0 
. 0 

Furthermore 0 
, 0 
we 0 
observed 0 
no 0 
correlation 0 
between 0 
the 0 
somatic 0 
mutation 0 
rate 0 
and 0 
tissue 0 
proliferation 0 
capacity 0 
. 0 

The 0 
somatic 0 
mutation 0 
rates 0 
in 0 
different 0 
tissues 0 
were 0 
also 0 
not 0 
correlated 0 
to 0 
the 0 
relative 0 
inter-tissue 0 
difference 0 
in 0 
transcriptional 0 
levels 0 
of 0 
the 0 
three 0 
genes 0 
-LRB- 0 
DMAHP 0 
, 0 
DMPK 0 
and 0 
_NUM2 0 
-RRB- 0 
surrounding 0 
the 0 
repeat 0 
. 0 
. 0 

ATM 0 
mutations 0 
and 0 
phenotypes 0 
in 0 
ataxia-telangiectasia 1
families 0 
in 0 
the 0 
British 0 
Isles 0 
: 0 
expression 0 
of 0 
mutant 0 
ATM 0 
and 0 
the 0 
risk 0 
of 0 
leukemia 1
, 0 
lymphoma 1
, 0 
and 0 
breast 1
cancer 1
. 0 

We 0 
report 0 
the 0 
spectrum 0 
of 0 
_NUM2 0 
ATM 0 
mutations 0 
observed 0 
in 0 
ataxia-telangiectasia 1
-LRB- 0 
A-T 1
-RRB- 0 
patients 0 
in 0 
the 0 
British 0 
Isles 0 
. 0 

Of 0 
_NUM2 0 
ATM 0 
mutations 0 
identified 0 
in 0 
families 0 
native 0 
to 0 
the 0 
British 0 
Isles 0 
, 0 
_NUM2 0 
were 0 
founder 0 
mutations 0 
, 0 
and 0 
_NUM1 0 
of 0 
these 0 
_NUM2 0 
conferred 0 
a 0 
milder 0 
clinical 0 
phenotype 0 
with 0 
respect 0 
to 0 
both 0 
cerebellar 1
degeneration 1
and 0 
cellular 0 
features 0 
. 0 

We 0 
report 0 
, 0 
in 0 
two 0 
A-T 1
families 0 
, 0 
an 0 
ATM 0 
mutation 0 
-LRB- 0 
7271T 0 
-- 0 
> 0 
G 0 
-RRB- 0 
that 0 
may 0 
be 0 
associated 0 
with 0 
an 0 
increased 0 
risk 0 
of 0 
breast 1
cancer 1
in 0 
both 0 
homozygotes 0 
and 0 
heterozygotes 0 
-LRB- 0 
relative 0 
risk 0 
_NUM2 0 
. 0 

_NUM1 0 
; 0 
P 0 
= 0 
. 0 

_NUM4 0 
-RRB- 0 
, 0 
although 0 
there 0 
is 0 
a 0 
less 0 
severe 0 
A-T 1
phenotype 0 
in 0 
terms 0 
of 0 
the 0 
degree 0 
of 0 
cerebellar 1
degeneration 1
. 0 

This 0 
mutation 0 
-LRB- 0 
7271T 0 
-- 0 
> 0 
G 0 
-RRB- 0 
also 0 
allows 0 
expression 0 
of 0 
full-length 0 
ATM 0 
protein 0 
at 0 
a 0 
level 0 
comparable 0 
with 0 
that 0 
in 0 
unaffected 0 
individuals 0 
. 0 

In 0 
addition 0 
, 0 
we 0 
have 0 
studied 0 
_NUM2 0 
A-T 1
patients 0 
, 0 
in 0 
_NUM2 0 
families 0 
, 0 
who 0 
developed 0 
leukemia 1
, 0 
lymphoma 1
, 0 
preleukemic 0 
T-cell 0 
proliferation 0 
, 0 
or 0 
Hodgkin 1
lymphoma 1
, 0 
mostly 0 
in 0 
childhood 0 
. 0 

A 0 
wide 0 
variety 0 
of 0 
ATM 0 
mutation 0 
types 0 
, 0 
including 0 
missense 0 
mutations 0 
and 0 
in-frame 0 
deletions 0 
, 0 
were 0 
seen 0 
in 0 
these 0 
patients 0 
. 0 

We 0 
also 0 
show 0 
that 0 
_NUM2 0 
% 0 
of 0 
all 0 
A-T 1
patients 0 
carried 0 
in-frame 0 
deletions 0 
or 0 
missense 0 
mutations 0 
, 0 
many 0 
of 0 
which 0 
were 0 
also 0 
associated 0 
with 0 
expression 0 
of 0 
mutant 0 
ATM 0 
protein 0 
. 0 

Low 0 
frequency 0 
of 0 
BRCA1 0 
germline 0 
mutations 0 
in 0 
_NUM2 0 
German 0 
breast 1
/ 1
ovarian 1
cancer 1
families 0 
. 0 

In 0 
this 0 
study 0 
we 0 
investigated 0 
_NUM2 0 
German 0 
breast 1
/ 1
ovarian 1
cancer 1
families 0 
for 0 
germline 0 
mutations 0 
in 0 
the 0 
BRCA1 0 
gene 0 
. 0 

We 0 
identified 0 
four 0 
germline 0 
mutations 0 
in 0 
three 0 
breast 1
cancer 1
families 0 
and 0 
in 0 
one 0 
breast-ovarian 1
cancer 1
family 0 
. 0 

among 0 
these 0 
were 0 
one 0 
frameshift 0 
mutation 0 
, 0 
one 0 
nonsense 0 
mutation 0 
, 0 
one 0 
novel 0 
splice 0 
site 0 
mutation 0 
, 0 
and 0 
one 0 
missense 0 
mutation 0 
. 0 

The 0 
missense 0 
mutation 0 
was 0 
also 0 
found 0 
in 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
of 0 
the 0 
general 0 
population 0 
, 0 
suggesting 0 
that 0 
it 0 
is 0 
not 0 
disease 0 
associated 0 
. 0 

The 0 
average 0 
age 0 
of 0 
disease 0 
onset 0 
in 0 
those 0 
families 0 
harbouring 0 
causative 0 
mutations 0 
was 0 
between 0 
_NUM2 0 
. 0 

_NUM1 0 
and 0 
_NUM2 0 
. 0 

_NUM1 0 
years 0 
, 0 
whereas 0 
the 0 
family 0 
harbouring 0 
the 0 
missense 0 
mutation 0 
had 0 
an 0 
average 0 
age 0 
of 0 
onset 0 
of 0 
_NUM2 0 
. 0 

_NUM1 0 
years 0 
. 0 

These 0 
findings 0 
show 0 
that 0 
BRCA1 0 
is 0 
implicated 0 
in 0 
a 0 
small 0 
fraction 0 
of 0 
breast 1
/ 1
ovarian 1
cancer 1
families 0 
suggesting 0 
the 0 
involvement 0 
of 0 
another 0 
susceptibility 0 
gene 0 
-LRB- 0 
s 0 
-RRB- 0 
Oral 0 
contraceptives 0 
and 0 
the 0 
risk 0 
of 0 
hereditary 1
ovarian 1
cancer 1
. 0 

Hereditary 1
Ovarian 1
Cancer 1
Clinical 0 
Study 0 
Group 0 
. 0 

BACKGROUND 0 
Women 0 
with 0 
mutations 0 
in 0 
either 0 
the 0 
BRCA1 0 
or 0 
the 0 
BRCA2 0 
gene 0 
have 0 
a 0 
high 0 
lifetime 0 
risk 0 
of 0 
ovarian 1
cancer 1
. 0 

Oral 0 
contraceptives 0 
protect 0 
against 0 
ovarian 1
cancer 1
in 0 
general 0 
, 0 
but 0 
it 0 
is 0 
not 0 
known 0 
whether 0 
they 0 
also 0 
protect 0 
against 0 
hereditary 1
forms 1
of 1
ovarian 1
cancer 1
. 0 

METHODS 0 
We 0 
enrolled 0 
_NUM3 0 
women 0 
with 0 
hereditary 1
ovarian 1
cancer 1
and 0 
_NUM3 0 
of 0 
their 0 
sisters 0 
as 0 
controls 0 
in 0 
a 0 
case-control 0 
study 0 
. 0 

All 0 
the 0 
patients 0 
carried 0 
a 0 
pathogenic 0 
mutation 0 
in 0 
either 0 
BRCA1 0 
-LRB- 0 
_NUM3 0 
women 0 
-RRB- 0 
or 0 
BRCA2 0 
-LRB- 0 
_NUM2 0 
women 0 
-RRB- 0 
. 0 

The 0 
control 0 
women 0 
were 0 
enrolled 0 
regardless 0 
of 0 
whether 0 
or 0 
not 0 
they 0 
had 0 
either 0 
mutation 0 
. 0 

Lifetime 0 
histories 0 
of 0 
oral-contraceptive 0 
use 0 
were 0 
obtained 0 
by 0 
interview 0 
or 0 
by 0 
written 0 
questionnaire 0 
and 0 
were 0 
compared 0 
between 0 
patients 0 
and 0 
control 0 
women 0 
, 0 
after 0 
adjustment 0 
for 0 
year 0 
of 0 
birth 0 
and 0 
parity 0 
. 0 

RESULTS 0 
The 0 
adjusted 0 
odds 0 
ratio 0 
for 0 
ovarian 1
cancer 1
associated 0 
with 0 
any 0 
past 0 
use 0 
of 0 
oral 0 
contraceptives 0 
was 0 
_NUM1 0 
. 0 

_NUM1 0 
-LRB- 0 
_NUM2 0 
percent 0 
confidence 0 
interval 0 
, 0 
_NUM1 0 
. 0 

_NUM1 0 
to 0 
_NUM1 0 
. 0 

_NUM1 0 
-RRB- 0 
. 0 

The 0 
risk 0 
decreased 0 
with 0 
increasing 0 
duration 0 
of 0 
use 0 
-LRB- 0 
P 0 
for 0 
trend 0 
, 0 
< 0 
_NUM1 0 
. 0 

_NUM3 0 
-RRB- 0 
; 0 
use 0 
for 0 
six 0 
or 0 
more 0 
years 0 
was 0 
associated 0 
with 0 
a 0 
_NUM2 0 
percent 0 
reduction 0 
in 0 
risk 0 
. 0 

Oral-contraceptive 0 
use 0 
protected 0 
against 0 
ovarian 1
cancer 1
both 0 
for 0 
carriers 0 
of 0 
the 0 
BRCA1 0 
mutation 0 
-LRB- 0 
odds 0 
ratio 0 
, 0 
_NUM1 0 
. 0 

_NUM1 0 
; 0 
_NUM2 0 
percent 0 
confidence 0 
interval 0 
, 0 
_NUM1 0 
. 0 

_NUM1 0 
to 0 
_NUM1 0 
. 0 

_NUM1 0 
-RRB- 0 
and 0 
for 0 
carriers 0 
of 0 
the 0 
BRCA2 0 
mutation 0 
-LRB- 0 
odds 0 
ratio 0 
, 0 
_NUM1 0 
. 0 

_NUM1 0 
; 0 
_NUM2 0 
percent 0 
confidence 0 
interval 0 
, 0 
_NUM1 0 
. 0 

_NUM1 0 
to 0 
_NUM1 0 
. 0 

_NUM1 0 
-RRB- 0 
. 0 

CONCLUSIONS 0 
Oral-contraceptive 0 
use 0 
may 0 
reduce 0 
the 0 
risk 0 
of 0 
ovarian 1
cancer 1
in 0 
women 0 
with 0 
pathogenic 0 
mutations 0 
in 0 
the 0 
BRCA1 0 
or 0 
BRCA2 0 
gene 0 
Founder 0 
BRCA1 0 
and 0 
BRCA2 0 
mutations 0 
in 0 
French 0 
Canadian 0 
breast 1
and 1
ovarian 1
cancer 1
families 0 
. 0 

We 0 
have 0 
identified 0 
four 0 
mutations 0 
in 0 
each 0 
of 0 
the 0 
breast 1
cancer 1
susceptibility 0 
genes 0 
, 0 
BRCA1 0 
and 0 
BRCA2 0 
, 0 
in 0 
French 0 
Canadian 0 
breast 1
cancer 1
and 0 
breast 1
/ 1
ovarian 1
cancer 1
families 0 
from 0 
Quebec 0 
. 0 

To 0 
identify 0 
founder 0 
effects 0 
, 0 
we 0 
examined 0 
independently 0 
ascertained 0 
French 0 
Canadian 0 
cancer 1
families 0 
for 0 
the 0 
distribution 0 
of 0 
these 0 
eight 0 
mutations 0 
. 0 

Mutations 0 
were 0 
found 0 
in 0 
_NUM2 0 
of 0 
_NUM2 0 
families 0 
. 0 

Six 0 
of 0 
eight 0 
mutations 0 
were 0 
observed 0 
at 0 
least 0 
twice 0 
. 0 

The 0 
BRCA1 0 
C4446T 0 
mutation 0 
was 0 
the 0 
most 0 
common 0 
mutation 0 
found 0 
, 0 
followed 0 
by 0 
the 0 
BRCA2 0 
8765delAG 0 
mutation 0 
. 0 

Together 0 
, 0 
these 0 
mutations 0 
were 0 
found 0 
in 0 
_NUM2 0 
of 0 
_NUM2 0 
families 0 
identified 0 
to 0 
have 0 
a 0 
mutation 0 
. 0 

The 0 
odds 0 
of 0 
detection 0 
of 0 
any 0 
of 0 
the 0 
four 0 
BRCA1 0 
mutations 0 
was 0 
_NUM2 0 
. 0 

7x 0 
greater 0 
if 0 
one 0 
or 0 
more 0 
cases 0 
of 0 
ovarian 1
cancer 1
were 0 
also 0 
present 0 
in 0 
the 0 
family 0 
. 0 

The 0 
odds 0 
of 0 
detection 0 
of 0 
any 0 
of 0 
the 0 
four 0 
BRCA2 0 
mutations 0 
was 0 
_NUM1 0 
. 0 

3x 0 
greater 0 
if 0 
there 0 
were 0 
at 0 
least 0 
five 0 
cases 0 
of 0 
breast 1
cancer 1
in 0 
the 0 
family 0 
. 0 

Interestingly 0 
, 0 
the 0 
presence 0 
of 0 
a 0 
breast 1
cancer 1
case 0 
< 0 
_NUM2 0 
years 0 
of 0 
age 0 
was 0 
strongly 0 
predictive 0 
of 0 
the 0 
presence 0 
of 0 
any 0 
of 0 
the 0 
eight 0 
mutations 0 
screened 0 
. 0 

Carriers 0 
of 0 
the 0 
same 0 
mutation 0 
, 0 
from 0 
different 0 
families 0 
, 0 
shared 0 
similar 0 
haplotypes 0 
, 0 
indicating 0 
that 0 
the 0 
mutant 0 
alleles 0 
were 0 
likely 0 
to 0 
be 0 
identical 0 
by 0 
descent 0 
for 0 
a 0 
mutation 0 
in 0 
the 0 
founder 0 
population 0 
. 0 

The 0 
identification 0 
of 0 
common 0 
BRCA1 0 
and 0 
BRCA2 0 
mutations 0 
will 0 
facilitate 0 
carrier 0 
detection 0 
in 0 
French 0 
Canadian 0 
breast 1
cancer 1
and 0 
breast 1
/ 1
ovarian 1
cancer 1
families 0 
. 0 

Truncation 0 
mutations 0 
in 0 
the 0 
transactivation 0 
region 0 
of 0 
PAX6 0 
result 0 
in 0 
dominant-negative 0 
mutants 0 
. 0 

PAX6 0 
is 0 
a 0 
transcription 0 
factor 0 
with 0 
two 0 
DNA-binding 0 
domains 0 
-LRB- 0 
paired 0 
box 0 
and 0 
homeobox 0 
-RRB- 0 
and 0 
a 0 
proline-serine-threonine 0 
-LRB- 0 
PST 0 
-RRB- 0 
- 0 
rich 0 
transactivation 0 
domain 0 
. 0 

PAX6 0 
regulates 0 
eye 0 
development 0 
in 0 
animals 0 
ranging 0 
from 0 
jellyfish 0 
to 0 
Drosophila 0 
to 0 
humans 0 
. 0 

Heterozygous 0 
mutations 0 
in 0 
the 0 
human 0 
PAX6 0 
gene 0 
result 0 
in 0 
various 0 
phenotypes 0 
, 0 
including 0 
aniridia 1
, 0 
Peters 1
anomaly 1
, 0 
autosomal 1
dominant 1
keratitis 1
, 0 
and 0 
familial 1
foveal 1
dysplasia 1
. 0 

It 0 
is 0 
believed 0 
that 0 
the 0 
mutated 0 
allele 0 
of 0 
PAX6 0 
produces 0 
an 0 
inactive 0 
protein 0 
and 0 
aniridia 1
is 0 
caused 0 
due 0 
to 0 
genetic 0 
haploinsufficiency 0 
. 0 

However 0 
, 0 
several 0 
truncation 0 
mutations 0 
have 0 
been 0 
found 0 
to 0 
occur 0 
in 0 
the 0 
C-terminal 0 
half 0 
of 0 
PAX6 0 
in 0 
patients 0 
with 0 
Aniridia 1
resulting 0 
in 0 
mutant 0 
proteins 0 
that 0 
retain 0 
the 0 
DNA-binding 0 
domains 0 
but 0 
have 0 
lost 0 
most 0 
of 0 
the 0 
transactivation 0 
domain 0 
. 0 

It 0 
is 0 
not 0 
clear 0 
whether 0 
such 0 
mutants 0 
really 0 
behave 0 
as 0 
loss-of-function 0 
mutants 0 
as 0 
predicted 0 
by 0 
haploinsufficiency 0 
. 0 

Contrary 0 
to 0 
this 0 
theory 0 
, 0 
our 0 
data 0 
showed 0 
that 0 
these 0 
mutants 0 
are 0 
dominant-negative 0 
in 0 
transient 0 
transfection 0 
assays 0 
when 0 
they 0 
are 0 
coexpressed 0 
with 0 
wild-type 0 
PAX6 0 
. 0 

We 0 
found 0 
that 0 
the 0 
dominant-negative 0 
effects 0 
result 0 
from 0 
the 0 
enhanced 0 
DNA 0 
binding 0 
ability 0 
of 0 
these 0 
mutants 0 
. 0 

Kinetic 0 
studies 0 
of 0 
binding 0 
and 0 
dissociation 0 
revealed 0 
that 0 
various 0 
truncation 0 
mutants 0 
have 0 
3-5-fold 0 
higher 0 
affinity 0 
to 0 
various 0 
DNA-binding 0 
sites 0 
when 0 
compared 0 
with 0 
the 0 
wild-type 0 
PAX6 0 
. 0 

These 0 
results 0 
provide 0 
a 0 
new 0 
insight 0 
into 0 
the 0 
role 0 
of 0 
mutant 0 
PAX6 0 
in 0 
causing 0 
aniridia 1
. 0 
. 0 

Crystal 0 
structure 0 
of 0 
the 0 
hemochromatosis 1
protein 0 
HFE 0 
and 0 
characterization 0 
of 0 
its 0 
interaction 0 
with 0 
transferrin 0 
receptor 0 
. 0 

HFE 0 
is 0 
an 0 
MHC-related 0 
protein 0 
that 0 
is 0 
mutated 0 
in 0 
the 0 
iron-overload 1
disease 1
hereditary 1
hemochromatosis 1
. 0 

HFE 0 
binds 0 
to 0 
transferrin 0 
receptor 0 
-LRB- 0 
TfR 0 
-RRB- 0 
and 0 
reduces 0 
its 0 
affinity 0 
for 0 
iron-loaded 0 
transferrin 0 
, 0 
implicating 0 
HFE 0 
in 0 
iron 0 
metabolism 0 
. 0 

The 0 
_NUM1 0 
. 0 

_NUM1 0 
A 0 
crystal 0 
structure 0 
of 0 
HFE 0 
reveals 0 
the 0 
locations 0 
of 0 
hemochromatosis 1
mutations 0 
and 0 
a 0 
patch 0 
of 0 
histidines 0 
that 0 
could 0 
be 0 
involved 0 
in 0 
pH-dependent 0 
interactions 0 
. 0 

We 0 
also 0 
demonstrate 0 
that 0 
soluble 0 
TfR 0 
and 0 
HFE 0 
bind 0 
tightly 0 
at 0 
the 0 
basic 0 
pH 0 
of 0 
the 0 
cell 0 
surface 0 
, 0 
but 0 
not 0 
at 0 
the 0 
acidic 0 
pH 0 
of 0 
intracellular 0 
vesicles 0 
. 0 

TfR 0 
HFE 0 
stoichiometry 0 
-LRB- 0 
_NUM1 0 
_NUM1 0 
-RRB- 0 
differs 0 
from 0 
TfR 0 
transferrin 0 
stoichiometry 0 
-LRB- 0 
_NUM1 0 
_NUM1 0 
-RRB- 0 
, 0 
implying 0 
a 0 
different 0 
mode 0 
of 0 
binding 0 
for 0 
HFE 0 
and 0 
transferrin 0 
to 0 
TfR 0 
, 0 
consistent 0 
with 0 
our 0 
demonstration 0 
that 0 
HFE 0 
, 0 
transferrin 0 
, 0 
and 0 
TfR 0 
form 0 
a 0 
ternary 0 
complex 0 
. 0 

Stable 0 
interaction 0 
between 0 
the 0 
products 0 
of 0 
the 0 
BRCA1 0 
and 0 
BRCA2 0 
tumor 1
suppressor 0 
genes 0 
in 0 
mitotic 0 
and 0 
meiotic 0 
cells 0 
. 0 

BRCA1 0 
and 0 
BRCA2 0 
account 0 
for 0 
most 0 
cases 0 
of 0 
familial 0 
, 0 
early 0 
onset 0 
breast 1
and 1
/ 1
or 1
ovarian 1
cancer 1
and 0 
encode 0 
products 0 
that 0 
each 0 
interact 0 
with 0 
hRAD51 0 
. 0 

Results 0 
presented 0 
here 0 
show 0 
that 0 
BRCA1 0 
and 0 
BRCA2 0 
coexist 0 
in 0 
a 0 
biochemical 0 
complex 0 
and 0 
colocalize 0 
in 0 
subnuclear 0 
foci 0 
in 0 
somatic 0 
cells 0 
and 0 
on 0 
the 0 
axial 0 
elements 0 
of 0 
developing 0 
synaptonemal 0 
complexes 0 
. 0 

Like 0 
BRCA1 0 
and 0 
RAD51 0 
, 0 
BRCA2 0 
relocates 0 
to 0 
PCNA 0 
+ 0 
replication 0 
sites 0 
following 0 
exposure 0 
of 0 
S 0 
phase 0 
cells 0 
to 0 
hydroxyurea 0 
or 0 
UV 0 
irradiation 0 
. 0 

Thus 0 
, 0 
BRCA1 0 
and 0 
BRCA2 0 
participate 0 
, 0 
together 0 
, 0 
in 0 
a 0 
pathway 0 
-LRB- 0 
s 0 
-RRB- 0 
associated 0 
with 0 
the 0 
activation 0 
of 0 
double-strand 0 
break 0 
repair 0 
and 0 
/ 0 
or 0 
homologous 0 
recombination 0 
. 0 

Dysfunction 0 
of 0 
this 0 
pathway 0 
may 0 
be 0 
a 0 
general 0 
phenomenon 0 
in 0 
the 0 
majority 0 
of 0 
cases 0 
of 0 
hereditary 1
breast 1
and 1
/ 1
or 1
ovarian 1
cancer 1
. 0 
. 0 

A 0 
novel 0 
Arg362Ser 0 
mutation 0 
in 0 
the 0 
sterol 0 
27-hydroxylase 0 
gene 0 
-LRB- 0 
CYP27 0 
-RRB- 0 
: 0 
its 0 
effects 0 
on 0 
pre-mRNA 0 
splicing 0 
and 0 
enzyme 0 
activity 0 
. 0 

A 0 
novel 0 
C 0 
to 0 
A 0 
mutation 0 
in 0 
the 0 
sterol 0 
27-hydroxylase 0 
gene 0 
-LRB- 0 
CYP27 0 
-RRB- 0 
was 0 
identified 0 
by 0 
sequencing 0 
amplified 0 
CYP27 0 
gene 0 
products 0 
from 0 
a 0 
patient 0 
with 0 
cerebrotendinous 1
xanthomatosis 1
-LRB- 0 
CTX 1
-RRB- 0 
. 0 

The 0 
mutation 0 
changed 0 
the 0 
adrenodoxin 0 
cofactor 0 
binding 0 
residue 0 
362Arg 0 
to 0 
362Ser 0 
-LRB- 0 
_DS 0 
362Arg 0 
to 0 
_DS 0 
362Ser 0 
-RRB- 0 
, 0 
and 0 
was 0 
responsible 0 
for 0 
deficiency 1
in 1
the 1
sterol 1
27-hydroxylase 1
activity 1
, 0 
as 0 
confirmed 0 
by 0 
expression 0 
of 0 
mutant 0 
cDNA 0 
into 0 
COS-1 0 
cells 0 
. 0 

Quantitative 0 
analysis 0 
showed 0 
that 0 
the 0 
expression 0 
of 0 
CYP27 0 
gene 0 
mRNA 0 
in 0 
the 0 
patient 0 
represented 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
of 0 
the 0 
normal 0 
level 0 
. 0 

As 0 
the 0 
mutation 0 
occurred 0 
at 0 
the 0 
penultimate 0 
nucleotide 0 
of 0 
exon 0 
_NUM1 0 
-LRB- 0 
-2 0 
position 0 
of 0 
exon 0 
6-intron 0 
_NUM1 0 
splice 0 
site 0 
-RRB- 0 
of 0 
the 0 
gene 0 
, 0 
we 0 
hypothesized 0 
that 0 
the 0 
mutation 0 
may 0 
partially 0 
affect 0 
the 0 
normal 0 
splicing 0 
efficiency 0 
in 0 
exon 0 
_NUM1 0 
and 0 
cause 0 
alternative 0 
splicing 0 
elsewhere 0 
, 0 
which 0 
resulted 0 
in 0 
decreased 0 
transcript 0 
in 0 
the 0 
patient 0 
. 0 

Transfection 0 
of 0 
constructed 0 
minigenes 0 
, 0 
with 0 
or 0 
without 0 
the 0 
mutation 0 
, 0 
into 0 
COS-1 0 
cells 0 
confirmed 0 
that 0 
the 0 
mutant 0 
minigene 0 
was 0 
responsible 0 
for 0 
a 0 
mRNA 0 
species 0 
alternatively 0 
spliced 0 
at 0 
an 0 
activated 0 
cryptic 0 
_NUM1 0 
splice 0 
site 0 
_NUM2 0 
bp 0 
upstream 0 
from 0 
the 0 
_NUM1 0 
end 0 
of 0 
exon 0 
_NUM1 0 
. 0 

Our 0 
data 0 
suggest 0 
that 0 
the 0 
C 0 
to 0 
A 0 
mutation 0 
at 0 
the 0 
penultimate 0 
nucleotide 0 
of 0 
exon 0 
_NUM1 0 
of 0 
the 0 
CYP27 0 
gene 0 
not 0 
only 0 
causes 0 
the 0 
deficiency 0 
in 0 
the 0 
sterol 0 
27-hydroxylase 0 
activity 0 
, 0 
but 0 
also 0 
partially 0 
leads 0 
to 0 
alternative 0 
pre-mRNA 0 
splicing 0 
of 0 
the 0 
gene 0 
. 0 

To 0 
our 0 
knowledge 0 
, 0 
this 0 
is 0 
the 0 
first 0 
report 0 
regarding 0 
effects 0 
on 0 
pre-mRNA 0 
splicing 0 
of 0 
a 0 
mutation 0 
at 0 
the 0 
-2 0 
position 0 
of 0 
a 0 
_NUM1 0 
splice 0 
site 0 
. 0 

A 0 
Japanese 0 
family 0 
with 0 
adrenoleukodystrophy 1
with 0 
a 0 
codon 0 
_NUM3 0 
deletion 0 
: 0 
a 0 
clinical 0 
, 0 
biochemical 0 
, 0 
pathological 0 
, 0 
and 0 
genetic 0 
report 0 
. 0 

We 0 
report 0 
a 0 
Japanese 0 
family 0 
with 0 
adrenoleukodystrophy 1
-LRB- 0 
ALD 1
-RRB- 0 
with 0 
a 0 
three 0 
base 0 
pair 0 
deletion 0 
-LRB- 0 
delGAG 0 
_NUM3 0 
-RRB- 0 
in 0 
the 0 
ALD 1
gene 0 
. 0 

A 0 
variety 0 
of 0 
phenotypes 0 
were 0 
observed 0 
within 0 
this 0 
family 0 
. 0 

While 0 
the 0 
proband 0 
-LRB- 0 
patient 0 
_NUM1 0 
-RRB- 0 
was 0 
classified 0 
as 0 
having 0 
a 0 
rare 0 
intermediate 0 
type 0 
of 0 
adult 0 
cerebral 0 
and 0 
cerebello-brain 0 
stem 0 
forms 0 
, 0 
his 0 
younger 0 
brother 0 
-LRB- 0 
patient 0 
_NUM1 0 
-RRB- 0 
and 0 
nephew 0 
-LRB- 0 
patient 0 
_NUM1 0 
-RRB- 0 
had 0 
a 0 
childhood 0 
ALD 1
type 0 
. 0 

Another 0 
nephew 0 
-LRB- 0 
patient 0 
_NUM1 0 
-RRB- 0 
of 0 
patient 0 
_NUM1 0 
was 0 
classified 0 
as 0 
having 0 
an 0 
adolescent 0 
form 0 
. 0 

The 0 
tau 0 
level 0 
in 0 
the 0 
cerebrospinal 0 
fluid 0 
-LRB- 0 
CSF 0 
-RRB- 0 
in 0 
patient 0 
_NUM1 0 
was 0 
as 0 
high 0 
as 0 
that 0 
of 0 
patients 0 
with 0 
Alzheimers 1
disease 1
-LRB- 0 
AD 1
-RRB- 0 
. 0 

His 0 
brain 0 
magnetic 0 
resonance 0 
image 0 
-LRB- 0 
MRI 0 
-RRB- 0 
showed 0 
abnormalities 1
in 1
the 1
bilateral 1
cerebellar 1
hemispheres 1
and 0 
brain 0 
stem 0 
, 0 
but 0 
not 0 
in 0 
the 0 
cerebral 0 
white 0 
matter 0 
, 0 
where 0 
marked 0 
reductions 0 
of 0 
the 0 
cerebral 0 
blood 0 
flow 0 
and 0 
oxygen 0 
metabolism 0 
were 0 
clearly 0 
demonstrated 0 
by 0 
positron 0 
emission 0 
tomography 0 
-LRB- 0 
PET 0 
-RRB- 0 
. 0 

In 0 
patients 0 
_NUM1 0 
and 0 
_NUM1 0 
, 0 
the 0 
autopsy 0 
findings 0 
showed 0 
massive 0 
demyelination 1
of 1
the 1
cerebral 1
white 1
matter 1
with 0 
sparing 0 
of 0 
the 0 
U-fibers 0 
, 0 
compatible 0 
with 0 
the 0 
findings 0 
of 0 
childhood 0 
ALD 1
. 0 

Oleic 0 
and 0 
erucic 0 
acids 0 
-LRB- 0 
Lorenzos 0 
Oil 0 
-RRB- 0 
were 0 
administered 0 
to 0 
patients 0 
_NUM1 0 
and 0 
_NUM1 0 
, 0 
but 0 
sufficient 0 
effectiveness 0 
was 0 
not 0 
obtained 0 
. 0 

The 0 
findings 0 
in 0 
this 0 
family 0 
suggest 0 
that 0 
delGAG291 0 
is 0 
part 0 
of 0 
the 0 
cause 0 
of 0 
Japanese 0 
ALD 1
with 0 
phenotypic 0 
variations 0 
. 0 

Moreover 0 
, 0 
although 0 
the 0 
scale 0 
of 0 
the 0 
study 0 
is 0 
limited 0 
, 0 
there 0 
is 0 
a 0 
possibility 0 
that 0 
PET 0 
can 0 
detect 0 
an 0 
insidious 1
lesion 1
which 0 
is 0 
undetectable 0 
by 0 
computed 0 
tomogram 0 
-LRB- 0 
_DS 0 
-RRB- 0 
or 0 
MRI 0 
analysis 0 
, 0 
and 0 
that 0 
the 0 
higher 0 
level 0 
of 0 
tau 0 
reflects 0 
the 0 
process 0 
of 0 
neuronal 1
degeneration 1
in 0 
ALD 1
. 0 

Lorenzos 0 
Oil 0 
should 0 
be 0 
given 0 
in 0 
the 0 
early 0 
stage 0 
. 0 
. 0 

Two 0 
frequent 0 
missense 0 
mutations 0 
in 0 
Pendred 1
syndrome 1
. 0 

Pendred 1
syndrome 1
is 0 
an 0 
autosomal 1
recessive 1
disorder 1
characterized 0 
by 0 
early 0 
childhood 0 
deafness 1
and 0 
goiter 1
. 0 

A 0 
century 0 
after 0 
its 0 
recognition 0 
as 0 
a 0 
syndrome 0 
by 0 
Vaughan 0 
Pendred 0 
, 0 
the 0 
disease 0 
gene 0 
-LRB- 0 
PDS 1
-RRB- 0 
was 0 
mapped 0 
to 0 
chromosome 0 
7q22-q31 0 
. 0 

_NUM1 0 
and 0 
, 0 
recently 0 
, 0 
found 0 
to 0 
encode 0 
a 0 
putative 0 
sulfate 0 
transporter 0 
. 0 

We 0 
performed 0 
mutation 0 
analysis 0 
of 0 
the 0 
PDS 0 
gene 0 
in 0 
patients 0 
from 0 
_NUM2 0 
Pendred 1
families 0 
originating 0 
from 0 
seven 0 
countries 0 
and 0 
identified 0 
all 0 
mutations 0 
. 0 

The 0 
mutations 0 
include 0 
three 0 
single 0 
base 0 
deletions 0 
, 0 
one 0 
splice 0 
site 0 
mutation 0 
and 0 
_NUM2 0 
missense 0 
mutations 0 
. 0 

One 0 
missense 0 
mutation 0 
-LRB- 0 
L236P 0 
-RRB- 0 
was 0 
found 0 
in 0 
a 0 
homozygous 0 
state 0 
in 0 
two 0 
consanguineous 0 
families 0 
and 0 
in 0 
a 0 
heterozygous 0 
state 0 
in 0 
five 0 
additional 0 
non-consanguineous 0 
families 0 
. 0 

Another 0 
missense 0 
mutation 0 
-LRB- 0 
T416P 0 
-RRB- 0 
was 0 
found 0 
in 0 
a 0 
homozygous 0 
state 0 
in 0 
one 0 
family 0 
and 0 
in 0 
a 0 
heterozygous 0 
state 0 
in 0 
four 0 
families 0 
. 0 

Pendred 1
patients 0 
in 0 
three 0 
non-consanguineous 0 
families 0 
were 0 
shown 0 
to 0 
be 0 
compound 0 
heterozygotes 0 
for 0 
L236P 0 
and 0 
T416P 0 
. 0 

In 0 
total 0 
, 0 
one 0 
or 0 
both 0 
of 0 
these 0 
mutations 0 
were 0 
found 0 
in 0 
nine 0 
of 0 
the 0 
_NUM2 0 
families 0 
analyzed 0 
. 0 

The 0 
identification 0 
of 0 
two 0 
frequent 0 
PDS 1
mutations 0 
will 0 
facilitate 0 
the 0 
molecular 0 
diagnosis 0 
of 0 
Pendred 1
syndrome 1
. 0 

Aspartylglucosaminuria 1
among 0 
Palestinian 0 
Arabs 0 
. 0 

Aspartylglucosaminuria 1
-LRB- 0 
AGU 1
-RRB- 0 
is 0 
a 0 
rare 0 
disorder 1
of 1
glycoprotein 1
metabolism 1
caused 0 
by 0 
the 0 
deficiency 1
of 1
the 1
lysosomal 1
enzyme 1
aspartylglucosaminidase 1
-LRB- 0 
_DS 0 
-RRB- 0 
. 0 

AGU 1
is 0 
inherited 0 
as 0 
an 0 
autosomal 0 
recessive 0 
trait 0 
and 0 
occurs 0 
with 0 
a 0 
high 0 
frequency 0 
in 0 
Finland 0 
because 0 
of 0 
a 0 
founder 0 
effect 0 
. 0 

While 0 
very 0 
few 0 
patients 0 
with 0 
AGU 1
have 0 
been 0 
reported 0 
from 0 
non-Finnish 0 
origin 0 
, 0 
we 0 
diagnosed 0 
the 0 
disorder 0 
in 0 
_NUM1 0 
patients 0 
originating 0 
from 0 
_NUM1 0 
unrelated 0 
families 0 
, 0 
all 0 
Palestinian 0 
Arabs 0 
from 0 
the 0 
region 0 
of 0 
Jerusalem 0 
. 0 

The 0 
clinical 0 
diagnosis 0 
of 0 
AGU 1
is 0 
often 0 
difficult 0 
, 0 
in 0 
particular 0 
early 0 
in 0 
the 0 
course 0 
of 0 
the 0 
disease 0 
, 0 
and 0 
most 0 
of 0 
the 0 
patients 0 
are 0 
diagnosed 0 
after 0 
the 0 
age 0 
of 0 
_NUM1 0 
years 0 
. 0 

However 0 
, 0 
since 0 
these 0 
patients 0 
excrete 0 
early 0 
large 0 
amounts 0 
of 0 
aspartylglucosamine 0 
in 0 
urine 0 
, 0 
biochemical 0 
screening 0 
is 0 
easy 0 
by 0 
urine 0 
chromatography 0 
. 0 
. 0 

Mutation 0 
spectrum 0 
and 0 
genotype-phenotype 0 
analyses 0 
in 0 
Cowden 1
disease 1
and 0 
Bannayan-Zonana 1
syndrome 1
, 0 
two 0 
hamartoma 1
syndromes 1
with 0 
germline 0 
PTEN 0 
mutation 0 
. 0 

The 0 
tumour 1
suppressor 0 
gene 0 
PTEN 0 
, 0 
which 0 
maps 0 
to 0 
10q23 0 
. 0 

_NUM1 0 
and 0 
encodes 0 
a 0 
_NUM3 0 
amino 0 
acid 0 
dual 0 
specificity 0 
phosphatase 0 
-LRB- 0 
protein 0 
tyrosine 0 
phosphatase 0 
; 0 
PTPase 0 
-RRB- 0 
, 0 
was 0 
shown 0 
recently 0 
to 0 
play 0 
a 0 
broad 0 
role 0 
in 0 
human 0 
malignancy 1
. 0 

Somatic 0 
PTEN 0 
deletions 0 
and 0 
mutations 0 
were 0 
observed 0 
in 0 
sporadic 1
breast 1
, 1
brain 1
, 1
prostate 1
and 1
kidney 1
cancer 1
cell 0 
lines 0 
and 0 
in 0 
several 0 
primary 0 
tumours 1
such 0 
as 0 
endometrial 1
carcinomas 1
, 0 
malignant 1
melanoma 1
and 0 
thyroid 1
tumours 1
. 0 

In 0 
addition 0 
, 0 
PTEN 0 
was 0 
identified 0 
as 0 
the 0 
susceptibility 0 
gene 0 
for 0 
two 0 
hamartoma 1
syndromes 1
Cowden 1
disease 1
-LRB- 0 
CD 1
; 0 
MIM 0 
_NUM6 0 
-RRB- 0 
and 0 
Bannayan-Zonana 1
-LRB- 1
BZS 1
-RRB- 1
or 1
Ruvalcaba-Riley-Smith 1
syndrome 1
-LRB- 0 
MIM 0 
_NUM6 0 
-RRB- 0 
. 0 

Constitutive 0 
DNA 0 
from 0 
_NUM2 0 
CD 1
families 0 
and 0 
seven 0 
BZS 1
families 0 
was 0 
screened 0 
for 0 
germline 0 
PTEN 0 
mutations 0 
. 0 

PTEN 0 
mutations 0 
were 0 
identified 0 
in 0 
_NUM2 0 
of 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
CD 1
families 0 
, 0 
including 0 
missense 0 
and 0 
nonsense 0 
point 0 
mutations 0 
, 0 
deletions 0 
, 0 
insertions 0 
, 0 
a 0 
deletion 0 
/ 0 
insertion 0 
and 0 
splice 0 
site 0 
mutations 0 
. 0 

These 0 
mutations 0 
were 0 
scattered 0 
over 0 
the 0 
entire 0 
length 0 
of 0 
PTEN 0 
, 0 
with 0 
the 0 
exception 0 
of 0 
the 0 
first 0 
, 0 
fourth 0 
and 0 
last 0 
exons 0 
. 0 

A 0 
hot 0 
spot 0 
for 0 
PTEN 0 
mutation 0 
in 0 
CD 1
was 0 
identified 0 
in 0 
exon 0 
_NUM1 0 
that 0 
contains 0 
the 0 
PTPase 0 
core 0 
motif 0 
, 0 
with 0 
_NUM2 0 
of 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
CD 1
mutations 0 
identified 0 
in 0 
this 0 
exon 0 
. 0 

Seven 0 
of 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
were 0 
within 0 
the 0 
core 0 
motif 0 
, 0 
the 0 
majority 0 
-LRB- 0 
five 0 
of 0 
seven 0 
-RRB- 0 
of 0 
which 0 
were 0 
missense 0 
mutations 0 
, 0 
possibly 0 
pointing 0 
to 0 
the 0 
functional 0 
significance 0 
of 0 
this 0 
region 0 
. 0 

Germline 0 
PTEN 0 
mutations 0 
were 0 
identified 0 
in 0 
four 0 
of 0 
seven 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
BZS 1
families 0 
studied 0 
. 0 

Interestingly 0 
, 0 
none 0 
of 0 
these 0 
mutations 0 
was 0 
observed 0 
in 0 
the 0 
PTPase 0 
core 0 
motif 0 
. 0 

It 0 
is 0 
also 0 
worthy 0 
of 0 
note 0 
that 0 
a 0 
single 0 
nonsense 0 
point 0 
mutation 0 
, 0 
R233X 0 
, 0 
was 0 
observed 0 
in 0 
the 0 
germline 0 
DNA 0 
from 0 
two 0 
unrelated 0 
CD 1
families 0 
and 0 
one 0 
BZS 1
family 0 
. 0 

Genotype-phenotype 0 
studies 0 
were 0 
not 0 
performed 0 
on 0 
this 0 
small 0 
group 0 
of 0 
BZS 1
families 0 
. 0 

However 0 
, 0 
genotype-phenotype 0 
analysis 0 
inthe 0 
group 0 
of 0 
CD 1
families 0 
revealed 0 
two 0 
possible 0 
associations 0 
worthy 0 
of 0 
follow-up 0 
in 0 
independent 0 
analyses 0 
. 0 

The 0 
first 0 
was 0 
an 0 
association 0 
noted 0 
in 0 
the 0 
group 0 
of 0 
CD 1
families 0 
with 0 
breast 1
disease 1
. 0 

A 0 
correlation 0 
was 0 
observed 0 
between 0 
the 0 
presence 0 
/ 0 
absence 0 
of 0 
a 0 
PTEN 0 
mutation 0 
and 0 
the 0 
type 0 
of 0 
breast 0 
involvement 0 
-LRB- 0 
unaffected 0 
versus 0 
benign 0 
versus 0 
malignant 0
-RRB- 0 
. 0 

Specifically 0 
and 0 
more 0 
directly 0 
, 0 
an 0 
association 0 
was 0 
also 0 
observed 0 
between 0 
the 0 
presence 0 
of 0 
a 0 
PTEN 0 
mutation 0 
and 0 
malignant 1
breast 1
disease 1
. 0 

Secondly 0 
, 0 
there 0 
appeared 0 
to 0 
be 0 
an 0 
interdependent 0 
association 0 
between 0 
mutations 0 
upstream 0 
and 0 
within 0 
the 0 
PTPase 0 
core 0 
motif 0 
, 0 
the 0 
core 0 
motif 0 
containing 0 
the 0 
majority 0 
of 0 
missense 0 
mutations 0 
, 0 
and 0 
the 0 
involvement 0 
of 0 
all 0 
major 0 
organ 0 
systems 0 
-LRB- 0 
central 0 
nervous 0 
system 0 
, 0 
thyroid 0 
, 0 
breast 0 
, 0 
skin 0 
and 0 
gastrointestinal 0 
tract 0 
-RRB- 0 
. 0 

However 0 
, 0 
these 0 
observations 0 
would 0 
need 0 
to 0 
be 0 
confirmed 0 
by 0 
studying 0 
a 0 
larger 0 
number 0 
of 0 
CD 1
families 0 
. 0 

I1307K 0 
APC 0 
and 0 
hMLH1 0 
mutations 0 
in 0 
a 0 
non-Jewish 0 
family 0 
with 0 
hereditary 1
non-polyposis 1
colorectal 1
cancer 1
. 0 

We 0 
describe 0 
a 0 
French 0 
Canadian 0 
hereditary 1
non-polyposis 1
colorectal 1
cancer 1
-LRB- 0 
HNPCC 1
-RRB- 0 
kindred 0 
which 0 
carries 0 
a 0 
novel 0 
truncating 0 
mutation 0 
in 0 
hMLH1 0 
. 0 

Interestingly 0 
, 0 
the 0 
I1307K 0 
APC 0 
polymorphism 0 
, 0 
associated 0 
with 0 
an 0 
increased 0 
risk 0 
of 0 
colorectal 1
cancer 1
, 0 
is 0 
also 0 
present 0 
in 0 
this 0 
family 0 
. 0 

The 0 
I1307K 0 
polymorphism 0 
has 0 
previously 0 
only 0 
been 0 
identified 0 
in 0 
individuals 0 
of 0 
self-reported 0 
Ashkenazi 0 
Jewish 0 
origins 0 
. 0 

In 0 
addition 0 
, 0 
in 0 
this 0 
family 0 
, 0 
there 0 
appears 0 
to 0 
be 0 
no 0 
relationship 0 
between 0 
the 0 
I1307K 0 
polymorphism 0 
and 0 
the 0 
presence 0 
or 0 
absence 0 
of 0 
cancer 1
. 0 
. 0 

Wilms 1
tumor 1
_NUM1 0 
and 0 
Dax-1 0 
modulate 0 
the 0 
orphan 0 
nuclear 0 
receptor 0 
SF-1 0 
in 0 
sex-specific 0 
gene 0 
expression 0 
. 0 

Products 0 
of 0 
steroidogenic 0 
factor 0 
_NUM1 0 
-LRB- 0 
SF-1 0 
-RRB- 0 
and 0 
Wilms 1
tumor 1
_NUM1 0 
-LRB- 0 
WT1 0 
-RRB- 0 
genes 0 
are 0 
essential 0 
for 0 
mammalian 0 
gonadogenesis 0 
prior 0 
to 0 
sexual 0 
differentiation 0 
. 0 

In 0 
males 0 
, 0 
SF-1 0 
participates 0 
in 0 
sexual 0 
development 0 
by 0 
regulating 0 
expression 0 
of 0 
the 0 
polypeptide 0 
hormone 0 
Mullerian 0 
inhibiting 0 
substance 0 
-LRB- 0 
MIS 0 
-RRB- 0 
. 0 

Here 0 
, 0 
we 0 
show 0 
that 0 
WT1 0 
- 0 
KTS 0 
isoforms 0 
associate 0 
and 0 
synergize 0 
with 0 
SF-1 0 
to 0 
promote 0 
MIS 0 
expression 0 
. 0 

In 0 
contrast 0 
, 0 
WT1 0 
missense 0 
mutations 0 
, 0 
associated 0 
with 0 
male 1
pseudohermaphroditism 1
in 0 
Denys-Drash 1
syndrome 1
, 0 
fail 0 
to 0 
synergize 0 
with 0 
SF-1 0 
. 0 

Additionally 0 
, 0 
the 0 
X-linked 0 
, 0 
candidate 0 
dosage-sensitive 0 
sex-reversal 0 
gene 0 
, 0 
Dax-1 0 
, 0 
antagonizes 0 
synergy 0 
between 0 
SF-1 0 
and 0 
WT1 0 
, 0 
most 0 
likely 0 
through 0 
a 0 
direct 0 
interaction 0 
with 0 
SF-1 0 
. 0 

We 0 
propose 0 
that 0 
WT1 0 
and 0 
Dax-1 0 
functionally 0 
oppose 0 
each 0 
other 0 
in 0 
testis 0 
development 0 
by 0 
modulating 0 
SF-1-mediated 0 
transactivation 0 
. 0 
. 0 

Ethnic 0 
differences 0 
in 0 
the 0 
HFE 0 
codon 0 
_NUM3 0 
-LRB- 0 
Cys 0 
/ 0 
Tyr 0 
-RRB- 0 
polymorphism 0 
. 0 

Recent 0 
studies 0 
have 0 
shown 0 
that 0 
hereditary 1
hemochromatosis 1
-LRB- 0 
HH 1
-RRB- 0 
is 0 
likely 0 
to 0 
be 0 
caused 0 
by 0 
homozygosity 0 
for 0 
a 0 
Cys282Tyr 0 
mutation 0 
in 0 
the 0 
HFE 0 
gene 0 
located 0 
_NUM1 0 
. 0 

_NUM1 0 
Mb 0 
telomeric 0 
to 0 
HLA-A 0 
. 0 

Population 0 
studies 0 
of 0 
this 0 
polymorphism 0 
are 0 
facilitated 0 
by 0 
the 0 
fact 0 
that 0 
the 0 
Cys282Tyr 0 
mutation 0 
creates 0 
a 0 
Rsal 0 
restriction 0 
site 0 
. 0 

We 0 
have 0 
studied 0 
the 0 
codon 0 
_NUM3 0 
-LRB- 0 
Cys 0 
/ 0 
Tyr 0 
-RRB- 0 
polymorphism 0 
in 0 
different 0 
ethnic 0 
groups 0 
. 0 

In 0 
agreement 0 
with 0 
previous 0 
observations 0 
the 0 
Tyr 0 
allele 0 
appeared 0 
to 0 
be 0 
rare 0 
or 0 
absent 0 
in 0 
Asiatic 0 
-LRB- 0 
Indian 0 
, 0 
Chinese 0 
-RRB- 0 
populations 0 
. 0 

The 0 
highest 0 
allele 0 
frequency 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
was 0 
found 0 
in 0 
Swedes 0 
. 0 

Saamis 0 
-LRB- 0 
_NUM1 0 
% 0 
-RRB- 0 
and 0 
Mordvinians 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
had 0 
significantly 0 
lower 0 
frequencies 0 
of 0 
the 0 
Tyr 0 
allele 0 
. 0 

Comparisons 0 
with 0 
allele 0 
frequencies 0 
based 0 
on 0 
prevalence 0 
estimates 0 
of 0 
HH 1
showed 0 
some 0 
disagreements 0 
with 0 
the 0 
RFLP 0 
data 0 
, 0 
particularly 0 
in 0 
Finns 0 
. 0 

The 0 
newly 0 
described 0 
HFE 0 
marker 0 
provides 0 
a 0 
new 0 
approach 0 
to 0 
the 0 
screening 0 
of 0 
HH 1
as 0 
well 0 
as 0 
studies 0 
of 0 
the 0 
relationship 0 
between 0 
the 0 
HFE 0 
Tyr 0 
allele 0 
and 0 
different 0 
disorders 0 
including 0 
cancer 1
Risk 0 
reversals 0 
in 0 
predictive 0 
testing 0 
for 0 
Huntington 1
disease 1
. 0 

The 0 
first 0 
predictive 0 
testing 0 
for 0 
Huntington 1
disease 1
-LRB- 0 
HD 1
-RRB- 0 
was 0 
based 0 
on 0 
analysis 0 
of 0 
linked 0 
polymorphic 0 
DNA 0 
markers 0 
to 0 
estimate 0 
the 0 
likelihood 0 
of 0 
inheriting 0 
the 0 
mutation 0 
for 0 
HD 1
. 0 

Limits 0 
to 0 
accuracy 0 
included 0 
recombination 0 
between 0 
the 0 
DNA 0 
markers 0 
and 0 
the 0 
mutation 0 
, 0 
pedigree 0 
structure 0 
, 0 
and 0 
whether 0 
DNA 0 
samples 0 
were 0 
available 0 
from 0 
family 0 
members 0 
. 0 

With 0 
direct 0 
tests 0 
for 0 
the 0 
HD 1
mutation 0 
, 0 
we 0 
have 0 
assessed 0 
the 0 
accuracy 0 
of 0 
results 0 
obtained 0 
by 0 
linkage 0 
approaches 0 
when 0 
requested 0 
to 0 
do 0 
so 0 
by 0 
the 0 
test 0 
individuals 0 
. 0 

For 0 
six 0 
such 0 
individuals 0 
, 0 
there 0 
was 0 
significant 0 
disparity 0 
between 0 
the 0 
tests 0 
. 0 

Three 0 
went 0 
from 0 
a 0 
decreased 0 
risk 0 
to 0 
an 0 
increased 0 
risk 0 
, 0 
while 0 
in 0 
another 0 
three 0 
the 0 
risk 0 
was 0 
decreased 0 
. 0 

Knowledge 0 
of 0 
the 0 
potential 0 
reasons 0 
for 0 
these 0 
changes 0 
in 0 
results 0 
and 0 
impact 0 
of 0 
these 0 
risk 0 
reversals 0 
on 0 
both 0 
patients 0 
and 0 
the 0 
counseling 0 
team 0 
can 0 
assist 0 
in 0 
the 0 
development 0 
of 0 
strategies 0 
for 0 
the 0 
prevention 0 
and 0 
, 0 
where 0 
necessary 0 
, 0 
management 0 
of 0 
a 0 
risk 0 
reversal 0 
in 0 
any 0 
predictive 0 
testing 0 
program 0 
. 0 
. 0 

Identification 0 
of 0 
three 0 
novel 0 
mutations 0 
and 0 
a 0 
high 0 
frequency 0 
of 0 
the 0 
Arg778Leu 0 
mutation 0 
in 0 
Korean 0 
patients 0 
with 0 
Wilson 1
disease 1
. 0 

Four 0 
mutations 0 
-- 0 
R778L 0 
, 0 
A874V 0 
, 0 
L1083F 0 
, 0 
and 0 
2304delC 0 
-- 0 
in 0 
the 0 
copper-transporting 0 
enzyme 0 
, 0 
P-type 0 
ATPase 0 
-LRB- 0 
ATP7B 0 
-RRB- 0 
, 0 
were 0 
identified 0 
in 0 
Korean 0 
Patients 0 
with 0 
Wilson 1
disease 1
. 0 

Arg778Leu 0 
, 0 
the 0 
most 0 
frequently 0 
reported 0 
mutation 0 
of 0 
this 0 
enzyme 0 
, 0 
was 0 
found 0 
in 0 
six 0 
of 0 
eight 0 
unrelated 0 
patients 0 
studied 0 
, 0 
an 0 
allele 0 
frequency 0 
of 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
, 0 
which 0 
is 0 
considerably 0 
higher 0 
than 0 
those 0 
in 0 
other 0 
Asian 0 
populations 0 
. 0 

The 0 
novel 0 
single 0 
nucleotide 0 
deletion 0 
, 0 
2304delC 0 
, 0 
was 0 
found 0 
in 0 
one 0 
patient 0 
. 0 

Since 0 
a 0 
mutation 0 
at 0 
cDNA 0 
nucleotide 0 
_NUM4 0 
-LRB- 0 
2302insC 0 
-RRB- 0 
had 0 
been 0 
previously 0 
described 0 
, 0 
this 0 
region 0 
of 0 
the 0 
ATP7B 0 
gene 0 
may 0 
be 0 
susceptible 0 
to 0 
gene 0 
rearrangements 0 
causing 0 
Wilson 1
disease 1
. 0 

Determination 0 
of 0 
the 0 
genomic 0 
structure 0 
of 0 
the 0 
COL4A4 0 
gene 0 
and 0 
of 0 
novel 0 
mutations 0 
causing 0 
autosomal 1
recessive 1
Alport 1
syndrome 1
. 0 

Autosomal 1
recessive 1
Alport 1
syndrome 1
is 0 
a 0 
progressive 0 
hematuric 1
glomerulonephritis 1
characterized 0 
by 0 
glomerular 1
basement 1
membrane 1
abnormalities 1
and 0 
associated 0 
with 0 
mutations 0 
in 0 
either 0 
the 0 
COL4A3 0 
or 0 
the 0 
COL4A4 0 
gene 0 
, 0 
which 0 
encode 0 
the 0 
alpha3 0 
and 0 
alpha4 0 
type 0 
IV 0 
collagen 0 
chains 0 
, 0 
respectively 0 
. 0 

To 0 
date 0 
, 0 
mutation 0 
screening 0 
in 0 
the 0 
two 0 
genes 0 
has 0 
been 0 
hampered 0 
by 0 
the 0 
lack 0 
of 0 
genomic 0 
structure 0 
information 0 
. 0 

We 0 
report 0 
here 0 
the 0 
complete 0 
characterization 0 
of 0 
the 0 
_NUM2 0 
exons 0 
of 0 
the 0 
COL4A4 0 
gene 0 
, 0 
a 0 
comprehensive 0 
gene 0 
screen 0 
, 0 
and 0 
the 0 
subsequent 0 
detection 0 
of 0 
_NUM2 0 
novel 0 
mutations 0 
in 0 
eight 0 
patients 0 
diagnosed 0 
with 0 
autosomal 1
recessive 1
Alport 1
syndrome 1
. 0 

Furthermore 0 
, 0 
we 0 
identified 0 
a 0 
glycine 0 
to 0 
alanine 0 
substitution 0 
in 0 
the 0 
collagenous 0 
domain 0 
that 0 
is 0 
apparently 0 
silent 0 
in 0 
the 0 
heterozygous 0 
carriers 0 
, 0 
in 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
of 0 
all 0 
control 0 
individuals 0 
, 0 
and 0 
in 0 
one 0 
control 0 
individual 0 
homozygous 0 
for 0 
this 0 
glycine 0 
substitution 0 
. 0 

There 0 
has 0 
been 0 
no 0 
previous 0 
finding 0 
of 0 
a 0 
glycine 0 
substitution 0 
that 0 
is 0 
not 0 
associated 0 
with 0 
any 0 
obvious 0 
phenotype 0 
in 0 
homozygous 0 
individuals 0 
. 0 

A 0 
gene 0 
encoding 0 
a 0 
transmembrane 0 
protein 0 
is 0 
mutated 0 
in 0 
patients 0 
with 0 
diabetes 1
mellitus 1
and 0 
optic 1
atrophy 1
-LRB- 0 
Wolfram 1
syndrome 1
-RRB- 0 
. 0 

Wolfram 1
syndrome 1
-LRB- 0 
WFS 1
; 0 
OMIM 0 
_NUM6 0 
-RRB- 0 
is 0 
an 0 
autosomal 1
recessive 1
neurodegenerative 1
disorder 1
defined 0 
by 0 
young-onset 0 
non-immune 0 
insulin-dependent 1
diabetes 1
mellitus 1
and 0 
progressive 0 
optic 1
atrophy 1
. 0 

Linkage 0 
to 0 
markers 0 
on 0 
chromosome 0 
4p 0 
was 0 
confirmed 0 
in 0 
five 0 
families 0 
. 0 

On 0 
the 0 
basis 0 
of 0 
meiotic 0 
recombinants 0 
and 0 
disease-associated 0 
haplotypes 0 
, 0 
the 0 
WFS 1
gene 0 
was 0 
localized 0 
to 0 
a 0 
BAC 0 
/ 0 
P1 0 
contig 0 
of 0 
less 0 
than 0 
_NUM3 0 
kb 0 
. 0 

Mutations 0 
in 0 
a 0 
novel 0 
gene 0 
-LRB- 0 
WFS1 0 
-RRB- 0 
encoding 0 
a 0 
putative 0 
transmembrane 0 
protein 0 
were 0 
found 0 
in 0 
all 0 
affected 0 
individuals 0 
in 0 
six 0 
WFS 1
families 0 
, 0 
and 0 
these 0 
mutations 0 
were 0 
associated 0 
with 0 
the 0 
disease 0 
phenotype 0 
. 0 

WFS1 0 
appears 0 
to 0 
function 0 
in 0 
survival 0 
of 0 
islet 0 
beta-cells 0 
and 0 
neurons 0 
. 0 
. 0 

Molecular 0 
defects 0 
leading 0 
to 0 
human 0 
complement 1
component 1
C6 1
deficiency 1
in 0 
an 0 
African-American 0 
family 0 
. 0 

Complement 1
component 1
C6 1
deficiency 1
-LRB- 0 
C6D 1
-RRB- 0 
was 0 
diagnosed 0 
in 0 
a 0 
16-year-old 0 
African-American 0 
male 0 
with 0 
meningococcal 1
meningitis 1
. 0 

The 0 
patients 0 
father 0 
and 0 
two 0 
brothers 0 
also 0 
had 0 
C6D 1
, 0 
but 0 
gave 0 
no 0 
history 0 
of 0 
meningitis 1
or 0 
other 0 
neisserial 1
infection 1
. 0 

By 0 
using 0 
exon-specific 0 
polymerase 0 
chain 0 
reaction 0 
-LRB- 0 
PCR 0 
-RRB- 0 
/ 0 
single-strand 0 
conformation 0 
polymorphism 0 
as 0 
a 0 
screening 0 
step 0 
and 0 
nucleotide 0 
sequencing 0 
of 0 
target 0 
exons 0 
, 0 
we 0 
determined 0 
that 0 
the 0 
proband 0 
was 0 
a 0 
compound 0 
heterozygote 0 
for 0 
two 0 
C6 0 
gene 0 
mutations 0 
. 0 

The 0 
first 0 
, 0 
1195delC 0 
located 0 
in 0 
exon 0 
_NUM1 0 
, 0 
is 0 
a 0 
novel 0 
mutation 0 
, 0 
while 0 
the 0 
second 0 
, 0 
1936delG 0 
in 0 
exon 0 
_NUM2 0 
, 0 
has 0 
been 0 
described 0 
before 0 
to 0 
cause 0 
C6D 1
in 0 
an 0 
unrelated 0 
African-American 0 
individual 0 
. 0 

Both 0 
mutations 0 
result 0 
in 0 
premature 0 
termination 0 
codons 0 
and 0 
C6 0 
null 0 
alleles 0 
. 0 

Allele-specific 0 
PCR 0 
indicated 0 
that 0 
the 0 
probands 0 
two 0 
brothers 0 
also 0 
inherited 0 
the 0 
1195delC 0 
mutation 0 
from 0 
their 0 
heterozygous 0 
mother 0 
and 0 
the 0 
1936delG 0 
mutation 0 
from 0 
their 0 
homozygous 0 
father 0 
. 0 
. 0 

Sperm 0 
DNA 0 
analysis 0 
in 0 
a 0 
Friedreich 1
ataxia 1
premutation 0 
carrier 0 
suggests 0 
both 0 
meiotic 0 
and 0 
mitotic 0 
expansion 0 
in 0 
the 0 
FRDA 1
gene 0 
. 0 

Friedreich 1
ataxia 1
is 0 
usually 0 
caused 0 
by 0 
an 0 
expansion 0 
of 0 
a 0 
_DS 0 
trinucleotide 0 
repeat 0 
in 0 
intron 0 
_NUM1 0 
of 0 
the 0 
FRDA 1
gene 0 
. 0 

Occasionally 0 
, 0 
a 0 
fully 0 
expanded 0 
allele 0 
has 0 
been 0 
found 0 
to 0 
arise 0 
from 0 
a 0 
premutation 0 
of 0 
_NUM3 0 
or 0 
less 0 
triplet 0 
repeats 0 
. 0 

We 0 
have 0 
examined 0 
the 0 
sperm 0 
DNA 0 
of 0 
a 0 
premutation 0 
carrier 0 
. 0 

This 0 
mans 0 
leucocyte 0 
DNA 0 
showed 0 
one 0 
normal 0 
allele 0 
and 0 
one 0 
allele 0 
of 0 
approximately 0 
_NUM3 0 
repeats 0 
. 0 

His 0 
sperm 0 
showed 0 
an 0 
expanded 0 
allele 0 
in 0 
a 0 
tight 0 
range 0 
centering 0 
on 0 
a 0 
size 0 
of 0 
approximately 0 
_NUM3 0 
trinucleotide 0 
repeats 0 
. 0 

His 0 
affected 0 
son 0 
has 0 
repeat 0 
sizes 0 
of 0 
_NUM4 0 
and 0 
_NUM3 0 
. 0 

These 0 
data 0 
suggest 0 
that 0 
expansion 0 
occurs 0 
in 0 
two 0 
stages 0 
, 0 
the 0 
first 0 
during 0 
meiosis 0 
followed 0 
by 0 
a 0 
second 0 
mitotic 0 
expansion 0 
. 0 

We 0 
also 0 
show 0 
that 0 
in 0 
all 0 
informative 0 
carrier 0 
father 0 
to 0 
affected 0 
child 0 
transmissions 0 
, 0 
with 0 
the 0 
notable 0 
exception 0 
of 0 
the 0 
premutation 0 
carrier 0 
, 0 
the 0 
expansion 0 
size 0 
decreases 0 
. 0 
. 0 

Eye 1
movement 1
abnormalities 1
correlate 0 
with 0 
genotype 0 
in 0 
autosomal 0 
dominant 0 
cerebellar 1
ataxia 1
type 1
I 1
. 0 

We 0 
compared 0 
horizontal 0 
eye 0 
movements 0 
-LRB- 0 
visually 0 
guided 0 
saccades 0 
, 0 
antisaccades 0 
, 0 
and 0 
smooth 0 
pursuit 0 
-RRB- 0 
in 0 
control 0 
subjects 0 
-LRB- 0 
n 0 
= 0 
_NUM2 0 
-RRB- 0 
and 0 
patients 0 
with 0 
three 0 
forms 0 
of 0 
autosomal 0 
dominant 0 
cerebellar 1
ataxias 1
type 1
I 1
spinocerebellar 1
ataxias 1
_NUM1 1
and 1
_NUM1 1
-LRB- 0 
SCA1 1
, 0 
n 0 
= 0 
_NUM2 0 
; 0 
SCA2 1
, 0 
n 0 
= 0 
_NUM2 0 
-RRB- 0 
and 0 
SCA3 1
/ 0 
Machado-Joseph 1
disease 1
-LRB- 0 
MJD 1
-RRB- 0 
-LRB- 0 
n 0 
= 0 
_NUM2 0 
-RRB- 0 
. 0 

In 0 
SCA1 1
, 0 
saccade 0 
amplitude 0 
was 0 
significantly 0 
increased 0 
, 0 
resulting 0 
in 0 
hypermetria 1
. 0 

The 0 
smooth 0 
pursuit 0 
gain 0 
was 0 
decreased 0 
. 0 

In 0 
SCA2 1
, 0 
saccade 0 
velocity 0 
was 0 
markedly 0 
decreased 0 
. 0 

The 0 
percentage 0 
of 0 
errors 0 
in 0 
antisaccades 0 
was 0 
greatly 0 
increased 0 
and 0 
was 0 
significantly 0 
correlated 0 
with 0 
age 0 
at 0 
disease 0 
onset 0 
. 0 

In 0 
addition 0 
, 0 
a 0 
correlation 0 
between 0 
smooth 0 
pursuit 0 
gain 0 
and 0 
the 0 
number 0 
of 0 
trinucleotide 0 
repeats 0 
was 0 
found 0 
. 0 

In 0 
SCA3 1
, 0 
gaze-evoked 1
nystagmus 1
was 0 
often 0 
present 0 
as 0 
was 0 
saccade 0 
hypometria 0 
and 0 
smooth 0 
pursuit 0 
gain 0 
was 0 
markedly 0 
decreased 0 
. 0 

Three 0 
major 0 
criteria 0 
, 0 
saccade 0 
amplitude 0 
, 0 
saccade 0 
velocity 0 
, 0 
and 0 
presence 0 
of 0 
gaze-evoked 1
nystagmus 1
, 0 
permitted 0 
the 0 
correct 0 
assignment 0 
of 0 
_NUM2 0 
% 0 
of 0 
the 0 
SCA1 1
, 0 
_NUM2 0 
% 0 
of 0 
the 0 
SCA2 1
, 0 
and 0 
_NUM2 0 
% 0 
of 0 
the 0 
patients 0 
with 0 
SCA3 1
to 0 
their 0 
genetically 0 
confirmed 0 
patient 0 
group 0 
and 0 
, 0 
therefore 0 
, 0 
may 0 
help 0 
orient 0 
diagnoses 0 
of 0 
SCA1 1
, 0 
SCA2 1
, 0 
and 0 
SCA3 1
at 0 
early 0 
clinical 0 
stages 0 
of 0 
the 0 
diseases 0 
. 0 
. 0 

Clustering 0 
of 0 
missense 0 
mutations 0 
in 0 
the 0 
ataxia-telangiectasia 1
gene 0 
in 0 
a 0 
sporadic 1
T-cell 1
leukaemia 1
. 0 

Ataxia-telangiectasia 1
-LRB- 0 
A-T 1
-RRB- 0 
is 0 
a 0 
recessive 1
multi-system 1
disorder 1
caused 0 
by 0 
mutations 0 
in 0 
the 0 
ATM 0 
gene 0 
at 0 
11q22-q23 0 
-LRB- 0 
ref 0 
. 0 

_NUM1 0 
-RRB- 0 
. 0 

The 0 
risk 0 
of 0 
cancer 1
, 0 
especially 0 
lymphoid 1
neoplasias 1
, 0 
is 0 
substantially 0 
elevated 0 
in 0 
A-T 1
patients 0 
and 0 
has 0 
long 0 
been 0 
associated 0 
with 0 
chromosomal 0 
instability 0 
. 0 

By 0 
analysing 0 
tumour 1
DNA 0 
from 0 
patients 0 
with 0 
sporadic 1
T-cell 1
prolymphocytic 1
leukaemia 1
-LRB- 0 
T-PLL 1
-RRB- 0 
, 0 
a 0 
rare 0 
clonal 1
malignancy 1
with 0 
similarities 0 
to 0 
a 0 
mature 1
T-cell 1
leukaemia 1
seen 0 
in 0 
A-T 1
, 0 
we 0 
demonstrate 0 
a 0 
high 0 
frequency 0 
of 0 
ATM 0 
mutations 0 
in 0 
T-PLL 1
. 0 

In 0 
marked 0 
contrast 0 
to 0 
the 0 
ATM 0 
mutation 0 
pattern 0 
in 0 
A-T 1
, 0 
the 0 
most 0 
frequent 0 
nucleotide 0 
changes 0 
in 0 
this 0 
leukaemia 1
were 0 
missense 0 
mutations 0 
. 0 

These 0 
clustered 0 
in 0 
the 0 
region 0 
corresponding 0 
to 0 
the 0 
kinase 0 
domain 0 
, 0 
which 0 
is 0 
highly 0 
conserved 0 
in 0 
ATM-related 0 
proteins 0 
in 0 
mouse 0 
, 0 
yeast 0 
and 0 
Drosophila 0 
. 0 

The 0 
resulting 0 
amino-acid 0 
substitutions 0 
are 0 
predicted 0 
to 0 
interfere 0 
with 0 
ATP 0 
binding 0 
or 0 
substrate 0 
recognition 0 
. 0 

Two 0 
of 0 
seventeen 0 
mutated 0 
T-PLL 1
samples 0 
had 0 
a 0 
previously 0 
reported 0 
A-T 1
allele 0 
. 0 

In 0 
contrast 0 
, 0 
no 0 
mutations 0 
were 0 
detected 0 
in 0 
the 0 
_AN 0 
gene 0 
, 0 
suggesting 0 
that 0 
this 0 
tumour 1
suppressor 0 
is 0 
not 0 
frequently 0 
altered 0 
in 0 
this 0 
leukaemia 1
. 0 

Occasional 0 
missense 0 
mutations 0 
in 0 
ATM 0 
were 0 
also 0 
found 0 
in 0 
tumour 1
DNA 0 
from 0 
patients 0 
with 0 
B-cell 1
non-Hodgkins 1
lymphomas 1
-LRB- 0 
B-NHL 1
-RRB- 0 
and 0 
a 0 
B-NHL 1
cell 0 
line 0 
. 0 

The 0 
evidence 0 
of 0 
a 0 
significant 0 
proportion 0 
of 0 
loss-of-function 0 
mutations 0 
and 0 
a 0 
complete 0 
absence 0 
of 0 
the 0 
normal 0 
copy 0 
of 0 
ATM 0 
in 0 
the 0 
majority 0 
of 0 
mutated 0 
tumours 1
establishes 0 
somatic 0 
inactivation 0 
of 0 
this 0 
gene 0 
in 0 
the 0 
pathogenesis 0 
of 0 
sporadic 1
T-PLL 1
and 0 
suggests 0 
that 0 
ATM 0 
acts 0 
as 0 
a 0 
tumour 1
suppressor 0 
. 0 

As 0 
constitutional 0 
DNA 0 
was 0 
not 0 
available 0 
, 0 
a 0 
putative 0 
hereditary 0 
predisposition 0 
to 0 
T-PLL 1
will 0 
require 0 
further 0 
investigation 0 
. 0 
. 0 

Identification 0 
of 0 
a 0 
novel 0 
nonsense 0 
mutation 0 
and 0 
a 0 
missense 0 
substitution 0 
in 0 
the 0 
vasopressin-neurophysin 0 
II 0 
gene 0 
in 0 
two 0 
Spanish 0 
kindreds 0 
with 0 
familial 1
neurohypophyseal 1
diabetes 1
insipidus 1
. 0 

Familial 1
neurohypophyseal 1
diabetes 1
insipidus 1
-LRB- 0 
FNDI 1
-RRB- 0 
is 0 
an 0 
autosomal 1
dominant 1
disease 1
caused 0 
by 0 
deficiency 0 
in 0 
the 0 
antidiuretic 0 
hormone 0 
arginine 0 
vasopressin 0 
-LRB- 0 
AVP 0 
-RRB- 0 
encoded 0 
by 0 
the 0 
AVP-neurophysin 0 
II 0 
-LRB- 0 
AVP-NPII 0 
-RRB- 0 
gene 0 
on 0 
chromosome 0 
20p13 0 
. 0 

In 0 
this 0 
study 0 
, 0 
we 0 
analyzed 0 
two 0 
families 0 
with 0 
FNDI 1
using 0 
direct 0 
automated 0 
fluorescent 0 
, 0 
solid 0 
phase 0 
, 0 
single-stranded 0 
DNA 0 
sequencing 0 
of 0 
PCR-amplified 0 
AVP-NPII 0 
DNA 0 
. 0 

In 0 
one 0 
of 0 
the 0 
families 0 
, 0 
affected 0 
individuals 0 
presented 0 
a 0 
novel 0 
nonsense 0 
mutation 0 
in 0 
exon 0 
_NUM1 0 
of 0 
the 0 
gene 0 
, 0 
consisting 0 
in 0 
a 0 
G 0 
to 0 
T 0 
transition 0 
at 0 
nucleotide 0 
_NUM4 0 
, 0 
which 0 
produces 0 
a 0 
stop 0 
signal 0 
in 0 
codon 0 
_NUM2 0 
-LRB- 0 
Glu 0 
-RRB- 0 
of 0 
NPII 0 
. 0 

The 0 
premature 0 
termination 0 
eliminates 0 
part 0 
of 0 
the 0 
C-terminal 0 
domain 0 
of 0 
NPII 0 
, 0 
including 0 
a 0 
cysteine 0 
residue 0 
in 0 
position 0 
_NUM2 0 
, 0 
which 0 
could 0 
be 0 
involved 0 
in 0 
the 0 
correct 0 
folding 0 
of 0 
the 0 
prohormone 0 
. 0 

In 0 
the 0 
second 0 
family 0 
, 0 
a 0 
G279A 0 
substitution 0 
at 0 
position 0 
-1 0 
of 0 
the 0 
signal 0 
peptide 0 
was 0 
observed 0 
in 0 
all 0 
affected 0 
individuals 0 
. 0 

This 0 
missense 0 
mutation 0 
, 0 
which 0 
replaces 0 
Ala 0 
with 0 
Thr 0 
, 0 
is 0 
frequent 0 
among 0 
FNDI 1
patients 0 
and 0 
is 0 
thought 0 
to 0 
reduce 0 
the 0 
efficiency 0 
of 0 
cleavage 0 
by 0 
signal 0 
peptidases 0 
. 0 
. 0 

Cloning 0 
of 0 
a 0 
novel 0 
member 0 
of 0 
the 0 
low-density 0 
lipoprotein 0 
receptor 0 
family 0 
. 0 

A 0 
gene 0 
encoding 0 
a 0 
novel 0 
transmembrane 0 
protein 0 
was 0 
identified 0 
by 0 
DNA 0 
sequence 0 
analysis 0 
within 0 
the 0 
insulin-dependent 1
diabetes 1
mellitus 1
-LRB- 0 
IDDM 1
-RRB- 0 
locus 0 
IDDM4 0 
on 0 
chromosome 0 
11q13 0 
. 0 

Based 0 
on 0 
its 0 
chromosomal 0 
position 0 
, 0 
this 0 
gene 0 
is 0 
a 0 
candidate 0 
for 0 
conferring 0 
susceptibility 0 
to 0 
diabetes 1
. 0 

The 0 
gene 0 
, 0 
termed 0 
low-density 0 
lipoprotein 0 
receptor 0 
related 0 
protein 0 
_NUM1 0 
-LRB- 0 
LRP5 0 
-RRB- 0 
, 0 
encodes 0 
a 0 
protein 0 
of 0 
_NUM4 0 
amino 0 
acids 0 
that 0 
contains 0 
conserved 0 
modules 0 
which 0 
are 0 
characteristic 0 
of 0 
the 0 
low-density 0 
lipoprotein 0 
-LRB- 0 
LDL 0 
-RRB- 0 
receptor 0 
family 0 
. 0 

These 0 
modules 0 
include 0 
a 0 
putative 0 
signal 0 
peptide 0 
for 0 
protein 0 
export 0 
, 0 
four 0 
epidermal 0 
growth 0 
factor 0 
-LRB- 0 
EGF 0 
-RRB- 0 
repeats 0 
with 0 
associated 0 
spacer 0 
domains 0 
, 0 
three 0 
LDL-receptor 0 
-LRB- 0 
LDLR 0 
-RRB- 0 
repeats 0 
, 0 
a 0 
single 0 
transmembrane 0 
spanning 0 
domain 0 
, 0 
and 0 
a 0 
cytoplasmic 0 
domain 0 
. 0 

The 0 
encoded 0 
protein 0 
has 0 
a 0 
unique 0 
organization 0 
of 0 
EGF 0 
and 0 
LDLR 0 
repeats 0 
; 0 
therefore 0 
, 0 
LRP5 0 
likely 0 
represents 0 
a 0 
new 0 
category 0 
of 0 
the 0 
LDLR 0 
family 0 
. 0 

Both 0 
human 0 
and 0 
mouse 0 
LRP5 0 
cDNAs 0 
have 0 
been 0 
isolated 0 
and 0 
the 0 
encoded 0 
mature 0 
proteins 0 
are 0 
_NUM2 0 
% 0 
identical 0 
, 0 
indicating 0 
a 0 
high 0 
degree 0 
of 0 
evolutionary 0 
conservation 0 
. 0 
. 0 

ATM 0 
germline 0 
mutations 0 
in 0 
classical 0 
ataxia-telangiectasia 1
patients 0 
in 0 
the 0 
Dutch 0 
population 0 
. 0 

Germline 0 
mutations 0 
in 0 
the 0 
ATM 0 
gene 0 
are 0 
responsible 0 
for 0 
the 0 
autosomal 1
recessive 1
disorder 1
ataxia-telangiectasia 1
-LRB- 0 
A-T 1
-RRB- 0 
. 0 

In 0 
our 0 
study 0 
, 0 
we 0 
have 0 
determined 0 
the 0 
ATM 0 
mutation 0 
spectrum 0 
in 0 
_NUM2 0 
classical 0 
A-T 1
patients 0 
, 0 
including 0 
some 0 
immigrant 0 
populations 0 
, 0 
as 0 
well 0 
as 0 
_NUM2 0 
of 0 
Dutch 0 
ethnic 0 
origin 0 
. 0 

Both 0 
the 0 
protein 0 
truncation 0 
test 0 
-LRB- 0 
PTT 0 
-RRB- 0 
and 0 
the 0 
restriction 0 
endonuclease 0 
fingerprinting 0 
-LRB- 0 
REF 0 
-RRB- 0 
method 0 
were 0 
used 0 
and 0 
compared 0 
for 0 
their 0 
detection 0 
efficiency 0 
, 0 
identifying 0 
_NUM2 0 
% 0 
and 0 
_NUM2 0 
% 0 
of 0 
the 0 
mutations 0 
, 0 
respectively 0 
. 0 

Most 0 
patients 0 
were 0 
found 0 
to 0 
be 0 
compound 0 
heterozygote 0 
. 0 

Seventeen 0 
mutations 0 
were 0 
distinct 0 
, 0 
of 0 
which 0 
_NUM2 0 
were 0 
not 0 
reported 0 
previously 0 
. 0 

Mutations 0 
are 0 
small 0 
deletions 0 
or 0 
point 0 
mutations 0 
frequently 0 
affecting 0 
splice 0 
sites 0 
. 0 

Moreover 0 
, 0 
a 0 
_NUM2 0 
. 0 

7-kb 0 
genomic 0 
deletion 0 
of 0 
the 0 
_NUM1 0 
end 0 
of 0 
the 0 
gene 0 
, 0 
most 0 
likely 0 
a 0 
result 0 
of 0 
recombination 0 
between 0 
two 0 
LINE 0 
elements 0 
, 0 
was 0 
identified 0 
. 0 

The 0 
most 0 
frequently 0 
found 0 
mutation 0 
, 0 
identified 0 
in 0 
three 0 
unrelated 0 
Turkish 0 
A-T 1
individuals 0 
, 0 
was 0 
previously 0 
described 0 
to 0 
be 0 
a 0 
Turkish 0 
A-T 1
founder 0 
mutation 0 
. 0 

The 0 
presence 0 
of 0 
a 0 
founder 0 
mutation 0 
among 0 
relatively 0 
small 0 
ethnic 0 
population 0 
groups 0 
in 0 
Western 0 
Europe 0 
could 0 
indicate 0 
a 0 
high 0 
carrier 0 
frequency 0 
in 0 
such 0 
communities 0 
. 0 

In 0 
patients 0 
of 0 
Dutch 0 
ethnic 0 
origin 0 
, 0 
however 0 
, 0 
no 0 
significant 0 
founder 0 
effect 0 
could 0 
be 0 
identified 0 
. 0 

The 0 
observed 0 
genetic 0 
heterogeneity 0 
including 0 
the 0 
relative 0 
high 0 
percentage 0 
of 0 
splice-site 0 
mutations 0 
had 0 
no 0 
reflection 0 
on 0 
the 0 
phenotype 0 
. 0 

All 0 
patients 0 
manifested 0 
classical 0 
A-T 1
and 0 
increased 0 
cellular 0 
radioresistant 0 
DNA 0 
synthesis 0 
. 0 

Diagnosis 0 
of 0 
hemochromatosis 1
. 0 

If 0 
untreated 0 
, 0 
hemochromatosis 1
can 0 
cause 0 
serious 0 
illness 0 
and 0 
early 1
death 1
, 0 
but 0 
the 0 
disease 0 
is 0 
still 0 
substantially 0 
under-diagnosed 0 
. 0 

The 0 
cornerstone 0 
of 0 
screening 0 
and 0 
case 0 
detection 0 
is 0 
the 0 
measurement 0 
of 0 
serum 0 
transferrin 0 
saturation 0 
and 0 
the 0 
serum 0 
ferritin 0 
level 0 
. 0 

Once 0 
the 0 
diagnosis 0 
is 0 
suspected 0 
, 0 
physicians 0 
must 0 
use 0 
serum 0 
ferritin 0 
levels 0 
and 0 
hepatic 0 
iron 0
stores 0 
on 0 
liver 0 
biopsy 0 
specimens 0 
to 0 
assess 0 
patients 0 
for 0 
the 0 
presence 0 
of 0 
iron 1
overload 1
. 0 

Liver 0 
biopsy 0 
is 0 
also 0 
used 0 
to 0 
establish 0 
the 0 
presence 0 
or 0 
absence 0 
of 0 
cirrhosis 1
, 0 
which 0 
can 0 
affect 0 
prognosis 0 
and 0 
management 0 
. 0 

A 0 
DNA-based 0 
test 0 
for 0 
the 0 
HFE 0 
gene 0 
is 0 
commercially 0 
available 0 
, 0 
but 0 
its 0 
place 0 
in 0 
the 0 
diagnosis 0 
of 0 
hemochromatosis 1
is 0 
still 0 
being 0 
evaluated 0 
. 0 

Currently 0 
, 0 
the 0 
most 0 
useful 0 
role 0 
for 0 
this 0 
test 0 
is 0 
in 0 
the 0 
detection 0 
of 0 
hemochromatosis 1
in 0 
the 0 
family 0 
members 0 
of 0 
patients 0 
with 0 
a 0 
proven 0 
case 0 
of 0 
the 0 
disease 0 
. 0 

It 0 
is 0 
crucial 0 
to 0 
diagnose 0 
hemochromatosis 1
before 0 
hepatic 1
cirrhosis 1
develops 0 
because 0 
phlebotomy 0 
therapy 0 
can 0 
avert 0 
serious 0 
chronic 0 
disease 0 
and 0 
can 0 
even 0 
lead 0 
to 0 
normal 0 
life 0 
expectancy 0 
. 0 
. 0 

PAX6 0 
mutations 0 
reviewed 0 
. 0 

Mutations 0 
in 0 
PAX6 0 
are 0 
responsible 0 
for 0 
human 0 
aniridia 1
and 0 
have 0 
also 0 
been 0 
found 0 
in 0 
patients 0 
with 0 
Peters 1
anomaly 1
, 0 
with 0 
congenital 1
cataracts 1
, 0 
with 0 
autosomal 1
dominant 1
keratitis 1
, 0 
and 0 
with 0 
isolated 1
foveal 1
hypoplasia 1
. 0 

No 0 
locus 0 
other 0 
than 0 
chromosome 0 
11p13 0 
has 0 
been 0 
implicated 0 
in 0 
aniridia 1
, 0 
and 0 
PAX6 0 
is 0 
clearly 0 
the 0 
major 0 
, 0 
if 0 
not 0 
only 0 
, 0 
gene 0 
responsible 0 
. 0 

Twenty-eight 0 
percent 0 
of 0 
identified 0 
PAX6 0 
mutations 0 
are 0 
C-T 0 
changes 0 
at 0 
CpG 0 
dinucleotides 0 
, 0 
_NUM2 0 
% 0 
are 0 
splicing 0 
errors 0 
, 0 
and 0 
more 0 
than 0 
_NUM2 0 
% 0 
are 0 
deletion 0 
or 0 
insertion 0 
events 0 
. 0 

There 0 
is 0 
a 0 
noticeably 0 
elevated 0 
level 0 
of 0 
mutation 0 
in 0 
the 0 
paired 0 
domain 0 
compared 0 
with 0 
the 0 
rest 0 
of 0 
the 0 
gene 0 
. 0 

Increased 0 
mutation 0 
in 0 
the 0 
homeodomain 0 
is 0 
accounted 0 
for 0 
by 0 
the 0 
hypermutable 0 
CpG 0 
dinucleotide 0 
in 0 
codon 0 
_NUM3 0 
. 0 

Very 0 
nearly 0 
all 0 
mutations 0 
appear 0 
to 0 
cause 0 
loss 0 
of 0 
function 0 
of 0 
the 0 
mutant 0 
allele 0 
, 0 
and 0 
more 0 
than 0 
_NUM2 0 
% 0 
of 0 
exonic 0 
substitutions 0 
result 0 
in 0 
nonsense 0 
codons 0 
. 0 

In 0 
a 0 
gene 0 
with 0 
such 0 
extraordinarily 0 
high 0 
sequence 0 
conservation 0 
throughout 0 
evolution 0 
, 0 
there 0 
are 0 
presumed 0 
undiscovered 0 
missense 0 
mutations 0 
, 0 
these 0 
are 0 
hypothesized 0 
to 0 
exist 0 
in 0 
as-yet 0 
unidentified 0 
phenotypes 0 
. 0 
. 0 

Schwartz-Jampel 1
syndrome 1
type 1
_NUM1 1
and 0 
Stuve-Wiedemann 1
syndrome 1
: 0 
a 0 
case 0 
for 0 
`` 0 
lumping 0 
'' 0 
. 0 

Recent 0 
studies 0 
demonstrated 0 
the 0 
existence 0 
of 0 
a 0 
genetically 0 
distinct 0 
, 0 
usually 0 
lethal 0 
form 0 
of 0 
the 0 
Schwartz-Jampel 1
syndrome 1
-LRB- 0 
SJS 1
-RRB- 0 
of 0 
myotonia 1
and 0 
skeletal 1
dysplasia 1
, 0 
which 0 
we 0 
called 0 
SJS 1
type 1
_NUM1 1
. 0 

This 0 
disorder 0 
is 0 
reminiscent 0 
of 0 
another 0 
rare 0 
condition 0 
, 0 
the 0 
Stuve-Wiedemann 1
syndrome 1
-LRB- 0 
SWS 1
-RRB- 0 
, 0 
which 0 
comprises 0 
campomelia 1
at 0 
birth 0 
with 0 
skeletal 1
dysplasia 1
, 0 
contractures 1
, 0 
and 0 
early 1
death 1
. 0 

To 0 
test 0 
for 0 
possible 0 
nosologic 0 
identity 0 
between 0 
these 0 
disorders 0 
, 0 
we 0 
reviewed 0 
the 0 
literature 0 
and 0 
obtained 0 
a 0 
follow-up 0 
of 0 
the 0 
only 0 
two 0 
surviving 0 
patients 0 
, 0 
one 0 
with 0 
SJS 1
type 1
_NUM1 1
at 0 
age 0 
_NUM2 0 
years 0 
and 0 
another 0 
with 0 
SWS 1
at 0 
age 0 
_NUM1 0 
years 0 
. 0 

Patients 0 
reported 0 
as 0 
having 0 
either 0 
neonatal 0 
SJS 1
or 0 
SWS 1
presented 0 
a 0 
combination 0 
of 0 
a 0 
severe 0 
, 0 
prenatal-onset 0 
neuromuscular 1
disorder 1
-LRB- 0 
with 0 
congenital 1
joint 1
contractures 1
, 0 
respiratory 0 
and 0 
feeding 0 
difficulties 0 
, 0 
tendency 0 
to 0 
hyperthermia 1
, 0 
and 0 
frequent 0 
death 0 
in 0 
infancy 0 
-RRB- 0 
with 0 
a 0 
distinct 0 
campomelic-metaphyseal 1
skeletal 1
dysplasia 1
. 0 

The 0 
similarity 0 
of 0 
the 0 
clinical 0 
and 0 
radiographic 0 
findings 0 
is 0 
so 0 
extensive 0 
that 0 
these 0 
disorders 0 
appear 0 
to 0 
be 0 
a 0 
single 0 
entity 0 
. 0 

The 0 
follow-up 0 
observation 0 
of 0 
an 0 
identical 0 
and 0 
unique 0 
pattern 0 
of 0 
progressive 0 
bone 1
dysplasia 1
in 0 
the 0 
two 0 
patients 0 
-LRB- 0 
one 0 
with 0 
SJS 1
type 1
_NUM1 1
, 0 
one 0 
with 0 
SWS 1
-RRB- 0 
surviving 0 
beyond 0 
infancy 0 
adds 0 
to 0 
the 0 
evidence 0 
in 0 
favor 0 
of 0 
identity 0 
. 0 

The 0 
hypothesis 0 
that 0 
SWS 1
and 0 
SJS 1
type 1
_NUM1 1
are 0 
the 0 
same 0 
disorder 0 
should 0 
be 0 
testable 0 
by 0 
molecular 0 
methods 0 
. 0 
. 0 

The 0 
185delAG 0 
BRCA1 0 
mutation 0 
originated 0 
before 0 
the 0 
dispersion 0 
of 0 
Jews 0 
in 0 
the 0 
diaspora 0 
and 0 
is 0 
not 0 
limited 0 
to 0 
Ashkenazim 0 
. 0 

The 0 
185delAG 0 
mutation 0 
in 0 
BRCA1 0 
is 0 
detected 0 
in 0 
Ashkenazi 0 
Jews 0 
both 0 
in 0 
familial 1
breast 1
and 1
ovarian 1
cancer 1
and 0 
in 0 
the 0 
general 0 
population 0 
. 0 

All 0 
tested 0 
Ashkenazi 0 
mutation 0 
carriers 0 
share 0 
the 0 
same 0 
allelic 0 
pattern 0 
at 0 
the 0 
BRCA1 0 
locus 0 
. 0 

Our 0 
previous 0 
study 0 
showed 0 
that 0 
this 0 
Ashkenazi 0 
mutation 0 
also 0 
occurs 0 
in 0 
Iraqi 0 
Jews 0 
with 0 
a 0 
similar 0 
allelic 0 
pattern 0 
. 0 

We 0 
extended 0 
our 0 
analysis 0 
to 0 
other 0 
non-Ashkenazi 0 
subsets 0 
_NUM3 0 
of 0 
Moroccan 0 
origin 0 
, 0 
_NUM3 0 
Yemenites 0 
and 0 
_NUM3 0 
Iranian 0 
Jews 0 
. 0 

Heteroduplex 0 
analysis 0 
complemented 0 
by 0 
direct 0 
DNA 0 
sequencing 0 
of 0 
abnormally 0 
migrating 0 
bands 0 
were 0 
employed 0 
. 0 

Four 0 
of 0 
Moroccan 0 
origin 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
and 0 
none 0 
of 0 
the 0 
Yemenites 0 
or 0 
Iranians 0 
was 0 
a 0 
carrier 0 
of 0 
the 0 
185delAG 0 
mutation 0 
. 0 

BRCA1 0 
allelic 0 
patterns 0 
were 0 
determined 0 
for 0 
four 0 
of 0 
these 0 
individuals 0 
and 0 
for 0 
_NUM2 0 
additional 0 
non-Ashkenazi 0 
185delAG 0 
mutation 0 
carriers 0 
who 0 
had 0 
breast 1
/ 1
ovarian 1
cancer 1
. 0 

Six 0 
non-Ashkenazi 0 
individuals 0 
shared 0 
the 0 
common 0 
Ashkenazi 0 
haplotype 0 
, 0 
four 0 
had 0 
a 0 
closely 0 
related 0 
pattern 0 
, 0 
and 0 
the 0 
rest 0 
-LRB- 0 
n 0 
= 0 
_NUM1 0 
-RRB- 0 
displayed 0 
a 0 
distinct 0 
BRCA1 0 
allelic 0 
pattern 0 
. 0 

We 0 
conclude 0 
that 0 
the 0 
185delAG 0 
BRCA1 0 
mutation 0 
occurs 0 
in 0 
some 0 
non-Ashkenazi 0 
populations 0 
at 0 
rates 0 
comparable 0 
with 0 
that 0 
of 0 
Ashkenazim 0 
. 0 

The 0 
majority 0 
of 0 
Jewish 0 
185delAG 0 
mutation 0 
carriers 0 
have 0 
a 0 
common 0 
allelic 0 
pattern 0 
, 0 
supporting 0 
the 0 
founder 0 
effect 0 
notion 0 
, 0 
but 0 
dating 0 
the 0 
mutations 0 
origin 0 
to 0 
an 0 
earlier 0 
date 0 
than 0 
currently 0 
estimated 0 
. 0 

However 0 
, 0 
the 0 
different 0 
allelic 0 
pattern 0 
at 0 
the 0 
BRCA1 0 
locus 0 
even 0 
in 0 
some 0 
Jewish 0 
mutation 0 
carriers 0 
, 0 
might 0 
suggest 0 
that 0 
the 0 
mutation 0 
arose 0 
independently 0 
. 0 
. 0 

The 0 
RB1 0 
gene 0 
mutation 0 
in 0 
a 0 
child 0 
with 0 
ectopic 1
intracranial 1
retinoblastoma 1
. 0 

The 0 
RB1 0 
gene 0 
mutation 0 
was 0 
investigated 0 
in 0 
a 0 
child 0 
with 0 
ectopic 1
intracranial 1
retinoblastoma 1
using 0 
DNA 0 
obtained 0 
from 0 
both 0 
the 0 
pineal 1
and 1
retinal 1
tumours 1
of 0 
the 0 
patient 0 
. 0 

A 0 
nonsense 0 
mutation 0 
in 0 
exon 0 
_NUM2 0 
-LRB- 0 
codon 0 
_NUM3 0 
-RRB- 0 
of 0 
the 0 
RB1 0 
gene 0 
was 0 
found 0 
to 0 
be 0 
present 0 
homozygously 0 
in 0 
both 0 
the 0 
retinal 1
and 1
the 1
pineal 1
tumours 1
. 0 

The 0 
same 0 
mutation 0 
was 0 
present 0 
heterozygously 0 
in 0 
the 0 
DNA 0 
from 0 
the 0 
constitutional 0 
cells 0 
of 0 
the 0 
patient 0 
, 0 
proving 0 
it 0 
to 0 
be 0 
of 0 
germline 0 
origin 0 
. 0 

The 0 
initial 0 
mutation 0 
was 0 
shown 0 
to 0 
have 0 
occurred 0 
in 0 
the 0 
paternally 0 
derived 0 
RB1 0 
allele 0 
. 0 

The 0 
mutation 0 
is 0 
in 0 
an 0 
area 0 
of 0 
the 0 
gene 0 
that 0 
encodes 0 
the 0 
protein-binding 0 
region 0 
known 0 
as 0 
the 0 
pocket 0 
region 0 
and 0 
has 0 
been 0 
detected 0 
in 0 
other 0 
cases 0 
of 0 
retinoblastoma 1
. 0 
. 0 

Genomic 0 
structure 0 
of 0 
the 0 
human 0 
congenital 1
chloride 1
diarrhea 1
-LRB- 0 
CLD 1
-RRB- 0 
gene 0 
. 0 

Congenital 1
chloride 1
diarrhea 1
-LRB- 0 
CLD 1
-RRB- 0 
is 0 
caused 0 
by 0 
mutations 0 
in 0 
a 0 
gene 0 
which 0 
encodes 0 
an 0 
intestinal 0 
anion 0 
transporter 0 
. 0 

We 0 
report 0 
here 0 
the 0 
complete 0 
genomic 0 
organization 0 
of 0 
the 0 
human 0 
CLD 1
gene 0 
which 0 
spans 0 
approximately 0 
39kb 0 
, 0 
and 0 
comprises 0 
_NUM2 0 
exons 0 
. 0 

All 0 
exon 0 
/ 0 
intron 0 
boundaries 0 
conform 0 
to 0 
the 0 
GT 0 
/ 0 
AG 0 
rule 0 
. 0 

An 0 
analysis 0 
of 0 
the 0 
putative 0 
promoter 0 
region 0 
sequence 0 
shows 0 
a 0 
putative 0 
_DS 0 
box 0 
and 0 
predicts 0 
multiple 0 
transcription 0 
factor 0 
binding 0 
sites 0 
. 0 

The 0 
genomic 0 
structure 0 
was 0 
determined 0 
using 0 
DNA 0 
from 0 
several 0 
sources 0 
including 0 
multiple 0 
large-insert 0 
libaries 0 
and 0 
genomic 0 
DNA 0 
from 0 
Finnish 0 
CLD 1
patients 0 
and 0 
controls 0 
. 0 

Exon-specific 0 
primers 0 
developed 0 
in 0 
this 0 
study 0 
will 0 
facilitate 0 
mutation 0 
screening 0 
studies 0 
of 0 
patients 0 
with 0 
the 0 
disease 0 
. 0 

Genomic 0 
sequencing 0 
of 0 
a 0 
BAC 0 
clone 0 
H_RG364P16 0 
revealed 0 
the 0 
presence 0 
of 0 
another 0 
, 0 
highly 0 
homologous 0 
gene 0 
_NUM1 0 
of 0 
the 0 
CLD 1
gene 0 
, 0 
with 0 
a 0 
similar 0 
genomic 0 
structure 0 
, 0 
recently 0 
identified 0 
as 0 
the 0 
Pendred 1
syndrome 1
gene 0 
-LRB- 0 
PDS 1
-RRB- 0 
. 0 
. 0 

Mutation 0 
analysis 0 
of 0 
UBE3A 0 
in 0 
Angelman 1
syndrome 1
patients 0 
. 0 

Angelman 1
syndrome 1
-LRB- 0 
AS 1
-RRB- 0 
is 0 
caused 0 
by 0 
chromosome 0 
15q11-q13 0 
deletions 0 
of 0 
maternal 0 
origin 0 
, 0 
by 0 
paternal 0 
uniparental 1
disomy 1
-LRB- 0 
UPD 1
-RRB- 0 
_NUM2 0 
, 0 
by 0 
imprinting 0 
defects 0 
, 0 
and 0 
by 0 
mutations 0 
in 0 
the 0 
UBE3A 0 
gene 0 
. 0 

UBE3A 0 
encodes 0 
a 0 
ubiquitin-protein 0 
ligase 0 
and 0 
shows 0 
brain-specific 0 
imprinting 0 
. 0 

Here 0 
we 0 
describe 0 
UBE3A 0 
coding-region 0 
mutations 0 
detected 0 
by 0 
SSCP 0 
analysis 0 
in 0 
_NUM2 0 
AS 1
individuals 0 
or 0 
families 0 
. 0 

Two 0 
identical 0 
de 0 
novo 0 
5-bp 0 
duplications 0 
in 0 
exon 0 
_NUM2 0 
were 0 
found 0 
. 0 

Among 0 
the 0 
other 0 
_NUM2 0 
unique 0 
mutations 0 
, 0 
_NUM1 0 
were 0 
small 0 
deletions 0 
or 0 
insertions 0 
predicted 0 
to 0 
cause 0 
frameshifts 0 
, 0 
_NUM1 0 
was 0 
a 0 
mutation 0 
to 0 
a 0 
stop 0 
codon 0 
, 0 
_NUM1 0 
was 0 
a 0 
missense 0 
mutation 0 
, 0 
and 0 
_NUM1 0 
was 0 
predicted 0 
to 0 
cause 0 
insertion 0 
of 0 
an 0 
isoleucine 0 
in 0 
the 0 
hect 0 
domain 0 
of 0 
the 0 
UBE3A 0 
protein 0 
, 0 
which 0 
functions 0 
in 0 
E2 0 
binding 0 
and 0 
ubiquitin 0 
transfer 0 
. 0 

Eight 0 
of 0 
the 0 
cases 0 
were 0 
familial 0 
, 0 
and 0 
five 0 
were 0 
sporadic 0 
. 0 

In 0 
two 0 
familial 0 
cases 0 
and 0 
one 0 
sporadic 0 
case 0 
, 0 
mosaicism 0 
for 0 
UBE3A 0 
mutations 0 
was 0 
detected 0 
in 0 
the 0 
mother 0 
of 0 
three 0 
AS 1
sons 0 
, 0 
in 0 
the 0 
maternal 0 
grandfather 0 
of 0 
two 0 
AS 1
first 0 
cousins 0 
, 0 
and 0 
in 0 
the 0 
mother 0 
of 0 
an 0 
AS 1
daughter 0 
. 0 

The 0 
frequencies 0 
with 0 
which 0 
we 0 
detected 0 
mutations 0 
were 0 
_NUM1 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
of 0 
_NUM2 0 
in 0 
sporadic 0 
cases 0 
and 0 
_NUM1 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
of 0 
_NUM2 0 
in 0 
familial 0 
cases 0 
. 0 
. 0 

Autosomal 1
dominant 1
neurohypophyseal 1
diabetes 1
insipidus 1
associated 0 
with 0 
a 0 
missense 0 
mutation 0 
encoding 0 
Gly23 0 
-- 0 
> 0 
Val 0 
in 0 
neurophysin 0 
II 0 
. 0 

Autosomal 1
dominant 1
neurohypophyseal 1
diabetes 1
insipidus 1
-LRB- 0 
ADNDI 1
-RRB- 0 
is 0 
an 0 
inherited 1
disease 1
caused 0 
by 0 
progressive 0 
degeneration 0 
of 0 
the 0 
magnocellular 0 
neurons 0 
of 0 
the 0 
hypothalamus 0 
leading 0 
to 0 
decreased 0 
ability 0 
to 0 
produce 0 
the 0 
hormone 0 
arginine 0 
vasopressin 0 
-LRB- 0 
AVP 0 
-RRB- 0 
. 0 

Affected 0 
individuals 0 
are 0 
not 0 
symptomatic 0 
at 0 
birth 0 
, 0 
but 0 
usually 0 
develop 0 
diabetes 1
insipidus 1
at 0 
1-6 0 
yr 0 
of 0 
age 0 
. 0 

The 0 
genetic 0 
locus 0 
of 0 
the 0 
disease 0 
is 0 
the 0 
AVP-neurophysin 0 
II 0 
-LRB- 0 
NPII 0 
-RRB- 0 
gene 0 
, 0 
and 0 
mutations 0 
that 0 
cause 0 
ADNDI 1
have 0 
been 0 
found 0 
in 0 
both 0 
the 0 
signal 0 
peptide 0 
of 0 
the 0 
prepro-AVP-NPII 0 
precursor 0 
and 0 
within 0 
NPII 0 
itself 0 
. 0 

An 0 
affected 0 
girl 0 
who 0 
presented 0 
at 0 
_NUM1 0 
months 0 
of 0 
age 0 
and 0 
her 0 
similarly 0 
affected 0 
younger 0 
brother 0 
and 0 
father 0 
were 0 
all 0 
found 0 
to 0 
have 0 
a 0 
novel 0 
missense 0 
mutation 0 
-LRB- 0 
_AN 0 
-- 0 
> 0 
T 0 
-RRB- 0 
encoding 0 
the 0 
amino 0 
acid 0 
substitution 0 
Gly23 0 
-- 0 
> 0 
Val 0 
within 0 
NPII 0 
. 0 

The 0 
mutation 0 
was 0 
confirmed 0 
by 0 
restriction 0 
endonuclease 0 
analysis 0 
. 0 

A 0 
T1-weighted 0 
magnetic 0 
resonance 0 
imaging 0 
of 0 
the 0 
fathers 0 
pituitary 0 
gland 0 
demonstrates 0 
an 0 
attenuated 0 
posterior 0 
pituitary 0 
bright 0 
spot 0 
. 0 

This 0 
mutation 0 
may 0 
be 0 
valuable 0 
for 0 
developing 0 
models 0 
of 0 
dominantly 1
inherited 1
neurodegeneration 1
, 0 
as 0 
the 0 
early 0 
age 0 
of 0 
onset 0 
of 0 
symptoms 0 
suggests 0 
that 0 
this 0 
mutation 0 
may 0 
be 0 
particularly 0 
deleterious 0 
to 0 
the 0 
magnocellular 0 
neuron 0 
. 0 
. 0 

Reversal 0 
of 0 
severe 0 
hypertrophic 1
cardiomyopathy 1
and 0 
excellent 0 
neuropsychologic 0 
outcome 0 
in 0 
very-long-chain 1
acyl-coenzyme 1
A 1
dehydrogenase 1
deficiency 1
. 0 

Very-long-chain 1
acyl-coenzyme 1
A 1
dehydrogenase 1
-LRB- 1
VLCAD 1
-RRB- 1
deficiency 1
is 0 
a 0 
disorder 0 
of 0 
fatty 0 
acid 0 
beta 0 
oxidation 0 
that 0 
reportedly 0 
has 0 
high 0 
rates 0 
of 0 
morbidity 0 
and 0 
mortality 0 
. 0 

We 0 
describe 0 
the 0 
outcome 0 
of 0 
a 0 
5-year-old 0 
girl 0 
with 0 
VLCAD 1
deficiency 1
who 0 
was 0 
first 0 
seen 0 
at 0 
_NUM1 0 
months 0 
of 0 
age 0 
with 0 
severe 0 
hypertrophic 1
cardiomyopathy 1
, 0 
hepatomegaly 1
, 0 
encephalopathy 1
, 0 
and 0 
hypotonia 1
. 0 

Biochemical 0 
studies 0 
indicated 0 
VLCAD 1
deficiency 1
caused 0 
by 0 
a 0 
stable 0 
yet 0 
inactive 0 
enzyme 0 
. 0 

Molecular 0 
genetic 0 
analysis 0 
of 0 
her 0 
VLCAD 0
gene 0 
revealed 0 
a 0 
T1372C 0 
-LRB- 0 
F458L 0 
-RRB- 0 
missense 0 
mutation 0 
and 0 
a 0 
_NUM4 0 
_DS 0 
_NUM4 0 
splice 0 
site 0 
mutation 0 
. 0 

After 0 
initial 0 
treatment 0 
with 0 
intravenous 0 
glucose 0 
and 0 
carnitine 0 
, 0 
the 0 
patient 0 
has 0 
thrived 0 
on 0 
a 0 
low-fat 0 
diet 0 
supplemented 0 
with 0 
medium-chain 0 
triglyceride 0 
oil 0 
and 0 
carnitine 0 
and 0 
avoidance 0 
of 0 
fasting 0 
. 0 

Her 0 
ventricular 0 
hypertrophy 0 
resolved 0 
significantly 0 
over 0 
_NUM1 0 
year 0 
, 0 
and 0 
cognitively 0 
, 0 
she 0 
is 0 
in 0 
the 0 
superior 0 
range 0 
for 0 
age 0 
. 0 

Clinical 0 
recognition 0 
of 0 
VLCAD 1
deficiency 1
is 0 
important 0 
because 0 
it 0 
is 0 
one 0 
of 0 
the 0 
few 0 
directly 0 
treatable 0 
causes 0 
of 0 
cardiomyopathy 1
in 0 
children 0 
. 0 
. 0 

Mutations 0 
of 0 
the 0 
ATM 0 
gene 0 
detected 0 
in 0 
Japanese 0 
ataxia-telangiectasia 1
patients 0 
: 0 
possible 0 
preponderance 0 
of 0 
the 0 
two 0 
founder 0 
mutations 0 
4612del165 0 
and 0 
7883del5 0 
. 0 

The 0 
ATM 0 
-LRB- 0 
A-T 0 
, 0 
mutated 0 
-RRB- 0 
gene 0 
on 0 
human 0 
chromosome 0 
11q22 0 
. 0 

_NUM1 0 
has 0 
recently 0 
been 0 
identified 0 
as 0 
the 0 
gene 0 
responsible 0 
for 0 
the 0 
human 0 
recessive 1
disease 1
ataxia-telangiectasia 1
-LRB- 0 
A-T 1
-RRB- 0 
. 0 

In 0 
order 0 
to 0 
define 0 
the 0 
types 0 
of 0 
disease-causing 0 
ATM 0 
mutations 0 
in 0 
Japanese 0 
A-T 1
patients 0 
as 0 
well 0 
as 0 
to 0 
look 0 
for 0 
possible 0 
mutational 0 
hotspots 0 
, 0 
reverse-transcribed 0 
RNA 0 
derived 0 
from 0 
ten 0 
patients 0 
belonging 0 
to 0 
eight 0 
unrelated 0 
Japanese 0 
A-T 1
families 0 
was 0 
analyzed 0 
for 0 
mutations 0 
by 0 
the 0 
restriction 0 
endonuclease 0 
fingerprinting 0 
method 0 
. 0 

As 0 
has 0 
been 0 
reported 0 
by 0 
others 0 
, 0 
mutations 0 
that 0 
lead 0 
to 0 
exon 0 
skipping 0 
or 0 
premature 0 
protein 0 
truncation 0 
were 0 
also 0 
predominant 0 
in 0 
our 0 
mutants 0 
. 0 

Six 0 
different 0 
mutations 0 
were 0 
identified 0 
on 0 
_NUM2 0 
of 0 
the 0 
_NUM2 0 
alleles 0 
examined 0 
. 0 

Four 0 
were 0 
deletions 0 
involving 0 
a 0 
loss 0 
of 0 
a 0 
single 0 
exon 0 
exon 0 
_NUM1 0 
, 0 
exon 0 
_NUM2 0 
, 0 
exon 0 
_NUM2 0 
or 0 
exon 0 
_NUM2 0 
. 0 

The 0 
others 0 
were 0 
minute 0 
deletions 0 
, 0 
4649delA 0 
in 0 
exon 0 
_NUM2 0 
and 0 
7883del5 0 
in 0 
exon 0 
_NUM2 0 
. 0 

The 0 
mutations 0 
4612del165 0 
and 0 
7883del5 0 
were 0 
found 0 
in 0 
more 0 
than 0 
two 0 
unrelated 0 
families 0 
; 0 
_NUM2 0 
% 0 
-LRB- 0 
_NUM1 0 
of 0 
_NUM2 0 
-RRB- 0 
of 0 
the 0 
mutant 0 
alleles 0 
had 0 
one 0 
of 0 
the 0 
two 0 
mutations 0 
. 0 

The 0 
4612del165 0 
mutations 0 
in 0 
three 0 
different 0 
families 0 
were 0 
all 0 
ascribed 0 
to 0 
the 0 
same 0 
T 0 
-- 0 
> 0 
A 0 
substitution 0 
at 0 
the 0 
splice 0 
donor 0 
site 0 
in 0 
intron 0 
_NUM2 0 
. 0 

Microsatellite 0 
genotyping 0 
around 0 
the 0 
ATM 0 
locus 0 
also 0 
indicated 0 
that 0 
a 0 
common 0 
haplotype 0 
was 0 
shared 0 
by 0 
the 0 
mutant 0 
alleles 0 
in 0 
both 0 
mutations 0 
. 0 

This 0 
suggests 0 
that 0 
these 0 
two 0 
founder 0 
mutations 0 
may 0 
be 0 
predominant 0 
among 0 
Japanese 0 
ATM 0 
mutant 0 
alleles 0 
. 0 

Down-regulation 0 
of 0 
transmembrane 0 
carbonic 0 
anhydrases 0 
in 0 
renal 1
cell 1
carcinoma 1
cell 0 
lines 0 
by 0 
wild-type 0 
von 1
Hippel-Lindau 1
transgenes 0 
. 0 

To 0 
discover 0 
genes 0 
involved 0 
in 0 
von 1
Hippel-Lindau 1
-LRB- 0 
VHL 1
-RRB- 0 
- 0 
mediated 0 
carcinogenesis 0 
, 0 
we 0 
used 0 
renal 1
cell 1
carcinoma 1
cell 0 
lines 0 
stably 0 
transfected 0 
with 0 
wild-type 0 
VHL-expressing 0 
transgenes 0 
. 0 

Large-scale 0 
RNA 0 
differential 0 
display 0 
technology 0 
applied 0 
to 0 
these 0 
cell 0 
lines 0 
identified 0 
several 0 
differentially 0 
expressed 0 
genes 0 
, 0 
including 0 
an 0 
alpha 0 
carbonic 0 
anhydrase 0 
gene 0 
, 0 
termed 0 
CA12 0 
. 0 

The 0 
deduced 0 
protein 0 
sequence 0 
was 0 
classified 0 
as 0 
a 0 
one-pass 0 
transmembrane 0 
_DS 0 
possessing 0 
an 0 
apparently 0 
intact 0 
catalytic 0 
domain 0 
in 0 
the 0 
extracellular 0 
_DS 0 
module 0 
. 0 

Reintroduced 0 
wild-type 0 
VHL 1
strongly 0 
inhibited 0 
the 0 
overexpression 0 
of 0 
the 0 
CA12 0 
gene 0 
in 0 
the 0 
parental 0 
renal 1
cell 1
carcinoma 1
cell 0 
lines 0 
. 0 

Similar 0 
results 0 
were 0 
obtained 0 
with 0 
CA9 0 
, 0 
encoding 0 
another 0 
transmembrane 0 
_DS 0 
with 0 
an 0 
intact 0 
catalytic 0 
domain 0 
. 0 

Although 0 
both 0 
domains 0 
of 0 
the 0 
VHL 1
protein 0 
contribute 0 
to 0 
regulation 0 
of 0 
CA12 0 
expression 0 
, 0 
the 0 
elongin 0 
binding 0 
domain 0 
alone 0 
could 0 
effectively 0 
regulate 0 
CA9 0 
expression 0 
. 0 

We 0 
mapped 0 
CA12 0 
and 0 
CA9 0 
loci 0 
to 0 
chromosome 0 
bands 0 
15q22 0 
and 0 
17q21 0 
. 0 

_NUM1 0 
respectively 0 
, 0 
regions 0 
prone 0 
to 0 
amplification 0 
in 0 
some 0 
human 0 
cancers 1
. 0 

Additional 0 
experiments 0 
are 0 
needed 0 
to 0 
define 0 
the 0 
role 0 
of 0 
_DS 0 
IX 0 
and 0 
_DS 0 
XII 0 
enzymes 0 
in 0 
the 0 
regulation 0 
of 0 
pH 0 
in 0 
the 0 
extracellular 0 
microenvironment 0 
and 0 
its 0 
potential 0 
impact 0 
on 0 
cancer 1
cell 0 
growth 0 
. 0 

A 0 
novel 0 
common 0 
missense 0 
mutation 0 
G301C 0 
in 0 
the 0 
N-acetylgalactosamine-6-sulfate 0 
sulfatase 0 
gene 0 
in 0 
mucopolysaccharidosis 1
IVA 1
. 0 

Mucopolysaccharidosis 1
IVA 1
-LRB- 0 
MPS 1
IVA 1
-RRB- 0 
is 0 
an 0 
autosomal 1
recessive 1
lysosomal 1
storage 1
disorder 1
caused 0 
by 0 
a 0 
genetic 1
defect 1
in 0 
N-acetylgalactosamine-6-sulfate 0 
sulfatase 0 
-LRB- 0 
GALNS 0 
-RRB- 0 
. 0 

In 0 
previous 0 
studies 0 
, 0 
we 0 
have 0 
found 0 
two 0 
common 0 
mutations 0 
in 0 
Caucasians 0 
and 0 
Japanese 0 
, 0 
respectively 0 
. 0 

To 0 
characterize 0 
the 0 
mutational 0 
spectrum 0 
in 0 
various 0 
ethnic 0 
groups 0 
, 0 
mutations 0 
in 0 
the 0 
GALNS 0 
gene 0 
in 0 
Colombian 0 
MPS 1
IVA 1
patients 0 
were 0 
investigated 0 
, 0 
and 0 
genetic 0 
backgrounds 0 
were 0 
extensively 0 
analyzed 0 
to 0 
identify 0 
racial 0 
origin 0 
, 0 
based 0 
on 0 
mitochondrial 0 
DNA 0 
-LRB- 0 
mtDNA 0 
-RRB- 0 
lineages 0 
. 0 

Three 0 
novel 0 
missense 0 
mutations 0 
never 0 
identified 0 
previously 0 
in 0 
other 0 
populations 0 
and 0 
found 0 
in 0 
_NUM2 0 
out 0 
of 0 
_NUM2 0 
Colombian 0 
MPS 1
IVA 1
unrelated 0 
alleles 0 
account 0 
for 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
of 0 
the 0 
alleles 0 
in 0 
this 0 
study 0 
. 0 

The 0 
G301C 0 
and 0 
S162F 0 
mutations 0 
account 0 
for 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
and 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
of 0 
mutations 0 
, 0 
respectively 0 
, 0 
whereas 0 
the 0 
remaining 0 
F69V 0 
is 0 
limited 0 
to 0 
a 0 
single 0 
allele 0 
. 0 

The 0 
skewed 0 
prevalence 0 
of 0 
G301C 0 
in 0 
only 0 
Colombian 0 
patients 0 
and 0 
haplotype 0 
analysis 0 
by 0 
restriction 0 
fragment 0 
length 0 
polymorphisms 0 
in 0 
the 0 
GALNS 0 
gene 0 
suggest 0 
that 0 
G301C 0 
originated 0 
from 0 
a 0 
common 0 
ancestor 0 
. 0 

Investigation 0 
of 0 
the 0 
genetic 0 
background 0 
by 0 
means 0 
of 0 
mtDNA 0 
lineages 0 
indicate 0 
that 0 
all 0 
our 0 
patients 0 
are 0 
probably 0 
of 0 
native 0 
American 0 
descent 0 
W474C 0 
amino 0 
acid 0 
substitution 0 
affects 0 
early 0 
processing 0 
of 0 
the 0 
alpha-subunit 0 
of 0 
beta-hexosaminidase 0 
A 0 
and 0 
is 0 
associated 0 
with 0 
subacute 0 
G 1
-LRB- 1
M2 1
-RRB- 1
gangliosidosis 1
. 0 

Mutations 0 
in 0 
the 0 
HEXA 0 
gene 0 
, 0 
encoding 0 
the 0 
alpha-subunit 0 
of 0 
beta-hexosaminidase 0 
A 0 
-LRB- 0 
Hex 0 
A 0 
-RRB- 0 
, 0 
that 0 
abolish 0 
Hex 0 
A 0 
enzyme 0 
activity 0 
cause 0 
Tay-Sachs 1
disease 1
-LRB- 0 
TSD 1
-RRB- 0 
, 0 
the 0 
fatal 0 
infantile 1
form 1
of 1
G 1
-LRB- 1
M2 1
-RRB- 1
gangliosidosis 1
, 1
Type 1
_NUM1 1
. 0 

Less 0 
severe 0 
, 0 
subacute 0 
-LRB- 0 
juvenile-onset 0 
-RRB- 0 
and 0 
chronic 0 
-LRB- 0 
adult-onset 0 
-RRB- 0 
variants 0 
are 0 
characterized 0 
by 0 
a 0 
broad 0 
spectrum 0 
of 0 
clinical 0 
manifestations 0 
and 0 
are 0 
associated 0 
with 0 
residual 0 
levels 0 
of 0 
Hex 0 
A 0 
enzyme 0 
activity 0 
. 0 

We 0 
identified 0 
a 0 
_NUM4 0 
G 0
-- 0 
> 0 
C 0 
-LRB- 0 
amino 0 
acid 0 
W474C 0 
-RRB- 0 
substitution 0 
in 0 
the 0 
first 0 
position 0 
of 0 
exon 0 
_NUM2 0 
of 0 
HEXA 0 
of 0 
a 0 
non-Jewish 0 
proband 0 
who 0 
manifested 0 
a 0 
subacute 0 
variant 0 
of 0 
G 1
-LRB- 1
M2 1
-RRB- 1
gangliosidosis 1
. 0 

On 0 
the 0 
second 0 
maternally 0 
inherited 0 
allele 0 
, 0 
we 0 
identified 0 
the 0 
common 0 
infantile 0 
disease-causing 0 
4-bp 0 
insertion 0 
, 0 
+ 0 
_DS 0 
_NUM4 0 
, 0 
in 0 
exon 0 
_NUM2 0 
. 0 

Pulse-chase 0 
analysis 0 
using 0 
proband 0 
fibroblasts 0 
revealed 0 
that 0 
the 0 
W474C-containing 0 
alpha-subunit 0 
precursor 0 
was 0 
normally 0 
synthesized 0 
, 0 
but 0 
not 0 
phosphorylated 0 
or 0 
secreted 0 
, 0 
and 0 
the 0 
mature 0 
lysosomal 0 
alpha-subunit 0 
was 0 
not 0 
detected 0 
. 0 

When 0 
the 0 
W474C-containing 0 
alpha-subunit 0 
was 0 
transiently 0 
co-expressed 0 
with 0 
the 0 
beta-subunit 0 
to 0 
produce 0 
Hex 0 
A 0 
-LRB- 0 
alphabeta 0 
-RRB- 0 
in 0 
COS-7 0 
cells 0 
, 0 
the 0 
mature 0 
alpha-subunit 0 
was 0 
present 0 
, 0 
but 0 
its 0 
level 0 
was 0 
much 0 
lower 0 
than 0 
that 0 
from 0 
normal 0 
alpha-subunit 0 
transfections 0 
, 0 
although 0 
higher 0 
than 0 
in 0 
those 0 
cells 0 
transfected 0 
with 0 
an 0 
alpha-subunit 0 
associated 0 
with 0 
infantile 0 
TSD 1
. 0 

Furthermore 0 
, 0 
the 0 
precursor 0 
level 0 
of 0 
the 0 
W474C 0 
alpha-subunit 0 
was 0 
found 0 
to 0 
accumulate 0 
in 0 
comparison 0 
to 0 
the 0 
normal 0 
alpha-subunit 0 
precursor 0 
levels 0 
. 0 

We 0 
conclude 0 
that 0 
the 0 
_NUM4 0 
G 0 
-- 0 
> 0 
C 0 
mutation 0 
is 0 
the 0 
cause 0 
of 0 
Hex 1
A 1
enzyme 1
deficiency 1
in 0 
the 0 
proband 0 
. 0 

The 0 
resulting 0 
W474C 0 
substitution 0 
clearly 0 
interferes 0 
with 0 
alpha-subunit 0 
processing 0 
, 0 
but 0 
because 0 
the 0 
base 0 
substitution 0 
falls 0 
at 0 
the 0 
first 0 
position 0 
of 0 
exon 0 
_NUM2 0 
, 0 
aberrant 0 
splicing 0 
may 0 
also 0 
contribute 0 
to 0 
Hex 1
A 1
deficiency 1
in 0 
this 0 
proband 0 
. 0 
. 0 

Myotonic 1
dystrophy 1
protein 0 
kinase 0 
is 0 
involved 0 
in 0 
the 0 
modulation 0 
of 0 
the 0 
Ca2 0 
+ 0 
homeostasis 0 
in 0 
skeletal 0 
muscle 0 
cells 0 
. 0 

Myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
, 0 
the 0 
most 0 
prevalent 0 
muscular 1
disorder 1
in 0 
adults 0 
, 0 
is 0 
caused 0 
by 0 
-LRB- 0 
_DS 0 
-RRB- 0 
n-repeat 0 
expansion 0 
in 0 
a 0 
gene 0 
encoding 0 
a 0 
protein 0 
kinase 0 
-LRB- 0 
DM 1
protein 0 
kinase 0 
; 0 
DMPK 0 
-RRB- 0 
and 0 
involves 0 
changes 0 
in 0 
cytoarchitecture 0 
and 0 
ion 0 
homeostasis 0 
. 0 

To 0 
obtain 0 
clues 0 
to 0 
the 0 
normal 0 
biological 0 
role 0 
of 0 
DMPK 0 
in 0 
cellular 0 
ion 0 
homeostasis 0 
, 0 
we 0 
have 0 
compared 0 
the 0 
resting 0 
-LSB- 0 
Ca2 0 
+ 0 
-RSB- 0 
i 0 
, 0 
the 0 
amplitude 0 
and 0 
shape 0 
of 0 
depolarization-induced 0 
Ca2 0 
+ 0 
transients 0 
, 0 
and 0 
the 0 
content 0 
of 0 
ATP-driven 0 
ion 0 
pumps 0 
in 0 
cultured 0 
skeletal 0 
muscle 0 
cells 0 
of 0 
wild-type 0 
and 0 
DMPK 0 
-LSB- 0 
- 0 
/ 0 
- 0 
-RSB- 0 
knockout 0 
mice 0 
. 0 

In 0 
vitro-differentiated 0 
DMPK 0 
-LSB- 0 
- 0 
/ 0 
- 0 
-RSB- 0 
myotubes 0 
exhibit 0 
a 0 
higher 0 
resting 0 
-LSB- 0 
Ca2 0 
+ 0 
-RSB- 0 
i 0 
than 0 
do 0 
wild-type 0 
myotubes 0 
because 0 
of 0 
an 0 
altered 0 
open 0 
probability 0 
of 0 
voltage-dependent 0 
l-type 0 
Ca2 0 
+ 0 
and 0 
Na 0 
+ 0 
channels 0 
. 0 

The 0 
mutant 0 
myotubes 0 
exhibit 0 
smaller 0 
and 0 
slower 0 
Ca2 0 
+ 0 
responses 0 
upon 0 
triggering 0 
by 0 
acetylcholine 0 
or 0 
high 0 
external 0 
K 0 
+ 0 
. 0 

In 0 
addition 0 
, 0 
we 0 
observed 0 
that 0 
these 0 
Ca2 0 
+ 0 
transients 0 
partially 0 
result 0 
from 0 
an 0 
influx 0 
of 0 
extracellular 0 
Ca2 0 
+ 0 
through 0 
the 0 
l-type 0 
Ca2 0 
+ 0 
channel 0 
. 0 

Neither 0 
the 0 
content 0 
nor 0 
the 0 
activity 0 
of 0 
Na 0 
+ 0 
/ 0 
K 0 
+ 0 
ATPase 0 
and 0 
sarcoplasmic 0 
reticulum 0 
Ca2 0 
+ 0 
- 0 
ATPase 0 
are 0 
affected 0 
by 0 
DMPK 0 
absence 0 
. 0 

In 0 
conclusion 0 
, 0 
our 0 
data 0 
suggest 0 
that 0 
DMPK 0 
is 0 
involved 0 
in 0 
modulating 0 
the 0 
initial 0 
events 0 
of 0 
excitation-contraction 0 
coupling 0 
in 0 
skeletal 0 
muscle 0 
. 0 
. 0 

Insertional 0 
mutation 0 
by 0 
transposable 0 
element 0 
, 0 
L1 0 
, 0 
in 0 
the 0 
DMD 1
gene 0 
results 0 
in 0 
X-linked 1
dilated 1
cardiomyopathy 1
. 0 

X-linked 1
dilated 1
cardiomyopathy 1
-LRB- 0 
XLDCM 1
-RRB- 0 
is 0 
a 0 
clinical 0 
phenotype 0 
of 0 
dystrophinopathy 1
which 0 
is 0 
characterized 0 
by 0 
preferential 0 
myocardial 1
involvement 1
without 0 
any 0 
overt 0 
clinical 0 
signs 0 
of 0 
skeletal 1
myopathy 1
. 0 

To 0 
date 0 
, 0 
several 0 
mutations 0 
in 0 
the 0 
Duchenne 1
muscular 1
dystrophy 1
gene 0 
, 0 
DMD 0 
, 0 
have 0 
been 0 
identified 0 
in 0 
patients 0 
with 0 
XLDCM 1
, 0 
but 0 
a 0 
pathogenic 0 
correlation 0 
of 0 
these 0 
cardiospecific 0 
mutations 0 
in 0 
DMD 0 
with 0 
the 0 
XLDCM 1
phenotype 0 
has 0 
remained 0 
to 0 
be 0 
elucidated 0 
. 0 

We 0 
report 0 
here 0 
the 0 
identification 0 
of 0 
a 0 
unique 0 
de 0 
novo 0 
L1 0 
insertion 0 
in 0 
the 0 
muscle 0 
exon 0 
_NUM1 0 
in 0 
DMD 0 
in 0 
three 0 
XLDCM 1
patients 0 
from 0 
two 0 
unrelated 0 
Japanese 0 
families 0 
. 0 

The 0 
insertion 0 
was 0 
a 0 
5-truncated 0 
form 0 
of 0 
human 0 
L1 0 
inversely 0 
integrated 0 
in 0 
the 0 
5-untranslated 0 
region 0 
in 0 
the 0 
muscle 0 
exon 0 
_NUM1 0 
, 0 
which 0 
affected 0 
the 0 
transcription 0 
or 0 
the 0 
stability 0 
of 0 
the 0 
muscle 0 
form 0 
of 0 
dystrophin 0 
transcripts 0 
but 0 
not 0 
that 0 
of 0 
the 0 
brain 0 
or 0 
Purkinje 0 
cell 0 
form 0 
, 0 
probably 0 
due 0 
to 0 
its 0 
unique 0 
site 0 
of 0 
integration 0 
. 0 

We 0 
speculate 0 
that 0 
this 0 
insertion 0 
of 0 
an 0 
L1 0 
sequence 0 
in 0 
DMD 0 
is 0 
responsible 0 
for 0 
some 0 
of 0 
the 0 
population 0 
of 0 
Japanese 0 
patients 0 
with 0 
XLDCM 1
. 0 
. 0 

Genetic 0 
heterogeneity 0 
of 0 
Saethre-Chotzen 1
syndrome 1
, 0 
due 0 
to 0 
TWIST 0 
and 0 
FGFR 0 
mutations 0 
. 0 

Thirty-two 0 
unrelated 0 
patients 0 
with 0 
features 0 
of 0 
Saethre-Chotzen 1
syndrome 1
, 0 
a 0 
common 0 
autosomal 1
dominant 1
condition 1
of 0 
craniosynostosis 1
and 0 
limb 1
anomalies 1
, 0 
were 0 
screened 0 
for 0 
mutations 0 
in 0 
TWIST 0 
, 0 
FGFR2 0 
, 0 
and 0 
FGFR3 0 
. 0 

Nine 0 
novel 0 
and 0 
three 0 
recurrent 0 
TWIST 0 
mutations 0 
were 0 
found 0 
in 0 
_NUM2 0 
families 0 
. 0 

Seven 0 
families 0 
were 0 
found 0 
to 0 
have 0 
the 0 
FGFR3 0 
P250R 0 
mutation 0 
, 0 
and 0 
one 0 
individual 0 
was 0 
found 0 
to 0 
have 0 
an 0 
FGFR2 0 
VV269-270 0 
deletion 0 
. 0 

To 0 
date 0 
, 0 
our 0 
detection 0 
rate 0 
for 0 
TWIST 0 
or 0 
FGFR 0 
mutations 0 
is 0 
_NUM2 0 
% 0 
in 0 
our 0 
Saethre-Chotzen 1
syndrome 1
patients 0 
, 0 
including 0 
our 0 
five 0 
patients 0 
elsewhere 0 
reported 0 
with 0 
TWIST 0 
mutations 0 
. 0 

More 0 
than 0 
_NUM2 0 
different 0 
TWIST 0 
mutations 0 
are 0 
now 0 
known 0 
in 0 
the 0 
literature 0 
. 0 

The 0 
most 0 
common 0 
phenotypic 0 
features 0 
, 0 
present 0 
in 0 
more 0 
than 0 
a 0 
third 0 
of 0 
our 0 
patients 0 
with 0 
TWIST 0 
mutations 0 
, 0 
are 0 
coronal 1
synostosis 1
, 0 
brachycephaly 1
, 0 
low 1
frontal 1
hairline 1
, 0 
facial 1
asymmetry 1
, 0 
ptosis 1
, 0 
hypertelorism 1
, 0 
broad 1
great 1
toes 1
, 0 
and 0 
clinodactyly 1
. 0 

Significant 0 
intra 0 
- 0 
and 0 
interfamilial 0 
phenotypic 0 
variability 0 
is 0 
present 0 
for 0 
either 0 
TWIST 0 
mutations 0 
or 0 
FGFR 0 
mutations 0 
. 0 

The 0 
overlap 0 
in 0 
clinical 0 
features 0 
and 0 
the 0 
presence 0 
, 0 
in 0 
the 0 
same 0 
genes 0 
, 0 
of 0 
mutations 0 
for 0 
more 0 
than 0 
one 0 
craniosynostotic 1
condition 1
such 0 
as 0 
Saethre-Chotzen 1
, 1
Crouzon 1
, 1
and 1
Pfeiffer 1
syndromes 1
support 0 
the 0 
hypothesis 0 
that 0 
TWIST 0 
and 0 
FGFRs 0 
are 0 
components 0 
of 0 
the 0 
same 0 
molecular 0 
pathway 0 
involved 0 
in 0 
the 0 
modulation 0 
of 0 
craniofacial 0 
and 0 
limb 0 
development 0 
in 0 
humans 0 
. 0 
. 0 

Frequent 0 
inactivation 0 
of 0 
PTEN 0 
/ 0 
MMAC1 0 
in 0 
primary 0 
prostate 1
cancer 1
. 0 

Sporadic 1
prostate 1
carcinoma 1
is 0 
the 0 
most 0 
common 0 
male 1
cancer 1
in 0 
the 0 
Western 0 
world 0 
, 0 
yet 0 
many 0 
of 0 
the 0 
major 0 
genetic 0 
events 0 
involved 0 
in 0 
the 0 
progression 0 
of 0 
this 0 
often 0 
fatal 0 
cancer 1
remain 0 
to 0 
be 0 
elucidated 0 
. 0 

Numerous 0 
cytogenetic 0 
and 0 
allelotype 0 
studies 0 
have 0 
reported 0 
frequent 0 
loss 0 
of 0 
heterozygosity 0 
on 0 
chromosomal 0 
arm 0 
10q 0 
in 0 
sporadic 1
prostate 1
cancer 1
. 0 

Deletion 0 
mapping 0 
studies 0 
have 0 
unambiguously 0 
identified 0 
a 0 
region 0 
of 0 
chromosome 0 
10q23 0 
to 0 
be 0 
the 0 
minimal 0 
area 0 
of 0 
loss 0 
. 0 

A 0 
new 0 
tumor 1
suppressor 0 
gene 0 
, 0 
PTEN 0 
/ 0 
MMAC1 0 
, 0 
was 0 
isolated 0 
recently 0 
at 0 
this 0 
region 0 
of 0 
chromosome 0 
10q23 0 
and 0 
found 0 
to 0 
be 0 
inactivated 0 
by 0 
mutation 0 
in 0 
three 0 
prostate 1
cancer 1
cell 0 
lines 0 
. 0 

We 0 
screened 0 
_NUM2 0 
prostate 1
tumors 1
by 0 
microsatellite 0 
analysis 0 
and 0 
found 0 
chromosome 0 
10q23 0 
to 0 
be 0 
deleted 0 
in 0 
_NUM2 0 
cases 0 
. 0 

We 0 
then 0 
proceeded 0 
with 0 
sequence 0 
analysis 0 
of 0 
the 0 
entire 0 
PTEN 0 
/ 0 
MMAC1 0 
coding 0 
region 0 
and 0 
tested 0 
for 0 
homozygous 0 
deletion 0 
with 0 
new 0 
intragenic 0 
markers 0 
in 0 
these 0 
_NUM2 0 
cases 0 
with 0 
10q23 0 
loss 0 
of 0 
heterozygosity 0 
. 0 

The 0 
identification 0 
of 0 
the 0 
second 0 
mutational 0 
event 0 
in 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
tumors 1
establishes 0 
PTEN 0 
/ 0 
MMAC1 0 
as 0 
a 0 
main 0 
inactivation 0 
target 0 
of 0 
10q 0 
loss 0 
in 0 
sporadic 1
prostate 1
cancer 1
. 0 
. 0 

Molecular 0 
heterogeneity 0 
in 0 
mucopolysaccharidosis 1
IVA 1
in 0 
Australia 0 
and 0 
Northern 0 
Ireland 0 
: 0 
nine 0 
novel 0 
mutations 0 
including 0 
T312S 0 
, 0 
a 0 
common 0 
allele 0 
that 0 
confers 0 
a 0 
mild 0 
phenotype 0 
. 0 

Mucopolysaccharidosis 1
IVA 1
-LRB- 0 
MPS 1
IVA 1
-RRB- 0 
is 0 
an 0 
autosomal 1
recessive 1
lysosomal 1
storage 1
disorder 1
caused 0 
by 0 
a 0 
genetic 1
defect 1
in 0 
N-acetylgalactosamine-6-sulfate 0 
sulfatase 0 
-LRB- 0 
GALNS 0 
-RRB- 0 
. 0 

Previous 0 
studies 0 
of 0 
patients 0 
from 0 
a 0 
British-Irish 0 
population 0 
showed 0 
that 0 
the 0 
I113F 0 
mutation 0 
is 0 
the 0 
most 0 
common 0 
single 0 
mutation 0 
among 0 
MPS 1
IVA 1
patients 0 
and 0 
produces 0 
a 0 
severe 0 
clinical 0 
phenotype 0 
. 0 

We 0 
studied 0 
mutations 0 
in 0 
the 0 
GALNS 0 
gene 0 
from 0 
_NUM2 0 
additional 0 
MPS 1
IVA 1
patients 0 
-LRB- 0 
_NUM2 0 
from 0 
Australia 0 
, 0 
_NUM1 0 
from 0 
Northern 0 
Ireland 0 
-RRB- 0 
, 0 
with 0 
various 0 
clinical 0 
phenotypes 0 
-LRB- 0 
severe 0 
, 0 
_NUM2 0 
cases 0 
; 0 
intermediate 0 
, 0 
_NUM1 0 
cases 0 
; 0 
mild 0 
, 0 
_NUM1 0 
cases 0 
-RRB- 0 
. 0 

We 0 
found 0 
two 0 
common 0 
mutations 0 
that 0 
together 0 
accounted 0 
for 0 
_NUM2 0 
% 0 
of 0 
the 0 
_NUM2 0 
unrelated 0 
alleles 0 
in 0 
these 0 
patients 0 
. 0 

One 0 
is 0 
the 0 
T312S 0 
mutation 0 
, 0 
a 0 
novel 0 
mutation 0 
found 0 
exclusively 0 
in 0 
milder 0 
patients 0 
. 0 

The 0 
other 0 
is 0 
the 0 
previously 0 
described 0 
I113F 0 
that 0 
produces 0 
a 0 
severe 0 
phenotype 0 
. 0 

The 0 
I113F 0 
and 0 
T312S 0 
mutations 0 
accounted 0 
for 0 
_NUM1 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
and 0 
_NUM1 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
of 0 
_NUM2 0 
unrelated 0 
alleles 0 
, 0 
respectively 0 
. 0 

The 0 
relatively 0 
high 0 
residual 0 
GALNS 0 
activity 0 
seen 0 
when 0 
the 0 
T312S 0 
mutant 0 
cDNA 0 
is 0 
overexpressed 0 
in 0 
mutant 0 
cells 0 
provides 0 
an 0 
explanation 0 
for 0 
the 0 
mild 0 
phenotype 0 
in 0 
patients 0 
with 0 
this 0 
mutation 0 
. 0 

The 0 
distribution 0 
and 0 
relative 0 
frequencies 0 
of 0 
the 0 
I113F 0 
and 0 
T312S 0 
mutations 0 
in 0 
Australia 0 
corresponded 0 
to 0 
those 0 
observed 0 
in 0 
Northern 0 
Ireland 0 
and 0 
are 0 
unique 0 
to 0 
these 0 
two 0 
populations 0 
, 0 
suggesting 0 
that 0 
both 0 
mutations 0 
were 0 
probably 0 
introduced 0 
to 0 
Australia 0 
by 0 
Irish 0 
migrants 0 
during 0 
the 0 
19th 0 
century 0 
. 0 

Haplotype 0 
analysis 0 
using 0 
_NUM1 0 
RFLPs 0 
provides 0 
additional 0 
data 0 
that 0 
the 0 
I113F 0 
mutation 0 
originated 0 
from 0 
a 0 
common 0 
ancestor 0 
. 0 

The 0 
other 0 
_NUM1 0 
novel 0 
mutations 0 
identified 0 
in 0 
these 0 
_NUM2 0 
patients 0 
were 0 
each 0 
limited 0 
to 0 
a 0 
single 0 
family 0 
. 0 

These 0 
data 0 
provide 0 
further 0 
evidence 0 
for 0 
extensive 0 
allelic 0 
heterogeneity 0 
in 0 
MPS 1
IVA 1
in 0 
British-Irish 0 
patients 0 
and 0 
provide 0 
evidence 0 
for 0 
their 0 
transmission 0 
to 0 
Australia 0 
by 0 
British-Irish 0 
migrants 0 
. 0 
. 0 

Further 0 
evidence 0 
for 0 
a 0 
major 0 
ancient 0 
mutation 0 
underlying 0 
myotonic 1
dystrophy 1
from 0 
linkage 0 
disequilibrium 0 
studies 0 
in 0 
the 0 
Japanese 0 
population 0 
. 0 

The 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
mutation 0 
is 0 
an 0 
unstable 0 
-LRB- 0 
_DS 0 
-RRB- 0 
n 0 
repeat 0 
, 0 
present 0 
at 0 
a 0 
copy 0 
number 0 
of 0 
5-37 0 
repeats 0 
on 0 
normal 0 
chromosomes 0 
but 0 
amplified 0 
to 0 
50-3000 0 
copies 0 
on 0 
DM 1
chromosomes 0 
. 0 

Previous 0 
findings 0 
in 0 
Caucasian 0 
populations 0 
of 0 
a 0 
DM 1
founder 0 
chromosome 0 
raise 0 
a 0 
question 0 
about 0 
the 0 
molecular 0 
events 0 
involved 0 
in 0 
the 0 
expansion 0 
mutation 0 
. 0 

To 0 
investigate 0 
whether 0 
a 0 
founder 0 
chromosome 0 
for 0 
the 0 
DM 1
mutation 0 
exists 0 
in 0 
the 0 
Japanese 0 
population 0 
, 0 
we 0 
genotyped 0 
families 0 
using 0 
polymorphic 0 
markers 0 
near 0 
the 0 
-LRB- 0 
_DS 0 
-RRB- 0 
n 0 
repeat 0 
region 0 
and 0 
constructed 0 
haplotypes 0 
. 0 

Six 0 
different 0 
haplotypes 0 
were 0 
found 0 
and 0 
DM 1
alleles 0 
were 0 
always 0 
haplotype 0 
A. 0 
To 0 
find 0 
an 0 
origin 0 
of 0 
the 0 
-LRB- 0 
_DS 0 
-RRB- 0 
n 0 
repeat 0 
mutation 0 
and 0 
to 0 
investigate 0 
the 0 
mechanism 0 
of 0 
the 0 
expansion 0 
mutation 0 
in 0 
the 0 
Japanese 0 
population 0 
we 0 
have 0 
studied 0 
_NUM2 0 
Japanese 0 
DM 1
families 0 
comprising 0 
_NUM3 0 
affected 0 
and 0 
_NUM3 0 
unaffected 0 
members 0 
. 0 

The 0 
results 0 
suggest 0 
that 0 
a 0 
few 0 
common 0 
ancestral 0 
mutations 0 
in 0 
both 0 
Caucasian 0 
and 0 
Japanese 0 
populations 0 
have 0 
originated 0 
by 0 
expansion 0 
of 0 
an 0 
ancestral 0 
n 0 
= 0 
_NUM1 0 
repeat 0 
to 0 
n 0 
= 0 
19-37 0 
copies 0 
. 0 

These 0 
data 0 
support 0 
multistep 0 
models 0 
of 0 
triplet 0 
repeat 0 
expansion 0 
that 0 
have 0 
been 0 
proposed 0 
for 0 
both 0 
DM 1
and 0 
Friedreichs 1
ataxia 1
. 0 
. 0 

Prevalence 0 
of 0 
_AN 0 
and 0 
CDK4 0 
germline 0 
mutations 0 
in 0 
_NUM2 0 
melanoma 1
prone 0 
families 0 
in 0 
France 0 
. 0 

The 0 
French 0 
Familial 1
Melanoma 1
Study 0 
Group 0 
. 0 

Germline 0 
mutations 0 
in 0 
the 0 
_AN 0 
and 0 
CDK4 0 
genes 0 
have 0 
been 0 
reported 0 
in 0 
a 0 
subset 0 
of 0 
melanoma 1
pedigrees 0 
, 0 
but 0 
their 0 
prevalence 0 
is 0 
not 0 
well 0 
known 0 
. 0 

We 0 
searched 0 
for 0 
such 0 
germline 0 
mutations 0 
in 0 
_NUM2 0 
French 0 
melanoma 1
prone 0 
families 0 
selected 0 
according 0 
to 0 
two 0 
major 0 
criteria 0 
families 0 
with 0 
at 0 
least 0 
three 0 
affected 0 
members 0 
-LRB- 0 
n 0 
= 0 
_NUM2 0 
-RRB- 0 
or 0 
families 0 
with 0 
two 0 
affected 0 
members 0 
, 0 
one 0 
of 0 
them 0 
affected 0 
before 0 
the 0 
age 0 
of 0 
_NUM2 0 
-LRB- 0 
n 0 
= 0 
_NUM2 0 
-RRB- 0 
, 0 
and 0 
one 0 
additional 0 
minor 0 
criterion 0 
. 0 

Sixteen 0 
different 0 
_AN 0 
germline 0 
mutations 0 
were 0 
found 0 
in 0 
_NUM2 0 
families 0 
, 0 
while 0 
one 0 
germline 0 
mutation 0 
, 0 
Arg24His 0 
, 0 
was 0 
detected 0 
in 0 
the 0 
CDK4 0 
gene 0 
. 0 

The 0 
frequency 0 
of 0 
_AN 0 
gene 0 
mutation 0 
in 0 
our 0 
sample 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
is 0 
among 0 
the 0 
highest 0 
rates 0 
yet 0 
reported 0 
and 0 
the 0 
CDK4 0 
mutation 0 
is 0 
the 0 
second 0 
mutation 0 
detected 0 
in 0 
this 0 
gene 0 
worldwide 0 
. 0 

In 0 
summary 0 
, 0 
our 0 
results 0 
show 0 
frequent 0 
involvement 0 
of 0 
the 0 
_AN 0 
gene 0 
in 0 
familial 1
melanoma 1
and 0 
confirm 0 
the 0 
role 0 
of 0 
the 0 
CDK4 0 
gene 0 
as 0 
a 0 
melanoma 1
predisposing 0 
gene 0 
. 0 
. 0 

Systematic 0 
analysis 0 
of 0 
coproporphyrinogen 0 
oxidase 0 
gene 0 
defects 0 
in 0 
hereditary 1
coproporphyria 1
and 0 
mutation 0 
update 0 
. 0 

Hereditary 1
coproporphyria 1
-LRB- 0 
HC 1
-RRB- 0 
is 0 
an 0 
acute 0 
hepatic 1
porphyria 1
with 0 
autosomal 0 
dominant 0 
inheritance 0 
caused 0 
by 0 
deficient 1
activity 1
of 1
coproporphyrinogen 1
III 1
oxidase 1
-LRB- 0 
CPO 0 
-RRB- 0 
. 0 

Clinical 0 
manifestations 0 
of 0 
the 0 
disease 0 
are 0 
characterized 0 
by 0 
acute 0 
attacks 0 
of 0 
neurological 1
dysfunction 1
often 0 
precipitated 0 
by 0 
drugs 0 
, 0 
fasting 0 
, 0 
cyclical 0 
hormonal 0 
changes 0 
, 0 
or 0 
infectious 1
diseases 1
. 0 

Skin 0 
photosensitivity 0 
may 0 
also 0 
be 0 
present 0 
. 0 

The 0 
seven 0 
exons 0 
, 0 
the 0 
exon 0 
/ 0 
intron 0 
boundaries 0 
and 0 
part 0 
of 0 
_NUM1 0 
noncoding 0 
sequence 0 
of 0 
the 0 
CPO 0 
gene 0 
were 0 
systematically 0 
analyzed 0 
by 0 
an 0 
exon-by-exon 0 
denaturing 0 
gradient 0 
gel 0 
electrophoresis 0 
-LRB- 0 
DGGE 0 
-RRB- 0 
strategy 0 
followed 0 
by 0 
direct 0 
sequencing 0 
in 0 
seven 0 
unrelated 0 
heterozygous 0 
HC 1
patients 0 
from 0 
France 0 
, 0 
Holland 0 
, 0 
and 0 
Czech 0 
Republic 0 
. 0 

Seven 0 
novel 0 
mutations 0 
and 0 
two 0 
new 0 
polymorphisms 0 
were 0 
detected 0 
. 0 

Among 0 
these 0 
mutations 0 
two 0 
are 0 
missense 0 
-LRB- 0 
G197W 0 
, 0 
W427R 0 
-RRB- 0 
, 0 
two 0 
are 0 
nonsense 0 
-LRB- 0 
Q306X 0 
, 0 
Q385X 0 
-RRB- 0 
, 0 
two 0 
are 0 
small 0 
deletions 0 
-LRB- 0 
662de14bp 0 
; 0 
1168del3bp 0 
removing 0 
a 0 
glycine 0 
at 0 
position 0 
_NUM3 0 
-RRB- 0 
, 0 
and 0 
one 0 
is 0 
a 0 
splicing 0 
mutation 0 
-LRB- 0 
IVS1-15c 0 
-- 0 
> 0 
g 0 
-RRB- 0 
which 0 
creates 0 
a 0 
new 0 
acceptor 0 
splice 0 
site 0 
. 0 

The 0 
pathological 0 
significance 0 
of 0 
the 0 
point 0 
mutations 0 
G197W 0 
, 0 
W427R 0 
, 0 
and 0 
the 0 
in-frame 0 
deletion 0 
390delGly 0 
were 0 
assessed 0 
by 0 
their 0 
respective 0 
expression 0 
in 0 
a 0 
prokaryotic 0 
system 0 
using 0 
site-directed 0 
mutagenesis 0 
. 0 

These 0 
mutations 0 
resulted 0 
in 0 
the 0 
absence 0 
or 0 
a 0 
dramatic 0 
decrease 0 
of 0 
CPO 0 
activity 0 
. 0 

The 0 
two 0 
polymorphisms 0 
were 0 
localized 0 
in 0 
noncoding 0 
part 0 
of 0 
the 0 
gene 0 
_NUM1 0 
-RRB- 0 
a 0 
C 0 
/ 0 
G 0 
polymorphism 0 
in 0 
the 0 
promotor 0 
region 0 
, 0 
_NUM3 0 
bp 0 
upstream 0 
from 0 
the 0 
transcriptional 0 
initiation 0 
site 0 
-LRB- 0 
-142 0 
C 0 
/ 0 
G 0 
-RRB- 0 
, 0 
and 0 
_NUM1 0 
-RRB- 0 
a 0 
_NUM1 0 
bp 0 
deletion 0 
polymorphism 0 
in 0 
the 0 
_NUM1 0 
noncoding 0 
part 0 
of 0 
the 0 
CPO 0 
gene 0 
, 0 
_NUM3 0 
bp 0 
downstream 0 
of 0 
the 0 
last 0 
base 0 
of 0 
the 0 
normal 0 
termination 0 
codon 0 
-LRB- 0 
+ 0 
_NUM3 0 
delATTCTT 0 
-RRB- 0 
. 0 

Five 0 
intragenic 0 
dimorphisms 0 
are 0 
now 0 
well 0 
characterized 0 
and 0 
the 0 
high 0 
degree 0 
of 0 
allelic 0 
heterogeneity 0 
in 0 
HC 1
is 0 
demonstrated 0 
with 0 
seven 0 
new 0 
different 0 
mutations 0 
making 0 
a 0 
total 0 
of 0 
nineteen 0 
CPO 0 
gene 1
defects 1
reported 0 
so 0 
far 0 
. 0 
. 0 

The 0 
haptoglobin-gene 0 
deletion 0 
responsible 0 
for 0 
anhaptoglobinemia 1
. 0 

We 0 
have 0 
found 0 
an 0 
allelic 0 
deletion 0 
of 0 
the 0 
haptoglobin 0 
-LRB- 0 
Hp 0 
-RRB- 0 
gene 0 
from 0 
an 0 
individual 0 
with 0 
anhaptoglobinemia 1
. 0 

The 0 
Hp 0 
gene 0 
cluster 0 
consists 0 
of 0 
coding 0 
regions 0 
of 0 
the 0 
alpha 0 
chain 0 
and 0 
beta 0 
chain 0 
of 0 
the 0 
haptoglobin 0 
gene 0 
-LRB- 0 
Hp 0 
-RRB- 0 
and 0 
of 0 
the 0 
alpha 0 
chain 0 
and 0 
beta 0 
chain 0 
of 0 
the 0 
haptoglobin-related 0 
gene 0 
-LRB- 0 
Hpr 0 
-RRB- 0 
, 0 
in 0 
tandem 0 
from 0 
the 0 
_NUM1 0 
side 0 
. 0 

Southern 0 
blot 0 
and 0 
PCR 0 
analyses 0 
have 0 
indicated 0 
that 0 
the 0 
individual 0 
with 0 
anhaptoglobinemia 1
was 0 
homozygous 0 
for 0 
the 0 
gene 0 
deletion 0 
and 0 
that 0 
the 0 
gene 0 
deletion 0 
was 0 
included 0 
at 0 
least 0 
from 0 
the 0 
promoter 0 
region 0 
of 0 
Hp 0 
to 0 
Hpr 0 
alpha 0 
but 0 
not 0 
to 0 
Hpr 0 
beta 0 
-LRB- 0 
Hpdel 0 
-RRB- 0 
. 0 

In 0 
addition 0 
, 0 
we 0 
found 0 
seven 0 
individuals 0 
with 0 
hypohaptoglobinemia 1
in 0 
three 0 
families 0 
, 0 
and 0 
the 0 
genotypes 0 
of 0 
six 0 
of 0 
the 0 
seven 0 
individuals 0 
were 0 
found 0 
to 0 
be 0 
Hp2 0 
/ 0 
Hpdel 0 
. 0 

The 0 
phenotypes 0 
and 0 
genotypes 0 
in 0 
one 0 
of 0 
these 0 
three 0 
families 0 
showed 0 
the 0 
father 0 
to 0 
be 0 
hypohaptoglobinemic 1
-LRB- 0 
Hp2 0 
-RRB- 0 
and 0 
Hp2 0 
/ 0 
Hpdel 0 
, 0 
the 0 
mother 0 
to 0 
be 0 
Hp2-1 0 
and 0 
Hp1 0 
/ 0 
Hp2 0 
, 0 
one 0 
of 0 
the 0 
two 0 
children 0 
to 0 
be 0 
hypohaptoglobinemic 1
-LRB- 0 
Hp2 0 
-RRB- 0 
and 0 
Hp2 0 
/ 0 
Hpdel 0 
, 0 
and 0 
the 0 
other 0 
child 0 
to 0 
be 0 
Hp1 0 
and 0 
Hp1 0 
/ 0 
Hpdel 0 
, 0 
showing 0 
an 0 
anomalous 0 
inheritance 0 
of 0 
Hp 0 
phenotypes 0 
in 0 
the 0 
child 0 
with 0 
Hp1 0 
. 0 

The 0 
Hp2 0 
/ 0 
Hpdel 0 
individuals 0 
had 0 
an 0 
extremely 0 
low 0 
level 0 
of 0 
Hp 0 
-LRB- 0 
mean 0 
+ 0 
/ 0 
- 0 
SD 0 
= 0 
_NUM1 0 
. 0 

_NUM3 0 
+ 0 
/ 0 
-0 0 
. 0 

_NUM3 0 
mg 0 
/ 0 
ml 0 
; 0 
n 0 
= 0 
_NUM1 0 
-RRB- 0 
, 0 
compared 0 
with 0 
the 0 
level 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM2 0 
+ 0 
/ 0 
-1 0 
. 0 

_NUM2 0 
mg 0 
/ 0 
ml 0 
-RRB- 0 
obtained 0 
from 0 
_NUM2 0 
healthy 0 
volunteers 0 
having 0 
phenotype 0 
Hp2 0 
, 0 
whereas 0 
the 0 
serum 0 
Hp 0 
level 0 
of 0 
an 0 
individual 0 
with 0 
Hp1 0 
/ 0 
Hpdel 0 
was 0 
_NUM1 0 
. 0 

_NUM2 0 
mg 0 
/ 0 
ml 0 
, 0 
which 0 
was 0 
approximately 0 
half 0 
the 0 
level 0 
of 0 
Hp 0 
in 0 
control 0 
sera 0 
from 0 
the 0 
Hp1 0 
phenotype 0 
-LRB- 0 
_NUM1 0 
. 0 

_NUM2 0 
+ 0 
/ 0 
-0 0 
. 0 

_NUM2 0 
mg 0 
/ 0 
ml 0 
; 0 
n 0 
= 0 
_NUM1 0 
-RRB- 0 
, 0 
showing 0 
a 0 
gene-dosage 0 
effect 0 
. 0 

The 0 
other 0 
allele 0 
-LRB- 0 
Hp2 0 
-RRB- 0 
of 0 
individuals 0 
with 0 
Hp2 0 
/ 0 
Hpdel 0 
was 0 
found 0 
to 0 
have 0 
, 0 
in 0 
all 0 
exons 0 
, 0 
no 0 
mutation 0 
, 0 
by 0 
DNA 0 
sequencing 0 
. 0 

On 0 
the 0 
basis 0 
of 0 
the 0 
present 0 
study 0 
, 0 
the 0 
mechanism 0 
of 0 
anhaptoglobinemia 1
and 0 
the 0 
mechanism 0 
of 0 
anomalous 0 
inheritance 0 
of 0 
Hp 0 
phenotypes 0 
were 0 
well 0 
explained 0 
. 0 

However 0 
, 0 
the 0 
mechanism 0 
of 0 
hypohaptoglobinemia 1
remains 0 
unknown 0 
Genotype-phenotype 0 
correlations 0 
in 0 
attenuated 1
adenomatous 1
polyposis 1
coli 1
. 0 

Germ-line 0 
mutations 0 
of 0 
the 0 
tumor 1
suppressor 0 
APC 0 
are 0 
implicated 0 
in 0 
attenuated 1
adenomatous 1
polyposis 1
coli 1
-LRB- 0 
AAPC 1
-RRB- 0 
, 0 
a 0 
variant 0 
of 0 
familial 1
adenomatous 1
polyposis 1
-LRB- 0 
FAP 1
-RRB- 0 
. 0 

AAPC 1
is 0 
recognized 0 
by 0 
the 0 
occurrence 0 
of 0 
< 0 
_NUM3 0 
colonic 1
adenomas 1
and 0 
a 0 
later 0 
onset 0 
of 0 
colorectal 1
cancer 1
-LRB- 0 
age 0 
> 0 
_NUM2 0 
years 0 
-RRB- 0 
. 0 

The 0 
aim 0 
of 0 
this 0 
study 0 
was 0 
to 0 
assess 0 
genotype-phenotype 0 
correlations 0 
in 0 
AAPC 1
families 0 
. 0 

By 0 
protein-truncation 0 
test 0 
-LRB- 0 
PTT 0 
-RRB- 0 
assay 0 
, 0 
the 0 
entire 0 
coding 0 
region 0 
of 0 
the 0 
APC 1
gene 0 
was 0 
screened 0 
in 0 
affected 0 
individuals 0 
from 0 
_NUM2 0 
AAPC 1
kindreds 0 
, 0 
and 0 
their 0 
phenotypic 0 
differences 0 
were 0 
examined 0 
. 0 

Five 0 
novel 0 
germ-line 0 
APC 1
mutations 0 
were 0 
identified 0 
in 0 
seven 0 
kindreds 0 
. 0 

Mutations 0 
were 0 
located 0 
in 0 
three 0 
different 0 
regions 0 
of 0 
the 0 
APC 1
gene 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
at 0 
the 0 
_NUM1 0 
end 0 
spanning 0 
exons 0 
_NUM1 0 
and 0 
_NUM1 0 
, 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
within 0 
exon 0 
_NUM1 0 
, 0 
and 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
at 0 
the 0 
_NUM1 0 
distal 0 
end 0 
of 0 
the 0 
gene 0 
. 0 

Variability 0 
in 0 
the 0 
number 0 
of 0 
colorectal 1
adenomas 1
was 0 
most 0 
apparent 0 
in 0 
individuals 0 
with 0 
mutations 0 
in 0 
region 0 
_NUM1 0 
, 0 
and 0 
upper-gastrointestinal 0 
manifestations 0 
were 0 
more 0 
severe 0 
in 0 
them 0 
. 0 

In 0 
individuals 0 
with 0 
mutations 0 
in 0 
either 0 
region 0 
_NUM1 0 
or 0 
region 0 
_NUM1 0 
, 0 
the 0 
average 0 
number 0 
of 0 
adenomas 1
tended 0 
to 0 
be 0 
lower 0 
than 0 
those 0 
in 0 
individuals 0 
with 0 
mutations 0 
in 0 
region 0 
_NUM1 0 
, 0 
although 0 
age 0 
at 0 
diagnosis 0 
was 0 
similar 0 
. 0 

In 0 
all 0 
AAPC 1
kindreds 0 
, 0 
a 0 
predominance 0 
of 0 
right-sided 0 
colorectal 1
adenomas 1
and 0 
rectal 1
polyp 1
sparing 0 
was 0 
observed 0 
. 0 

No 0 
desmoid 1
tumors 1
were 0 
found 0 
in 0 
these 0 
kindreds 0 
. 0 

Our 0 
data 0 
suggest 0 
that 0 
, 0 
in 0 
AAPC 1
families 0 
, 0 
the 0 
location 0 
of 0 
the 0 
APC 1
mutation 0 
may 0 
partially 0 
predict 0 
specific 0 
phenotypic 0 
expression 0 
. 0 

This 0 
should 0 
help 0 
in 0 
the 0 
design 0 
of 0 
tailored 0 
clinical-management 0 
protocols 0 
in 0 
this 0 
subset 0 
of 0 
FAP 1
patients 0 
. 0 
. 0 

The 0 
APC 1
variants 0 
I1307K 0 
and 0 
E1317Q 0 
are 0 
associated 0 
with 0 
colorectal 1
tumors 1
, 0 
but 0 
not 0 
always 0 
with 0 
a 0 
family 0 
history 0 
. 0 

Classical 0 
familial 1
adenomatous 1
polyposis 1
-LRB- 0 
FAP 1
-RRB- 0 
is 0 
a 0 
high-penetrance 0 
autosomal 1
dominant 1
disease 1
that 0 
predisposes 0 
to 0 
hundreds 0 
or 0 
thousands 0 
of 0 
colorectal 1
adenomas 1
and 1
carcinoma 1
and 0 
that 0 
results 0 
from 0 
truncating 0 
mutations 0 
in 0 
the 0 
APC 1
gene 0 
. 0 

A 0 
variant 0 
of 0 
FAP 1
is 0 
attenuated 1
adenomatous 1
polyposis 1
coli 1
, 0 
which 0 
results 0 
from 0 
germ-line 0 
mutations 0 
in 0 
the 0 
_NUM1 0 
and 0 
_NUM1 0 
regions 0 
of 0 
the 0 
APC 1
gene 0 
. 0 

Attenuated 1
adenomatous 1
polyposis 1
coli 1
patients 0 
have 0 
'' 0 
multiple 0 
'' 0 
colorectal 1
adenomas 1
-LRB- 0 
typically 0 
fewer 0 
than 0 
_NUM3 0 
-RRB- 0 
without 0 
the 0 
florid 0 
phenotype 0 
of 0 
classical 0 
FAP 1
. 0 

Another 0 
group 0 
of 0 
patients 0 
with 0 
multiple 0 
adenomas 1
has 0 
no 0 
mutations 0 
in 0 
the 0 
APC 1
gene 0 
, 0 
and 0 
their 0 
phenotype 0 
probably 0 
results 0 
from 0 
variation 0 
at 0 
a 0 
locus 0 
, 0 
or 0 
loci 0 
, 0 
elsewhere 0 
in 0 
the 0 
genome 0 
. 0 

Recently 0 
, 0 
however 0 
, 0 
a 0 
missense 0 
variant 0 
of 0 
APC 1
-LRB- 0 
I1307K 0 
-RRB- 0 
was 0 
described 0 
that 0 
confers 0 
an 0 
increased 0 
risk 0 
of 0 
colorectal 1
tumors 1
, 0 
including 0 
multiple 0 
adenomas 1
, 0 
in 0 
Ashkenazim 0 
. 0 

We 0 
have 0 
studied 0 
a 0 
set 0 
of 0 
_NUM3 0 
patients 0 
with 0 
multiple 0 
colorectal 1
adenomas 1
and 1
/ 1
or 1
carcinoma 1
and 0 
analyzed 0 
codons 0 
1263-1377 0 
-LRB- 0 
exon 0 
15G 0 
-RRB- 0 
of 0 
the 0 
APC 1
gene 0 
for 0 
germ-line 0 
variants 0 
. 0 

Three 0 
patients 0 
with 0 
the 0 
I1307K 0 
allele 0 
were 0 
detected 0 
, 0 
each 0 
of 0 
Ashkenazi 0 
descent 0 
. 0 

Four 0 
patients 0 
had 0 
a 0 
germ-line 0 
E1317Q 0 
missense 0 
variant 0 
of 0 
APC 0 
that 0 
was 0 
not 0 
present 0 
in 0 
controls 0 
; 0 
one 0 
of 0 
these 0 
individuals 0 
had 0 
an 0 
unusually 0 
large 0 
number 0 
of 0 
metaplastic 1
polyps 1
of 1
the 1
colorectum 1
. 0 

There 0 
is 0 
increasing 0 
evidence 0 
that 0 
there 0 
exist 0 
germ-line 0 
variants 0 
of 0 
the 0 
APC 1
gene 0 
that 0 
predispose 0 
to 0 
the 0 
development 0 
of 0 
multiple 0 
colorectal 1
adenomas 1
and 1
carcinoma 1
, 0 
but 0 
without 0 
the 0 
florid 0 
phenotype 0 
of 0 
classical 0 
FAP 1
, 0 
and 0 
possibly 0 
with 0 
importance 0 
for 0 
colorectal 1
cancer 1
risk 0 
in 0 
the 0 
general 0 
population 0 
. 0 
. 0 

The 0 
hemochromatosis 1
_NUM3 0 
G 0 
-- 0 
> 0 
A 0 
and 0 
_NUM3 0 
C 0 
-- 0 
> 0 
G 0 
mutations 0 
: 0 
prevalence 0 
in 0 
non-Caucasian 0 
populations 0 
. 0 

Hemochromatosis 1
, 0 
the 0 
inherited 1
disorder 1
of 1
iron 1
metabolism 1
, 0 
leads 0 
, 0 
if 0 
untreated 0 
, 0 
to 0 
progressive 0 
iron 1
overload 1
and 0 
premature 1
death 1
. 0 

The 0 
hemochromatosis 1
gene 0 
, 0 
HFE 0 
, 0 
recently 0 
has 0 
been 0 
identified 0 
, 0 
and 0 
characterization 0 
of 0 
this 0 
gene 0 
has 0 
shown 0 
that 0 
it 0 
contains 0 
two 0 
mutations 0 
that 0 
result 0 
in 0 
amino 0 
acid 0 
substitutions-cDNA 0 
nucleotides 0 
_NUM3 0 
G 0 
-- 0 
> 0 
A 0 
-LRB- 0 
C282Y 0 
-RRB- 0 
and 0 
_NUM3 0 
C 0 
-- 0 
> 0 
G 0 
-LRB- 0 
H63D 0 
-RRB- 0 
. 0 

Although 0 
hemochromatosis 1
is 0 
common 0 
in 0 
Caucasians 0 
, 0 
affecting 0 
> 0 
= 0 
1 0 
/ 0 
300 0 
individuals 0 
of 0 
northern 0 
European 0 
origin 0 
, 0 
it 0 
has 0 
not 0 
been 0 
recognized 0 
in 0 
other 0 
populations 0 
. 0 

The 0 
present 0 
study 0 
used 0 
PCR 0 
and 0 
restriction-enzyme 0 
digestion 0 
to 0 
analyze 0 
the 0 
frequency 0 
of 0 
the 0 
_NUM3 0 
G 0 
-- 0 
> 0 
A 0 
and 0 
_NUM3 0 
C 0 
-- 0 
> 0 
G 0 
mutations 0 
in 0 
HLA-typed 0 
samples 0 
from 0 
non-Caucasian 0 
populations 0 
, 0 
comprising 0 
Australian 0 
Aboriginal 0 
, 0 
Chinese 0 
, 0 
and 0 
Pacific 0 
Islanders 0 
. 0 

Results 0 
showed 0 
that 0 
the 0 
_NUM3 0 
G 0 
-- 0 
> 0 
A 0 
mutation 0 
was 0 
present 0 
in 0 
these 0 
populations 0 
-LRB- 0 
allele 0 
frequency 0 
_NUM1 0 
. 0 

_NUM2 0 
% 0 
-RRB- 0 
, 0 
and 0 
, 0 
furthermore 0 
, 0 
it 0 
was 0 
always 0 
seen 0 
in 0 
conjunction 0 
with 0 
HLA 0 
haplotypes 0 
common 0 
in 0 
Caucasians 0 
, 0 
suggesting 0 
that 0 
_NUM3 0 
G 0 
-- 0 
> 0 
A 0 
may 0 
have 0 
been 0 
introduced 0 
into 0 
these 0 
populations 0 
by 0 
Caucasian 0 
admixture 0 
. 0 

_NUM3 0 
C 0 
-- 0 
> 0 
G 0 
was 0 
present 0 
at 0 
an 0 
allele 0 
frequency 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
% 0 
in 0 
the 0 
two 0 
populations 0 
analyzed 0 
-LRB- 0 
Australian 0 
Aboriginal 0 
and 0 
Chinese 0 
-RRB- 0 
. 0 

In 0 
the 0 
Australian 0 
Aboriginal 0 
samples 0 
, 0 
_NUM3 0 
C 0 
-- 0 
> 0 
G 0 
was 0 
found 0 
to 0 
be 0 
associated 0 
with 0 
HLA 0 
haplotypes 0 
common 0 
in 0 
Caucasians 0 
, 0 
suggesting 0 
that 0 
it 0 
was 0 
introduced 0 
by 0 
recent 0 
admixture 0 
. 0 

In 0 
the 0 
Chinese 0 
samples 0 
analyzed 0 
, 0 
_NUM3 0 
C 0 
-- 0 
> 0 
G 0 
was 0 
present 0 
in 0 
association 0 
with 0 
a 0 
wide 0 
variety 0 
of 0 
HLA 0 
haplotypes 0 
, 0 
showing 0 
this 0 
mutation 0 
to 0 
be 0 
widespread 0 
and 0 
likely 0 
to 0 
predate 0 
the 0 
more 0 
genetically 0 
restricted 0 
_NUM3 0 
G 0 
-- 0 
> 0 
A 0 
mutation 0 
. 0 

BRCA1 0 
required 0 
for 0 
transcription-coupled 0 
repair 0 
of 0 
oxidative 0 
DNA 0 
damage 0 
. 0 

The 0 
breast 1
and 1
ovarian 1
cancer 1
susceptibility 0 
gene 0 
BRCA1 0 
encodes 0 
a 0 
zinc 0 
finger 0 
protein 0 
of 0 
unknown 0 
function 0 
. 0 

Association 0 
of 0 
the 0 
BRCA1 0 
protein 0 
with 0 
the 0 
DNA 0 
repair 0 
protein 0 
Rad51 0 
and 0 
changes 0 
in 0 
the 0 
phosphorylation 0 
and 0 
cellular 0 
localization 0 
of 0 
the 0 
protein 0 
after 0 
exposure 0 
to 0 
DNA-damaging 0 
agents 0 
are 0 
consistent 0 
with 0 
a 0 
role 0 
for 0 
BRCA1 0 
in 0 
DNA 0 
repair 0 
. 0 

Here 0 
, 0 
it 0 
is 0 
shown 0 
that 0 
mouse 0 
embryonic 0 
stem 0 
cells 0 
deficient 1
in 1
BRCA1 1
are 0 
defective 0 
in 0 
the 0 
ability 0 
to 0 
carry 0 
out 0 
transcription-coupled 0 
repair 0 
of 0 
oxidative 0 
DNA 0 
damage 0 
, 0 
and 0 
are 0 
hypersensitive 0 
to 0 
ionizing 0 
radiation 0 
and 0 
hydrogen 0 
peroxide 0 
. 0 

These 0 
results 0 
suggest 0 
that 0 
BRCA1 0 
participates 0 
, 0 
directly 0 
or 0 
indirectly 0 
, 0 
in 0 
transcription-coupled 0 
repair 0 
of 0 
oxidative 0 
DNA 0 
damage 0 
. 0 
. 0 

A 0 
mouse 0 
model 0 
of 0 
severe 0 
von 1
Willebrand 1
disease 1
: 0 
defects 0 
in 0 
hemostasis 0 
and 0 
thrombosis 1
. 0 

von 1
Willebrand 1
factor 1
-LRB- 1
vWf 1
-RRB- 1
deficiency 1
causes 0 
severe 0 
von 1
Willebrand 1
disease 1
in 0 
humans 0 
. 0 

We 0 
generated 0 
a 0 
mouse 0 
model 0 
for 0 
this 0 
disease 0 
by 0 
using 0 
gene 0 
targeting 0 
. 0 

vWf-deficient 1
mice 0 
appeared 0 
normal 0 
at 0 
birth 0 
; 0 
they 0 
were 0 
viable 0 
and 0 
fertile 0 
. 0 

Neither 0 
vWf 0 
nor 0 
vWf 0 
propolypeptide 0 
-LRB- 0 
von 1
Willebrand 1
antigen 0 
II 0 
-RRB- 0 
were 0 
detectable 0 
in 0 
plasma 0 
, 0 
platelets 0 
, 0 
or 0 
endothelial 0 
cells 0 
of 0 
the 0 
homozygous 0 
mutant 0 
mice 0 
. 0 

The 0 
mutant 0 
mice 0 
exhibited 0 
defects 0 
in 0 
hemostasis 0 
with 0 
a 0 
highly 0 
prolonged 0 
bleeding 0 
time 0 
and 0 
spontaneous 0 
bleeding 0 
events 0 
in 0 
approximately 0 
_NUM2 0 
% 0 
of 0 
neonates 0 
. 0 

As 0 
in 0 
the 0 
human 0 
disease 0 
, 0 
the 0 
factor 0 
VIII 0 
level 0 
in 0 
these 0 
mice 0 
was 0 
reduced 0 
strongly 0 
as 0 
a 0 
result 0 
of 0 
the 0 
lack 0 
of 0 
protection 0 
provided 0 
by 0 
vWf 0 
. 0 

Defective 0 
thrombosis 1
in 0 
mutant 0 
mice 0 
was 0 
also 0 
evident 0 
in 0 
an 0 
in 0 
vivo 0 
model 0 
of 0 
vascular 1
injury 1
. 0 

In 0 
this 0 
model 0 
, 0 
the 0 
exteriorized 0 
mesentery 0 
was 0 
superfused 0 
with 0 
ferric 0 
chloride 0 
and 0 
the 0 
accumulation 0 
of 0 
fluorescently 0 
labeled 0 
platelets 0 
was 0 
observed 0 
by 0 
intravital 0 
microscopy 0 
. 0 

We 0 
conclude 0 
that 0 
these 0 
mice 0 
very 0 
closely 0 
mimic 0 
severe 0 
human 0 
von 1
Willebrand 1
disease 1
and 0 
will 0 
be 0 
very 0 
useful 0 
for 0 
investigating 0 
the 0 
role 0 
of 0 
vWf 0 
in 0 
normal 0 
physiology 0 
and 0 
in 0 
disease 0 
models 0 
. 0 
. 0 

The 0 
von 1
Hippel-Lindau 1
tumor 1
suppressor 0 
gene 0 
is 0 
required 0 
for 0 
cell 0 
cycle 0 
exit 0 
upon 0 
serum 0 
withdrawal 0 
. 0 

The 0 
inactivation 0 
of 0 
the 0 
von 1
Hippel-Lindau 1
-LRB- 1
VHL 1
-RRB- 1
tumor 1
suppressor 0 
gene 0 
predisposes 0 
affected 0 
individuals 0 
to 0 
the 0 
human 0 
VHL 1
cancer 1
syndrome 1
and 0 
is 0 
associated 0 
with 0 
sporadic 1
renal 1
cell 1
carcinomas 1
-LRB- 0 
RCC 1
-RRB- 0 
and 0 
brain 1
hemangioblastomas 1
. 0 

VHL-negative 0 
786-0 0 
RCC 1
cells 0 
are 0 
tumorigenic 0 
in 0 
nude 0 
mice 0 
which 0 
is 0 
suppressed 0 
by 0 
the 0 
reintroduction 0 
of 0 
VHL 1
. 0 

Remarkably 0 
, 0 
this 0 
occurs 0 
without 0 
affecting 0 
the 0 
growth 0 
rate 0 
and 0 
cell 0 
cycle 0 
profile 0 
of 0 
these 0 
cells 0 
in 0 
culture 0 
. 0 

The 0 
786-0 0 
cell 0 
line 0 
, 0 
like 0 
many 0 
cancer 1
cells 0 
, 0 
fails 0 
to 0 
exit 0 
the 0 
cell 0 
cycle 0 
upon 0 
serum 0 
withdrawal 0 
. 0 

Here 0 
, 0 
it 0 
is 0 
shown 0 
that 0 
reintroduction 0 
of 0 
the 0 
wild-type 0 
VHL 1
gene 0 
restores 0 
the 0 
ability 0 
of 0 
VHL-negative 0 
RCC 1
cancer 1
cells 0 
to 0 
exit 0 
the 0 
cell 0 
cycle 0 
and 0 
enter 0 
G0 0 
/ 0 
quiescence 0 
in 0 
low 0 
serum 0 
. 0 

Both 0 
VHL-positive 0 
and 0 
VHL-negative 0 
RCC 1
cells 0 
exit 0 
the 0 
cell 0 
cycle 0 
by 0 
contact 0 
inhibition 0 
. 0 

The 0 
cyclin-dependent 0 
kinase 0 
inhibitor 0 
, 0 
_AN 0 
, 0 
accumulates 0 
upon 0 
serum 0 
withdrawal 0 
, 0 
only 0 
in 0 
the 0 
presence 0 
of 0 
VHL 1
, 0 
as 0 
a 0 
result 0 
of 0 
the 0 
stabilization 0 
of 0 
the 0 
protein 0 
. 0 

We 0 
propose 0 
that 0 
the 0 
loss 0 
of 0 
wild-type 0 
VHL 1
gene 0 
results 0 
in 0 
a 0 
specific 0 
cellular 0 
defect 0 
in 0 
serum-dependent 0 
growth 0 
control 0 
, 0 
which 0 
may 0 
initiate 0 
tumor 1
formation 0 
. 0 

This 0 
is 0 
corrected 0 
by 0 
the 0 
reintroduction 0 
of 0 
wild-type 0 
VHL 1
, 0 
implicating 0 
VHL 1
as 0 
the 0 
first 0 
tumor 1
suppressor 0 
involved 0 
in 0 
the 0 
regulation 0 
of 0 
cell 0 
cycle 0 
exit 0 
, 0 
which 0 
is 0 
consistent 0 
with 0 
its 0 
gatekeeper 0 
function 0 
in 0 
the 0 
kidney 0 
. 0 
. 0 

Nonsense 0 
mutation 0 
in 0 
exon 0 
_NUM1 0 
of 0 
human 0 
complement 0
C9 0 
gene 0 
is 0 
the 0 
major 0 
cause 0 
of 0 
Japanese 0 
complement 1
C9 1
deficiency 1
. 0 

Deficiency 1
of 1
the 1
ninth 1
component 1
of 1
human 1
complement 1
-LRB- 0 
C9 0 
-RRB- 0 
is 0 
the 0 
most 0 
common 0 
complement 1
deficiency 1
in 0 
Japan 0 
but 0 
is 0 
rare 0 
in 0 
other 0 
countries 0 
. 0 

We 0 
studied 0 
the 0 
molecular 0 
basis 0 
of 0 
C9 1
deficiency 1
in 0 
four 0 
Japanese 0 
C9-deficient 1
patients 0 
who 0 
had 0 
suffered 0 
from 0 
meningococcal 1
meningitis 1
. 0 

Direct 0 
sequencing 0 
of 0 
amplified 0 
C9 0 
cDNA 0 
and 0 
DNA 0 
revealed 0 
a 0 
nonsense 0 
substitution 0 
-LRB- 0 
_DS 0 
-- 0 
> 0 
_DS 0 
-RRB- 0 
at 0 
codon 0 
_NUM2 0 
in 0 
exon 0 
_NUM1 0 
in 0 
the 0 
four 0 
C9-deficient 1
individuals 0 
. 0 

An 0 
allele-specific 0 
polymerase 0 
chain 0 
reaction 0 
system 0 
designed 0 
to 0 
detect 0 
exclusively 0 
only 0 
one 0 
of 0 
the 0 
normal 0 
and 0 
mutant 0 
alleles 0 
indicated 0 
that 0 
all 0 
the 0 
four 0 
patients 0 
were 0 
homozygous 0 
for 0 
the 0 
mutation 0 
in 0 
exon 0 
_NUM1 0 
and 0 
that 0 
the 0 
parents 0 
of 0 
patient 0 
_NUM1 0 
were 0 
heterozygous 0 
. 0 

The 0 
common 0 
mutation 0 
at 0 
codon 0 
_NUM2 0 
in 0 
exon 0 
_NUM1 0 
might 0 
be 0 
responsible 0 
for 0 
most 0 
Japanese 0 
C9 1
deficiency 1
. 0 
. 0 

Human 1
complement 1
factor 1
H 1
deficiency 1
associated 0 
with 0 
hemolytic 1
uremic 1
syndrome 1
. 0 

This 0 
study 0 
reports 0 
on 0 
six 0 
cases 0 
of 0 
deficiency 1
in 1
the 1
human 1
complement 1
regulatory 1
protein 1
Factor 1
H 1
-LRB- 0 
FH 0 
-RRB- 0 
in 0 
the 0 
context 0 
of 0 
an 0 
acute 1
renal 1
disease 1
. 0 

Five 0 
of 0 
the 0 
cases 0 
were 0 
observed 0 
in 0 
children 0 
presenting 0 
with 0 
idiopathic 0 
hemolytic 1
uremic 1
syndrome 1
-LRB- 0 
HUS 1
-RRB- 0 
. 0 

Two 0 
of 0 
the 0 
children 0 
exhibited 0 
a 0 
homozygous 0 
deficiency 0 
characterized 0 
by 0 
the 0 
absence 0 
of 0 
the 0 
150-kD 0 
form 0 
of 0 
Factor 0
H 0 
and 0 
the 0 
presence 0 
, 0 
upon 0 
immunoblotting 0 
, 0 
of 0 
the 0 
42-kD 0 
Factor 0
H-like 0 
protein 0 
_NUM1 0 
-LRB- 0 
FHL-1 0 
-RRB- 0 
and 0 
other 0 
FH-related 0 
protein 0 
-LRB- 0 
FHR 0 
-RRB- 0 
bands 0 
. 0 

Southern 0 
blot 0 
and 0 
PCR 0 
analysis 0 
of 0 
DNA 0 
of 0 
one 0 
patient 0 
with 0 
homozygous 0 
deficiency 0 
ruled 0 
out 0 
the 0 
presence 0 
of 0 
a 0 
large 0 
deletion 0 
of 0 
the 0 
FH 0 
gene 0 
as 0 
the 0 
underlying 0 
defect 0 
for 0 
the 0 
deficiency 0 
. 0 

The 0 
other 0 
four 0 
children 0 
presented 0 
with 0 
heterozygous 0 
deficiency 0 
and 0 
exhibited 0 
a 0 
normal 0 
immunoblotting 0 
pattern 0 
of 0 
proteins 0 
of 0 
the 0 
FH 0 
family 0 
. 0 

Factor 1
H 1
deficiency 1
is 0 
the 0 
only 0 
complement 1
deficiency 1
associated 0 
with 0 
HUS 1
. 0 

These 0 
observations 0 
suggest 0 
a 0 
role 0 
for 0 
FH 0 
and 0 
/ 0 
or 0 
FH 0 
receptors 0 
in 0 
the 0 
pathogenesis 0 
of 0 
idiopathic 0 
HUS 1
. 0 
. 0 

Cell 0 
cycle-dependent 0 
colocalization 0 
of 0 
BARD1 0 
and 0 
BRCA1 0 
proteins 0 
in 0 
discrete 0 
nuclear 0 
domains 0 
. 0 

Germ-line 0 
mutations 0 
of 0 
the 0 
BRCA1 0 
gene 0 
predispose 0 
women 0 
to 0 
early-onset 0 
breast 1
and 1
ovarian 1
cancer 1
by 0 
compromising 0 
the 0 
genes 0 
presumptive 0 
function 0 
as 0 
a 0 
tumor 1
suppressor 0 
. 0 

Although 0 
the 0 
biochemical 0 
properties 0 
of 0 
BRCA1 0 
polypeptides 0 
are 0 
not 0 
understood 0 
, 0 
their 0 
expression 0 
pattern 0 
and 0 
subcellular 0 
localization 0 
suggest 0 
a 0 
role 0 
in 0 
cell-cycle 0 
regulation 0 
. 0 

When 0 
resting 0 
cells 0 
are 0 
induced 0 
to 0 
proliferate 0 
, 0 
the 0 
steady-state 0 
levels 0 
of 0 
BRCA1 0 
increase 0 
in 0 
late 0 
G1 0 
and 0 
reach 0 
a 0 
maximum 0 
during 0 
S 0 
phase 0 
. 0 

Moreover 0 
, 0 
in 0 
S 0 
phase 0 
cells 0 
, 0 
BRCA1 0 
polypeptides 0 
are 0 
hyperphosphorylated 0 
and 0 
accumulate 0 
into 0 
discrete 0 
subnuclear 0 
foci 0 
termed 0 
'' 0 
BRCA1 0 
nuclear 0 
dots 0 
. 0 
'' 0 

BRCA1 0 
associates 0 
in 0 
vivo 0 
with 0 
a 0 
structurally 0 
related 0 
protein 0 
termed 0 
BARD1 0 
. 0 

Here 0 
we 0 
show 0 
that 0 
the 0 
steady-state 0 
levels 0 
of 0 
BARD1 0 
, 0 
unlike 0 
those 0 
of 0 
BRCA1 0 
, 0 
remain 0 
relatively 0 
constant 0 
during 0 
cell 0 
cycle 0 
progression 0 
. 0 

However 0 
, 0 
immunostaining 0 
revealed 0 
that 0 
BARD1 0 
resides 0 
within 0 
BRCA1 0 
nuclear 0 
dots 0 
during 0 
S 0 
phase 0 
of 0 
the 0 
cell 0 
cycle 0 
, 0 
but 0 
not 0 
during 0 
the 0 
G1 0 
phase 0 
. 0 

Nevertheless 0 
, 0 
BARD1 0 
polypeptides 0 
are 0 
found 0 
exclusively 0 
in 0 
the 0 
nuclear 0 
fractions 0 
of 0 
both 0 
G1 0 
- 0 
and 0 
S-phase 0 
cells 0 
. 0 

Therefore 0 
, 0 
progression 0 
to 0 
S 0 
phase 0 
is 0 
accompanied 0 
by 0 
the 0 
aggregation 0 
of 0 
nuclear 0 
BARD1 0 
polypeptides 0 
into 0 
BRCA1 0 
nuclear 0 
dots 0 
. 0 

This 0 
cell 0 
cycle-dependent 0 
colocalization 0 
of 0 
BARD1 0 
and 0 
BRCA1 0 
indicates 0 
a 0 
role 0 
for 0 
BARD1 0 
in 0 
BRCA1-mediated 0 
tumor 1
suppression 0 
. 0 

Genetic 0 
basis 0 
and 0 
molecular 0 
mechanism 0 
for 0 
idiopathic 1
ventricular 1
fibrillation 1
. 0 

Ventricular 1
fibrillation 1
causes 0 
more 0 
than 0 
_NUM3 0 
, 0 
_NUM3 0 
sudden 0 
deaths 0 
each 0 
year 0 
in 0 
the 0 
USA 0 
alone 0 
. 0 

In 0 
approximately 0 
5-12 0 
% 0 
of 0 
these 0 
cases 0 
, 0 
there 0 
are 0 
no 0 
demonstrable 0 
cardiac 0 
or 0 
non-cardiac 0 
causes 0 
to 0 
account 0 
for 0 
the 0 
episode 0 
, 0 
which 0 
is 0 
therefore 0 
classified 0 
as 0 
idiopathic 1
ventricular 1
fibrillation 1
-LRB- 0 
IVF 1
-RRB- 0 
. 0 

A 0 
distinct 0 
group 0 
of 0 
IVF 1
patients 0 
has 0 
been 0 
found 0 
to 0 
present 0 
with 0 
a 0 
characteristic 0 
electrocardiographic 0 
pattern 0 
. 0 

Because 0 
of 0 
the 0 
small 0 
size 0 
of 0 
most 0 
pedigrees 0 
and 0 
the 0 
high 0 
incidence 0 
of 0 
sudden 1
death 1
, 0 
however 0 
, 0 
molecular 0 
genetic 0 
studies 0 
of 0 
IVF 1
have 0 
not 0 
yet 0 
been 0 
done 0 
. 0 

Because 0 
IVF 1
causes 0 
cardiac 0 
rhythm 0 
disturbance 0 
, 0 
we 0 
investigated 0 
whether 0 
malfunction 0 
of 0 
ion 0 
channels 0 
could 0 
cause 0 
the 0 
disorder 0 
by 0 
studying 0 
mutations 0 
in 0 
the 0 
cardiac 0 
sodium 0 
channel 0 
gene 0 
SCN5A 0 
. 0 

We 0 
have 0 
now 0 
identified 0 
a 0 
missense 0 
mutation 0 
, 0 
a 0 
splice-donor 0 
mutation 0 
, 0 
and 0 
a 0 
frameshift 0 
mutation 0 
in 0 
the 0 
coding 0 
region 0 
of 0 
SCN5A 0 
in 0 
three 0 
IVF 1
families 0 
. 0 

We 0 
show 0 
that 0 
sodium 0 
channels 0 
with 0 
the 0 
missense 0 
mutation 0 
recover 0 
from 0 
inactivation 0 
more 0 
rapidly 0 
than 0 
normal 0 
and 0 
that 0 
the 0 
frameshift 0 
mutation 0 
causes 0 
the 0 
sodium 0 
channel 0 
to 0 
be 0 
non-functional 0 
. 0 

Our 0 
results 0 
indicate 0 
that 0 
mutations 0 
in 0 
cardiac 0 
ion-channel 0 
genes 0 
contribute 0 
to 0 
the 0 
risk 0 
of 0 
developing 0 
IVF 1
. 0 
. 0 

Prevalence 0 
of 0 
the 0 
I1307K 0 
APC 1
gene 0 
variant 0 
in 0 
Israeli 0 
Jews 0 
of 0 
differing 0 
ethnic 0 
origin 0 
and 0 
risk 0 
for 0 
colorectal 1
cancer 1
. 0 

BACKGROUND 0 
& 0 
AIMS 0 
Israeli 0 
Jews 0 
of 0 
European 0 
birth 0 
, 0 
i. 0 
e. 0 
, 0 
Ashkenazim 0 
, 0 
have 0 
the 0 
highest 0 
colorectal 1
cancer 1
incidence 0 
of 0 
any 0 
Israeli 0 
ethnic 0 
group 0 
. 0 

The 0 
I1307K 0 
APC 1
gene 0 
variant 0 
was 0 
found 0 
in 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
of 0 
American 0 
Jews 0 
, 0 
_NUM2 0 
% 0 
of 0 
their 0 
familial 0 
colorectal 1
cancer 1
cases 0 
, 0 
but 0 
not 0 
in 0 
non-Jews 0 
. 0 

We 0 
assessed 0 
the 0 
I1307K 0 
prevalence 0 
in 0 
Israeli 0 
Jews 0 
of 0 
differing 0 
ethnic 0 
origin 0 
and 0 
risk 0 
for 0 
colorectal 1
cancer 1
. 0 

METHODS 0 
DNA 0 
samples 0 
from 0 
_NUM3 0 
unrelated 0 
Jews 0 
of 0 
European 0 
or 0 
non-European 0 
origin 0 
, 0 
with 0 
or 0 
without 0 
a 0 
personal 0 
and 0 
/ 0 
or 0 
family 0 
history 0 
of 0 
neoplasia 1
, 0 
were 0 
examined 0 
for 0 
the 0 
I1307K 0 
variant 0 
by 0 
the 0 
allele-specific 0 
oligonucleotide 0 
-LRB- 0 
ASO 0 
-RRB- 0 
method 0 
. 0 

RESULTS 0 
In 0 
persons 0 
at 0 
average 0 
risk 0 
for 0 
colorectal 1
cancer 1
, 0 
I1307K 0 
was 0 
found 0 
in 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
of 0 
_NUM3 0 
European 0 
and 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
of 0 
_NUM3 0 
non-European 0 
Jews 0 
-LRB- 0 
P 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

It 0 
occurred 0 
in 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
of 0 
_NUM2 0 
Ashkenazi 0 
Israelis 0 
with 0 
familial 0 
cancer 1
-LRB- 0 
P 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
-RRB- 0 
and 0 
was 0 
not 0 
detected 0 
in 0 
_NUM2 0 
non-European 0 
Jews 0 
at 0 
increased 0 
cancer 1
risk 0 
. 0 

Colorectal 1
neoplasia 1
occurred 0 
personally 0 
or 0 
in 0 
the 0 
families 0 
of 0 
_NUM2 0 
of 0 
_NUM2 0 
Ashkenazi 0 
I1307K 0 
carriers 0 
, 0 
_NUM1 0 
of 0 
whom 0 
also 0 
had 0 
a 0 
personal 0 
or 0 
family 0 
history 0 
of 0 
noncolonic 0 
neoplasia 1
. 0 

CONCLUSIONS 0 
The 0 
I1307K 0 
APC 0 
variant 0 
may 0 
represent 0 
a 0 
susceptibility 0 
gene 0 
for 0 
colorectal 1
, 1
or 1
other 1
, 1
cancers 1
in 0 
Ashkenazi 0 
Jews 0 
, 0 
and 0 
partially 0 
explains 0 
the 0 
higher 0 
incidence 0 
of 0 
colorectal 1
cancer 1
in 0 
European 0 
Israelis 0 
. 0 

Susceptibility 0 
to 0 
ankylosing 1
spondylitis 1
in 0 
twins 0 
: 0 
the 0 
role 0 
of 0 
genes 0 
, 0 
HLA 0 
, 0 
and 0 
the 0 
environment 0 
. 0 

OBJECTIVE 0 
To 0 
determine 0 
the 0 
relative 0 
effects 0 
of 0 
genetic 0 
and 0 
environmental 0 
factors 0 
in 0 
susceptibility 0 
to 0 
ankylosing 1
spondylitis 1
-LRB- 0 
AS 1
-RRB- 0 
. 0 

METHODS 0 
Twins 0 
with 0 
AS 1
were 0 
identified 0 
from 0 
the 0 
Royal 0 
National 0 
Hospital 0 
for 0 
Rheumatic 1
Diseases 1
database 0 
. 0 

Clinical 0 
and 0 
radiographic 0 
examinations 0 
were 0 
performed 0 
to 0 
establish 0 
diagnoses 0 
, 0 
and 0 
disease 0 
severity 0 
was 0 
assessed 0 
using 0 
a 0 
combination 0 
of 0 
validated 0 
scoring 0 
systems 0 
. 0 

HLA 0 
typing 0 
for 0 
HLA-B27 0 
, 0 
HLA-B60 0 
, 0 
and 0 
HLA-DR1 0 
was 0 
performed 0 
by 0 
polymerase 0 
chain 0 
reaction 0 
with 0 
sequence-specific 0 
primers 0 
, 0 
and 0 
zygosity 0 
was 0 
assessed 0 
using 0 
microsatellite 0 
markers 0 
. 0 

Genetic 0 
and 0 
environmental 0 
variance 0 
components 0 
were 0 
assessed 0 
with 0 
the 0 
program 0 
Mx 0 
, 0 
using 0 
data 0 
from 0 
this 0 
and 0 
previous 0 
studies 0 
of 0 
twins 0 
with 0 
AS 1
. 0 

RESULTS 0 
Six 0 
of 0 
_NUM1 0 
monozygotic 0 
-LRB- 0 
MZ 0 
-RRB- 0 
twin 0 
pairs 0 
were 0 
disease 0 
concordant 0 
, 0 
compared 0 
with 0 
_NUM1 0 
of 0 
_NUM2 0 
B27-positive 0 
dizygotic 0 
-LRB- 0 
DZ 0 
-RRB- 0 
twin 0 
pairs 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
and 0 
_NUM1 0 
of 0 
_NUM2 0 
DZ 0 
twin 0 
pairs 0 
overall 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
. 0 

Nonsignificant 0 
increases 0 
in 0 
similarity 0 
with 0 
regard 0 
to 0 
age 0 
at 0 
disease 0 
onset 0 
and 0 
all 0 
of 0 
the 0 
disease 0 
severity 0 
scores 0 
assessed 0 
were 0 
noted 0 
in 0 
disease-concordant 0 
MZ 0 
twins 0 
compared 0 
with 0 
concordant 0 
DZ 0 
twins 0 
. 0 

HLA-B27 0 
and 0 
_AN 0 
were 0 
associated 0 
with 0 
the 0 
disease 0 
in 0 
probands 0 
, 0 
and 0 
the 0 
rate 0 
of 0 
disease 0 
concordance 0 
was 0 
significantly 0 
increased 0 
among 0 
DZ 0 
twin 0 
pairs 0 
in 0 
which 0 
the 0 
co-twin 0 
was 0 
positive 0 
for 0 
both 0 
_AN 0 
and 0 
DR1 0 
. 0 

Additive 0 
genetic 0 
effects 0 
were 0 
estimated 0 
to 0 
contribute 0 
_NUM2 0 
% 0 
of 0 
the 0 
population 0 
variance 0 
. 0 

CONCLUSION 0 
Susceptibility 0 
to 0 
AS 1
is 0 
largely 0 
genetically 0 
determined 0 
, 0 
and 0 
the 0 
environmental 0 
trigger 0 
for 0 
the 0 
disease 0 
is 0 
probably 0 
ubiquitous 0 
. 0 

HLA-B27 0 
accounts 0 
for 0 
a 0 
minority 0 
of 0 
the 0 
overall 0 
genetic 0 
susceptibility 0 
to 0 
AS 1
. 0 

The 0 
APCI1307K 0 
allele 0 
and 0 
cancer 1
risk 0 
in 0 
a 0 
community-based 0 
study 0 
of 0 
Ashkenazi 0 
Jews 0 
. 0 

Mutations 0 
in 0 
APC 0 
are 0 
classically 0 
associated 0 
with 0 
familial 1
adenomatous 1
polyposis 1
-LRB- 0 
FAP 1
-RRB- 0 
, 0 
a 0 
highly 0 
penetrant 0 
autosomal 1
dominant 1
disorder 1
characterized 0 
by 0 
multiple 0 
intestinal 0 
polyps 1
and 0 
, 0 
without 0 
surgical 0 
intervention 0 
, 0 
the 0 
development 0 
of 0 
colorectal 1
cancer 1
-LRB- 0 
CRC 1
-RRB- 0 
. 0 

APC 1
is 0 
a 0 
tumour-suppressor 0 
gene 0 
, 0 
and 0 
somatic 0 
loss 0 
occurs 0 
in 0 
tumours 1
. 0 

The 0 
germline 0 
T-to-A 0 
transversion 0 
responsible 0 
for 0 
the 0 
APC 0 
I1307K 0 
allele 0 
converts 0 
the 0 
wild-type 0 
sequence 0 
to 0 
a 0 
homopolymer 0 
tract 0 
-LRB- 0 
A8 0 
-RRB- 0 
that 0 
is 0 
genetically 0 
unstable 0 
and 0 
prone 0 
to 0 
somatic 0 
mutation 0 
. 0 

The 0 
I1307K 0 
allele 0 
was 0 
found 0 
in 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
of 0 
unselected 0 
Ashkenazi 0 
Jews 0 
and 0 
higher 0 
proportions 0 
of 0 
Ashkenazim 0 
with 0 
family 0 
or 0 
personal 0 
histories 0 
of 0 
CRC 1
-LRB- 0 
ref 0 
. 0 

_NUM1 0 
-RRB- 0 
. 0 

To 0 
evaluate 0 
the 0 
role 0 
of 0 
I1307K 0 
in 0 
cancer 1
, 0 
we 0 
genotyped 0 
_NUM1 0 
, 0 
_NUM3 0 
Ashkenazi 0 
volunteers 0 
in 0 
a 0 
community 0 
survey 0 
. 0 

Risk 0 
of 0 
developing 0 
colorectal 1
, 1
breast 1
and 1
other 1
cancers 1
were 0 
compared 0 
between 0 
genotyped 0 
I1307K 0 
carriers 0 
and 0 
non-carriers 0 
and 0 
their 0 
first-degree 0 
relatives 0 
. 0 

The 0 
hemochromatosis 1
gene 0 
product 0 
complexes 0 
with 0 
the 0 
transferrin 0 
receptor 0 
and 0 
lowers 0 
its 0 
affinity 0 
for 0 
ligand 0 
binding 0 
. 0 

We 0 
recently 0 
reported 0 
the 0 
positional 0 
cloning 0 
of 0 
a 0 
candidate 0 
gene 0 
for 0 
hereditary 1
hemochromatosis 1
called 0 
HFE 0 
. 0 

The 0 
gene 0 
product 0 
, 0 
a 0 
member 0 
of 0 
the 0 
major 0 
histocompatibility 0 
complex 0 
class 0 
I-like 0 
family 0 
, 0 
was 0 
found 0 
to 0 
have 0 
a 0 
mutation 0 
, 0 
Cys-282 0 
-- 0 
> 0 
Tyr 0 
-LRB- 0 
C282Y 0 
-RRB- 0 
, 0 
in 0 
_NUM2 0 
% 0 
of 0 
patient 0 
chromosomes 0 
. 0 

This 0 
mutation 0 
eliminates 0 
the 0 
ability 0 
of 0 
HFE 0 
to 0 
associate 0 
with 0 
beta2-microglobulin 0 
-LRB- 0 
beta2m 0 
-RRB- 0 
and 0 
prevents 0 
cell-surface 0 
expression 0 
. 0 

A 0 
second 0 
mutation 0 
that 0 
has 0 
no 0 
effect 0 
on 0 
beta2m 0 
association 0 
, 0 
H63D 0 
, 0 
was 0 
found 0 
in 0 
eight 0 
out 0 
of 0 
nine 0 
patients 0 
heterozygous 0 
for 0 
the 0 
C282Y 0 
mutant 0 
. 0 

In 0 
this 0 
report 0 
, 0 
we 0 
demonstrate 0 
in 0 
cultured 0 
_NUM3 0 
cells 0 
overexpressing 0 
wild-type 0 
or 0 
mutant 0 
HFE 0 
proteins 0 
that 0 
both 0 
the 0 
wild-type 0 
and 0 
H63D 0 
HFE 0 
proteins 0 
form 0 
stable 0 
complexes 0 
with 0 
the 0 
transferrin 0 
receptor 0 
-LRB- 0 
TfR 0 
-RRB- 0 
. 0 

The 0 
C282Y 0 
mutation 0 
nearly 0 
completely 0 
prevents 0 
the 0 
association 0 
of 0 
the 0 
mutant 0 
HFE 0 
protein 0 
with 0 
the 0 
TfR 0 
. 0 

Studies 0 
on 0 
cell-associated 0 
transferrin 0 
at 0 
_NUM2 0 
degrees 0 
C 0 
suggest 0 
that 0 
the 0 
overexpressed 0 
wild-type 0 
HFE 0 
protein 0 
decreases 0 
the 0 
affinity 0 
of 0 
the 0 
TfR 0 
for 0 
transferrin 0 
. 0 

The 0 
overexpressed 0 
H63D 0 
protein 0 
does 0 
not 0 
have 0 
this 0 
effect 0 
, 0 
providing 0 
the 0 
first 0 
direct 0 
evidence 0 
for 0 
a 0 
functional 0 
consequence 0 
of 0 
the 0 
H63D 0 
mutation 0 
. 0 

Addition 0 
of 0 
soluble 0 
wild-type 0 
HFE 0 
/ 0 
beta2m 0 
heterodimers 0 
to 0 
cultured 0 
cells 0 
also 0 
decreased 0 
the 0 
apparent 0 
affinity 0 
of 0 
the 0 
TfR 0 
for 0 
its 0 
ligand 0 
under 0 
steady-state 0 
conditions 0 
, 0 
both 0 
in 0 
_NUM3 0 
cells 0 
and 0 
in 0 
HeLa 0 
cells 0 
. 0 

Furthermore 0 
, 0 
at 0 
_NUM1 0 
degrees 0 
C 0 
, 0 
the 0 
added 0 
soluble 0 
complex 0 
of 0 
HFE 0 
/ 0 
beta2m 0 
inhibited 0 
binding 0 
of 0 
transferrin 0 
to 0 
HeLa 0 
cell 0 
TfR 0 
in 0 
a 0 
concentration-dependent 0 
manner 0 
. 0 

Scatchard 0 
plots 0 
of 0 
these 0 
data 0 
indicate 0 
that 0 
the 0 
added 0 
heterodimer 0 
substantially 0 
reduced 0 
the 0 
affinity 0 
of 0 
TfR 0 
for 0 
transferrin 0 
. 0 

These 0 
results 0 
establish 0 
a 0 
molecular 0 
link 0 
between 0 
HFE 0 
and 0 
a 0 
key 0 
protein 0 
involved 0 
in 0 
iron 0 
transport 0 
, 0 
the 0 
TfR 0 
, 0 
and 0 
raise 0 
the 0 
possibility 0 
that 0 
alterations 0 
in 0 
this 0 
regulatory 0 
mechanism 0 
may 0 
play 0 
a 0 
role 0 
in 0 
the 0 
pathogenesis 0 
of 0 
hereditary 1
hemochromatosis 1
. 0 
. 0 

Cycloheximide 0 
facilitates 0 
the 0 
identification 0 
of 0 
aberrant 0 
transcripts 0 
resulting 0 
from 0 
a 0 
novel 0 
splice-site 0 
mutation 0 
in 0 
COL17A1 0 
in 0 
a 0 
patient 0 
with 0 
generalized 0 
atrophic 1
benign 1
epidermolysis 1
bullosa 1
. 0 

Patients 0 
with 0 
generalized 0 
atrophic 1
benign 1
epidermolysis 1
bullosa 1
often 0 
show 0 
decreased 0 
expression 0 
of 0 
type 0 
XVII 0 
collagen 0 
, 0 
a 0 
transmembrane 0 
hemidesmosomal 0 
protein 0 
encoded 0 
by 0 
COL17A1 0 
. 0 

This 0 
report 0 
documents 0 
a 0 
novel 0 
splice-site 0 
mutation 0 
in 0 
COL17A1 0 
in 0 
a 0 
patient 0 
with 0 
generalized 0 
atrophic 1
benign 1
epidermolysis 1
bullosa 1
, 0 
and 0 
applies 0 
a 0 
new 0 
methodology 0 
to 0 
define 0 
and 0 
characterize 0 
the 0 
resulting 0 
mRNA 0 
splice 0 
variants 0 
. 0 

Mutational 0 
analysis 0 
of 0 
COL17A1 0 
identified 0 
a 0 
maternally 0 
inherited 0 
G-to-T 0 
transversion 0 
at 0 
the 0 
-1 0 
position 0 
of 0 
exon 0 
_NUM2 0 
. 0 

This 0 
acceptor 0 
splice-site 0 
mutation 0 
led 0 
to 0 
the 0 
formation 0 
of 0 
aberrant 0 
transcripts 0 
present 0 
at 0 
extremely 0 
low 0 
levels 0 
. 0 

Based 0 
on 0 
our 0 
recent 0 
finding 0 
that 0 
cycloheximide 0 
stabilized 0 
mutant 0 
COL17A1 0 
transcripts 0 
in 0 
keratinocytes 0 
homozygous 0 
for 0 
a 0 
frameshift 0 
mutation 0 
, 0 
the 0 
effects 0 
of 0 
the 0 
splice-site 0 
mutation 0 
on 0 
splicing 0 
of 0 
COL17A1 0 
transcripts 0 
were 0 
determined 0 
using 0 
reverse 0 
transcriptase 0 
polymerase 0 
chain 0 
reaction 0 
of 0 
total 0 
RNA 0 
from 0 
keratinocytes 0 
incubated 0 
for 0 
_NUM1 0 
. 0 

_NUM1 0 
h 0 
in 0 
the 0 
presence 0 
or 0 
absence 0 
of 0 
_NUM2 0 
microg 0 
cycloheximide 0 
per 0 
ml 0 
. 0 

Using 0 
this 0 
approach 0 
, 0 
an 0 
abnormally 0 
spliced 0 
transcript 0 
was 0 
identified 0 
that 0 
contains 0 
an 0 
extra 0 
_NUM3 0 
bases 0 
upstream 0 
from 0 
exon 0 
_NUM2 0 
, 0 
resulting 0 
in 0 
a 0 
premature 0 
termination 0 
codon 0 
_NUM2 0 
bp 0 
downstream 0 
from 0 
the 0 
cryptic 0 
splice 0 
site 0 
. 0 

Three 0 
other 0 
splice 0 
variants 0 
, 0 
including 0 
one 0 
derived 0 
from 0 
the 0 
skipping 0 
of 0 
exon 0 
_NUM2 0 
, 0 
were 0 
also 0 
identified 0 
. 0 

These 0 
results 0 
indicate 0 
the 0 
usefulness 0 
of 0 
cycloheximide 0 
treatment 0 
in 0 
evaluating 0 
the 0 
abnormal 0 
processing 0 
of 0 
mRNA 0 
due 0 
to 0 
splice-site 0 
mutations 0 
, 0 
because 0 
-LRB- 0 
i 0 
-RRB- 0 
aberrant 0 
splicing 0 
often 0 
generates 0 
a 0 
premature 0 
termination 0 
codon 0 
, 0 
-LRB- 0 
ii 0 
-RRB- 0 
transcripts 0 
with 0 
premature 0 
termination 0 
codons 0 
can 0 
occur 0 
at 0 
low 0 
or 0 
undetectable 0 
levels 0 
due 0 
to 0 
nonsense-mediated 0 
mRNA 0 
decay 0 
, 0 
and 0 
-LRB- 0 
iii 0 
-RRB- 0 
the 0 
levels 0 
of 0 
these 0 
transcripts 0 
can 0 
be 0 
increased 0 
by 0 
cycloheximide 0 
. 0 

The 0 
DMPK 0 
gene 0 
of 0 
severely 0 
affected 0 
myotonic 1
dystrophy 1
patients 0 
is 0 
hypermethylated 0 
proximal 0 
to 0 
the 0 
largely 0 
expanded 0 
_DS 0 
repeat 0 
. 0 

Using 0 
methylation-sensitive 0 
restriction 0 
enzymes 0 
, 0 
we 0 
characterized 0 
the 0 
methylation 0 
pattern 0 
on 0 
the 0 
_NUM1 0 
side 0 
of 0 
the 0 
_DS 0 
repeat 0 
in 0 
the 0 
DMPK 0 
gene 0 
of 0 
normal 0 
individuals 0 
and 0 
of 0 
patients 0 
affected 0 
with 0 
myotonic 1
dystrophy 1
, 0 
showing 0 
expansions 0 
of 0 
the 0 
repetitive 0 
sequence 0 
. 0 

The 0 
gene 0 
segment 0 
analyzed 0 
corresponds 0 
to 0 
the 0 
genomic 0 
SacI-HindIII 0 
fragment 0 
carrying 0 
exons 0 
11-15 0 
. 0 

There 0 
is 0 
constitutive 0 
methylation 0 
in 0 
intron 0 
_NUM2 0 
at 0 
restriction 0 
sites 0 
of 0 
SacII 0 
and 0 
HhaI 0 
, 0 
localized 0 
_NUM1 0 
, 0 
159-1 0 
, 0 
_NUM3 0 
bp 0 
upstream 0 
of 0 
the 0 
_DS 0 
repeat 0 
, 0 
whereas 0 
most 0 
, 0 
if 0 
not 0 
all 0 
, 0 
of 0 
the 0 
other 0 
sites 0 
of 0 
SacII 0 
, 0 
HhaI 0 
, 0 
and 0 
HpaII 0 
in 0 
this 0 
region 0 
are 0 
unmethylated 0 
, 0 
in 0 
normal 0 
individuals 0 
and 0 
most 0 
of 0 
the 0 
patients 0 
. 0 

In 0 
a 0 
number 0 
of 0 
young 0 
and 0 
severely 0 
affected 0 
patients 0 
, 0 
however 0 
, 0 
complete 0 
methylation 0 
of 0 
these 0 
restriction 0 
sites 0 
was 0 
found 0 
in 0 
the 0 
mutated 0 
allele 0 
. 0 

In 0 
most 0 
of 0 
these 0 
patients 0 
, 0 
the 0 
onset 0 
of 0 
the 0 
disease 0 
was 0 
congenital 0 
. 0 

Preliminary 0 
in 0 
vivo 0 
footprinting 0 
data 0 
gave 0 
evidence 0 
for 0 
protein-DNA 0 
contact 0 
in 0 
normal 0 
genes 0 
at 0 
an 0 
Sp1 0 
consensus 0 
binding 0 
site 0 
upstream 0 
of 0 
the 0 
_DS 0 
repeat 0 
and 0 
for 0 
a 0 
significant 0 
reduction 0 
of 0 
this 0 
interaction 0 
in 0 
cells 0 
with 0 
a 0 
hypermethylated 0 
DMPK 0 
gene 0 
. 0 
. 0 

Progression 0 
of 0 
somatic 0 
_DS 0 
repeat 0 
length 0 
heterogeneity 0 
in 0 
the 0 
blood 0 
cells 0 
of 0 
myotonic 1
dystrophy 1
patients 0 
. 0 

The 0 
genetic 0 
basis 0 
of 0 
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
is 0 
the 0 
expansion 0 
of 0 
an 0 
unstable 0 
_DS 0 
repeat 0 
in 0 
the 0 
_NUM2 0 
UTR 0 
of 0 
the 0 
DM 1
protein 0 
kinase 0 
gene 0 
on 0 
chromosome 0 
_NUM2 0 
. 0 

One 0 
of 0 
the 0 
principal 0 
features 0 
of 0 
the 0 
DM 1
mutation 0 
is 0 
an 0 
extraordinarily 0 
high 0 
level 0 
of 0 
somatic 0 
mosaicism 0 
, 0 
due 0 
to 0 
an 0 
extremely 0 
high 0 
degree 0 
of 0 
somatic 0 
instability 0 
both 0 
within 0 
and 0 
between 0 
different 0 
tissues 0 
. 0 

This 0 
instability 0 
appears 0 
to 0 
be 0 
biased 0 
towards 0 
further 0 
expansion 0 
and 0 
continuous 0 
throughout 0 
the 0 
life 0 
of 0 
an 0 
individual 0 
, 0 
features 0 
that 0 
could 0 
be 0 
associated 0 
with 0 
the 0 
progressive 0 
nature 0 
of 0 
the 0 
disease 0 
. 0 

Although 0 
increasing 0 
measured 0 
allele 0 
size 0 
between 0 
patients 0 
clearly 0 
correlates 0 
with 0 
an 0 
increased 0 
severity 0 
of 0 
symptoms 0 
and 0 
an 0 
earlier 0 
age 0 
of 0 
onset 0 
, 0 
this 0 
correlation 0 
is 0 
not 0 
precise 0 
and 0 
measured 0 
allele 0 
length 0 
can 0 
not 0 
be 0 
used 0 
as 0 
an 0 
accurate 0 
predictor 0 
of 0 
age 0 
of 0 
onset 0 
. 0 

In 0 
order 0 
to 0 
further 0 
characterize 0 
the 0 
dynamics 0 
of 0 
DM 1
_DS 0 
repeat 0 
somatic 0 
instability 0 
, 0 
we 0 
have 0 
studied 0 
repeat 0 
length 0 
changes 0 
over 0 
time 0 
in 0 
_NUM3 0 
myotonic 1
dystrophy 1
patients 0 
with 0 
varying 0 
clinical 0 
severity 0 
and 0 
_DS 0 
repeat 0 
size 0 
over 0 
time 0 
intervals 0 
of 0 
1-7 0 
years 0 
. 0 

We 0 
have 0 
found 0 
a 0 
direct 0 
progression 0 
of 0 
the 0 
size 0 
heterogeneity 0 
over 0 
time 0 
related 0 
to 0 
initial 0 
_DS 0 
repeat 0 
size 0 
and 0 
the 0 
time 0 
interval 0 
and 0 
always 0 
biased 0 
towards 0 
further 0 
expansion 0 
. 0 

Attempts 0 
to 0 
mathematically 0 
model 0 
the 0 
dynamics 0 
have 0 
proved 0 
only 0 
partially 0 
successful 0 
suggesting 0 
that 0 
individual 0 
specific 0 
genetic 0 
and 0 
/ 0 
or 0 
environmental 0 
factors 0 
also 0 
play 0 
a 0 
role 0 
in 0 
somatic 0 
mosaicism 0 
. 0 
. 0 

Inherited 1
colorectal 1
polyposis 1
and 0 
cancer 1
risk 0 
of 0 
the 0 
APC 1
I1307K 0 
polymorphism 0 
. 0 

Germ-line 0 
and 0 
somatic 0 
truncating 0 
mutations 0 
of 0 
the 0 
APC 0 
gene 0 
are 0 
thought 0 
to 0 
initiate 0 
colorectal 1
tumor 1
formation 0 
in 0 
familial 1
adenomatous 1
polyposis 1
syndrome 1
and 0 
sporadic 0 
colorectal 0 
carcinogenesis 0 
, 0 
respectively 0 
. 0 

Recently 0 
, 0 
an 0 
isoleucine 0 
-- 0 
> 0 
lysine 0 
polymorphism 0 
at 0 
codon 0 
_NUM4 0 
-LRB- 0 
I1307K 0 
-RRB- 0 
of 0 
the 0 
APC 1
gene 0 
has 0 
been 0 
identified 0 
in 0 
_NUM1 0 
% 0 
-7 0 
% 0 
of 0 
the 0 
Ashkenazi 0 
Jewish 0 
population 0 
. 0 

To 0 
assess 0 
the 0 
risk 0 
of 0 
this 0 
common 0 
APC 1
allelic 0 
variant 0 
in 0 
colorectal 0 
carcinogenesis 0 
, 0 
we 0 
have 0 
analyzed 0 
a 0 
large 0 
cohort 0 
of 0 
unselected 0 
Ashkenazi 0 
Jewish 0 
subjects 0 
with 0 
adenomatous 1
polyps 1
and 0 
. 0 

or 0 
colorectal 1
cancer 1
, 1
for 0 
the 0 
APC 0 
I1307K 0 
polymorphism 0 
. 0 

The 0 
APC 0 
I1307K 0 
allele 0 
was 0 
identified 0 
in 0 
_NUM2 0 
-LRB- 0 
_NUM2 0 
. 0 

_NUM1 0 
% 0 
-RRB- 0 
of 0 
_NUM3 0 
patients 0 
. 0 

Compared 0 
with 0 
the 0 
frequency 0 
in 0 
two 0 
separate 0 
population 0 
control 0 
groups 0 
, 0 
the 0 
APC 0 
I1307K 0 
allele 0 
is 0 
associated 0 
with 0 
an 0 
estimated 0 
relative 0 
risk 0 
of 0 
_NUM1 0 
. 0 

5-1 0 
. 0 

_NUM1 0 
for 0 
colorectal 1
neoplasia 1
-LRB- 0 
both 0 
P 0 
= 0 
. 0 

_NUM2 0 
-RRB- 0 
. 0 

Furthermore 0 
, 0 
compared 0 
with 0 
noncarriers 0 
, 0 
APC 0 
I1307K 0 
carriers 0 
had 0 
increased 0 
numbers 0 
of 0 
adenomas 1
and 0 
colorectal 1
cancers 1
per 0 
patient 0 
-LRB- 0 
P 0 
= 0 
. 0 

_NUM2 0 
-RRB- 0 
, 0 
as 0 
well 0 
as 0 
a 0 
younger 0 
age 0 
at 0 
diagnosis 0 
. 0 

We 0 
conclude 0 
that 0 
the 0 
APC 0 
I1307K 0 
variant 0 
leads 0 
to 0 
increased 0 
adenoma 1
formation 0 
and 0 
directly 0 
contributes 0 
to 0 
_NUM1 0 
% 0 
-4 0 
% 0 
of 0 
all 0 
Ashkenazi 0 
Jewish 0 
colorectal 1
cancer 1
. 0 

The 0 
estimated 0 
relative 0 
risk 0 
for 0 
carriers 0 
may 0 
justify 0 
specific 0 
clinical 0 
screening 0 
for 0 
the 0 
_NUM3 0 
, 0 
_NUM3 0 
Americans 0 
expected 0 
to 0 
harbor 0 
this 0 
allele 0 
, 0 
and 0 
genetic 0 
testing 0 
in 0 
the 0 
setting 0 
of 0 
long-term-outcome 0 
studies 0 
may 0 
impact 0 
significantly 0 
on 0 
colorectal 1
cancer 1
prevention 0 
in 0 
this 0 
population 0 
. 0 

Human 0 
MLH1 0 
deficiency 0 
predisposes 0 
to 0 
hematological 1
malignancy 1
and 0 
neurofibromatosis 1
type 1
_NUM1 1
. 0 

Heterozygous 0 
germ-line 0 
mutations 0 
in 0 
the 0 
DNA 0 
mismatch 0 
repair 0 
genes 0 
lead 0 
to 0 
hereditary 1
nonpolyposis 1
colorectal 1
cancer 1
. 0 

The 0 
disease 0 
susceptibility 0 
of 0 
individuals 0 
who 0 
constitutionally 0 
lack 0 
both 0 
wild-type 0 
alleles 0 
is 0 
unknown 0 
. 0 

We 0 
have 0 
identified 0 
three 0 
offspring 0 
in 0 
a 0 
hereditary 1
nonpolyposis 1
colorectal 1
cancer 1
family 0 
who 0 
developed 0 
hematological 1
malignancy 1
at 0 
a 0 
very 0 
early 0 
age 0 
, 0 
and 0 
at 0 
least 0 
two 0 
of 0 
them 0 
displayed 0 
signs 0 
of 0 
neurofibromatosis 1
type 1
_NUM1 1
-LRB- 0 
NF1 1
-RRB- 0 
. 0 

DNA 0 
sequence 0 
analysis 0 
and 0 
allele-specific 0 
amplification 0 
in 0 
two 0 
siblings 0 
revealed 0 
a 0 
homozygous 0 
MLH1 0 
mutation 0 
-LRB- 0 
C676T 0 
-- 0 
> 0 
Arg226Stop 0 
-RRB- 0 
. 0 

Thus 0 
, 0 
a 0 
homozygous 0 
germ-line 0 
MLH1 0 
mutation 0 
and 0 
consequent 0 
mismatch 0 
repair 0 
deficiency 0 
results 0 
in 0 
a 0 
mutator 0 
phenotype 0 
characterized 0 
by 0 
leukemia 1
and 0 
/ 0 
or 0 
lymphoma 1
associated 0 
with 0 
neurofibromatosis 1
type 1
_NUM1 1
. 0 
. 0 

Are 0 
Dp71 0 
and 0 
Dp140 0 
brain 0 
dystrophin 0 
isoforms 0 
related 0 
to 0 
cognitive 1
impairment 1
in 0 
Duchenne 1
muscular 1
dystrophy 1
? 0 

Molecular 0 
study 0 
and 0 
neuropsychological 0 
analysis 0 
were 0 
performed 0 
concurrently 0 
on 0 
_NUM2 0 
patients 0 
with 0 
Duchenne 1
muscular 1
dystrophy 1
-LRB- 0 
DMD 1
-RRB- 0 
in 0 
order 0 
to 0 
find 0 
a 0 
molecular 0 
explanation 0 
for 0 
the 0 
cognitive 1
impairment 1
observed 0 
in 0 
most 0 
DMD 1
patients 0 
. 0 

Complete 0 
analysis 0 
of 0 
the 0 
dystrophin 0 
gene 0 
was 0 
performed 0 
to 0 
define 0 
the 0 
localization 0 
of 0 
deletions 0 
and 0 
duplications 0 
in 0 
relation 0 
to 0 
the 0 
different 0 
DMD 1
promoters 0 
. 0 

Qualitative 0 
analysis 0 
of 0 
the 0 
Dp71 0 
transcript 0 
and 0 
testing 0 
for 0 
the 0 
specific 0 
first 0 
exon 0 
of 0 
Dp140 0 
were 0 
also 0 
carried 0 
out 0 
. 0 

Neuropsychological 0 
analysis 0 
assessed 0 
verbal 0 
and 0 
visuospatial 0 
intelligence 0 
, 0 
verbal 0 
memory 0 
, 0 
and 0 
reading 0 
skills 0 
. 0 

Comparison 0 
of 0 
molecular 0 
and 0 
psychometric 0 
findings 0 
demonstrated 0 
that 0 
deletions 0 
and 0 
duplications 0 
that 0 
were 0 
localized 0 
in 0 
the 0 
distal 0 
part 0 
of 0 
the 0 
gene 0 
seemed 0 
to 0 
be 0 
preferentially 0 
associated 0 
with 0 
cognitive 1
impairment 1
. 0 

Two 0 
altered 0 
Dp71 0 
transcripts 0 
and 0 
two 0 
deleted 0 
Dp140 0 
DNA 0 
sequences 0 
were 0 
found 0 
in 0 
four 0 
patients 0 
with 0 
severe 0 
cerebral 1
dysfunction 1
. 0 

These 0 
findings 0 
suggest 0 
that 0 
some 0 
sequences 0 
located 0 
in 0 
the 0 
distal 0 
part 0 
of 0 
the 0 
gene 0 
and 0 
, 0 
in 0 
particular 0 
, 0 
some 0 
DMD 1
isoforms 0 
expressed 0 
in 0 
the 0 
brain 0 
may 0 
be 0 
related 0 
to 0 
the 0 
cognitive 1
impairment 1
associated 0 
with 0 
DMD 1
. 0 
. 0 

A 0 
genome-wide 0 
search 0 
for 0 
chromosomal 0 
loci 0 
linked 0 
to 0 
mental 0 
health 0 
wellness 0 
in 0 
relatives 0 
at 0 
high 0 
risk 0 
for 0 
bipolar 1
affective 1
disorder 1
among 0 
the 0 
Old 0 
Order 0 
Amish 0 
. 0 

Bipolar 1
affective 1
disorder 1
-LRB- 0 
BPAD 1
; 0 
manic-depressive 1
illness 1
-RRB- 0 
is 0 
characterized 0 
by 0 
episodes 0 
of 0 
mania 1
and 0 
/ 0 
or 0 
hypomania 1
interspersed 0 
with 0 
periods 0 
of 0 
depression 1
. 0 

Compelling 0 
evidence 0 
supports 0 
a 0 
significant 0 
genetic 0 
component 0 
in 0 
the 0 
susceptibility 0 
to 0 
develop 0 
BPAD 1
. 0 

To 0 
date 0 
, 0 
however 0 
, 0 
linkage 0 
studies 0 
have 0 
attempted 0 
only 0 
to 0 
identify 0 
chromosomal 0 
loci 0 
that 0 
cause 0 
or 0 
increase 0 
the 0 
risk 0 
of 0 
developing 0 
BPAD 1
. 0 

To 0 
determine 0 
whether 0 
there 0 
could 0 
be 0 
protective 0 
alleles 0 
that 0 
prevent 0 
or 0 
reduce 0 
the 0 
risk 0 
of 0 
developing 0 
BPAD 1
, 0 
similar 0 
to 0 
what 0 
is 0 
observed 0 
in 0 
other 0 
genetic 1
disorders 1
, 0 
we 0 
used 0 
mental 0 
health 0 
wellness 0 
-LRB- 0 
absence 0 
of 0 
any 0 
psychiatric 1
disorder 1
-RRB- 0 
as 0 
the 0 
phenotype 0 
in 0 
our 0 
genome-wide 0 
linkage 0 
scan 0 
of 0 
several 0 
large 0 
multigeneration 0 
Old 0 
Order 0 
Amish 0 
pedigrees 0 
exhibiting 0 
an 0 
extremely 0 
high 0 
incidence 0 
of 0 
BPAD 1
. 0 

We 0 
have 0 
found 0 
strong 0 
evidence 0 
for 0 
a 0 
locus 0 
on 0 
chromosome 0 
4p 0 
at 0 
D4S2949 0 
-LRB- 0 
maximum 0 
GENEHUNTER-PLUS 0 
nonparametric 0 
linkage 0 
score 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
P 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
x 0 
_NUM2 0 
-LRB- 0 
-4 0 
-RRB- 0 
; 0 
SIBPAL 0 
Pempirical 0 
value 0 
< 0 
_NUM1 0 
x 0 
_NUM2 0 
-LRB- 0 
-5 0 
-RRB- 0 
-RRB- 0 
and 0 
suggestive 0 
evidence 0 
for 0 
a 0 
locus 0 
on 0 
chromosome 0 
4q 0 
at 0 
D4S397 0 
-LRB- 0 
maximum 0 
GENEHUNTER-PLUS 0 
nonparametric 0 
linkage 0 
score 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
P 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
x 0 
_NUM2 0 
-LRB- 0 
-3 0 
-RRB- 0 
; 0 
SIBPAL 0 
Pempirical 0 
value 0 
< 0 
_NUM1 0 
x 0 
_NUM2 0 
-LRB- 0 
-3 0 
-RRB- 0 
-RRB- 0 
that 0 
are 0 
linked 0 
to 0 
mental 0 
health 0 
wellness 0 
. 0 

These 0 
findings 0 
are 0 
consistent 0 
with 0 
the 0 
hypothesis 0 
that 0 
certain 0 
alleles 0 
could 0 
prevent 0 
or 0 
modify 0 
the 0 
clinical 0 
manifestations 0 
of 0 
BPAD 1
and 0 
perhaps 0 
other 0 
related 0 
affective 1
disorders 1
. 0 

Hereditary 1
deficiency 1
of 1
the 1
fifth 1
component 1
of 1
complement 1
in 0 
man 0 
. 0 

I. 0 
Clinical 0 
, 0 
immunochemical 0 
, 0 
and 0 
family 0 
studies 0 
. 0 

The 0 
first 0 
recognized 0 
human 0 
kindred 0 
with 0 
hereditary 1
deficiency 1
of 1
the 1
fifth 1
component 1
of 1
complement 1
-LRB- 0 
C5 0 
-RRB- 0 
is 0 
described 0 
. 0 

The 0 
proband 0 
, 0 
a 0 
20-year-old 0 
black 0 
female 0 
with 0 
systemic 1
lupus 1
erythematosus 1
since 0 
age 0 
_NUM2 0 
, 0 
lacked 0 
serum 0 
hemolytic 0 
complement 0 
activity 0 
, 0 
even 0 
during 0 
remission 0 
. 0 

C5 0
was 0 
undetectable 0 
in 0 
her 0 
serum 0 
by 0 
both 0 
immunodiffusion 0 
and 0 
hemolytic 0 
assays 0 
. 0 

Other 0 
complement 0 
components 0 
were 0 
normal 0 
during 0 
remission 0 
of 0 
lupus 0 
, 0 
but 0 
C1 0 
, 0 
C4 0 
, 0 
C2 0 
, 0 
and 0 
C3 0 
levels 0 
fell 0 
during 0 
exacerbations 0 
. 0 

A 0 
younger 0 
half-sister 0 
, 0 
who 0 
had 0 
no 0 
underlying 0 
disease 0 
, 0 
was 0 
also 0 
found 0 
to 0 
lack 0 
immunochemically 0 
detectable 0 
C5 0
. 0 

By 0 
hemolytic 0 
assay 0 
, 0 
she 0 
exhibited 0 
1-2 0 
% 0 
of 0 
the 0 
normal 0 
serum 0 
C5 0
level 0 
and 0 
normal 0 
concentrations 0 
of 0 
other 0 
complement 0 
components 0 
. 0 

C5 0
levels 0 
of 0 
other 0 
family 0 
members 0 
were 0 
either 0 
normal 0 
or 0 
approximately 0 
half-normal 0 
, 0 
consistent 0 
with 0 
autosomal 0 
codominant 0 
inheritance 0 
of 0 
the 0 
gene 0 
determining 0 
C5 1
deficiency 1
. 0 

Normal 0 
hemolytic 0 
titers 0 
were 0 
restored 0 
to 0 
both 0 
homozygous 0 
C5-deficient 1
-LRB- 0 
C5D 1
-RRB- 0 
sera 0 
by 0 
addition 0 
of 0 
highly 0 
purified 0 
human 0 
C5 0 
. 0 

In 0 
specific 0 
C5 0 
titrations 0 
, 0 
however 0 
, 0 
it 0 
was 0 
noted 0 
that 0 
when 0 
limited 0 
amounts 0 
of 0 
C5 0 
were 0 
assayed 0 
in 0 
the 0 
presence 0 
of 0 
low 0 
dilutions 0 
of 0 
either 0 
C5D 1
serum 0 
, 0 
curving 0 
rather 0 
than 0 
linear 0 
dose-response 0 
plots 0 
were 0 
consistently 0 
obtained 0 
, 0 
suggesting 0 
some 0 
inhibitory 0 
effect 0 
. 0 

Further 0 
studies 0 
suggested 0 
that 0 
low 0 
dilutions 0 
of 0 
C5D 1
serum 0 
contain 0 
a 0 
factor 0 
-LRB- 0 
or 0 
factors 0 
-RRB- 0 
interfering 0 
at 0 
some 0 
step 0 
in 0 
the 0 
hemolytic 0 
assay 0 
of 0 
C5 0 
, 0 
rather 0 
than 0 
a 0 
true 0 
C5 0 
inhibitor 0 
or 0 
inactivator 0 
. 0 

Of 0 
clinical 0 
interest 0 
are 0 
-LRB- 0 
a 0 
-RRB- 0 
the 0 
documentation 0 
of 0 
membranous 0 
glomerulonephritis 1
, 0 
vasculitis 1
, 0 
and 0 
arthritis 1
in 0 
an 0 
individual 0 
lacking 0 
C5 0 
-LRB- 0 
and 0 
its 0 
biologic 0 
functions 0 
-RRB- 0 
, 0 
and 0 
-LRB- 0 
b 0 
-RRB- 0 
a 0 
remarkable 0 
propensity 0 
to 0 
bacterial 1
infections 1
in 0 
the 0 
proband 0 
, 0 
even 0 
during 0 
periods 0 
of 0 
low-dose 0 
or 0 
alternate-day 0 
corticosteroid 0 
therapy 0 
. 0 

Other 0 
observations 0 
indicate 0 
that 0 
the 0 
C5D 1
state 0 
is 0 
compatible 0 
with 0 
normal 0 
coagulation 0 
function 0 
and 0 
the 0 
capacity 0 
to 0 
mount 0 
a 0 
neutrophilic 0 
leukocytosis 0 
during 0 
pyogenic 1
infection 1
. 0 
. 0 

Detection 0 
of 0 
heterozygous 0 
carriers 0 
of 0 
the 0 
ataxia-telangiectasia 1
-LRB- 0 
ATM 0 
-RRB- 0 
gene 0 
by 0 
G2 0 
phase 0 
chromosomal 0 
radiosensitivity 0 
of 0 
peripheral 0 
blood 0 
lymphocytes 0 
. 0 

In 0 
ataxia-telangiectasia 1
-LRB- 0 
A-T 1
-RRB- 0 
patients 0 
, 0 
mutations 0 
in 0 
a 0 
single 0 
gene 0 
, 0 
ATM 0 
, 0 
result 0 
in 0 
an 0 
autosomal 1
recessive 1
syndrome 1
that 0 
embraces 0 
a 0 
variety 0 
of 0 
clinical 0 
features 0 
and 0 
manifests 0 
extreme 0 
radiosensitivity 0 
and 0 
a 0 
strong 0 
pre-disposition 0 
to 0 
malignancy 1
. 0 

Heterozygotes 0 
for 0 
the 0 
ATM 0 
gene 0 
have 0 
no 0 
clinical 0 
expression 0 
of 0 
A-T 1
but 0 
may 0 
be 0 
cancer 1
prone 0 
with 0 
a 0 
moderate 0 
increase 0 
in 0 
in 0 
vitro 0 
radiosensitivity 0 
. 0 

We 0 
performed 0 
a 0 
blind 0 
chromosomal 0 
analysis 0 
on 0 
G2-phase 0 
lymphocytes 0 
from 0 
_NUM1 0 
unrelated 0 
A-T 1
patients 0 
, 0 
_NUM2 0 
obligate 0 
A-T 1
heterozygotes 0 
-LRB- 0 
parents 0 
of 0 
the 0 
patients 0 
-RRB- 0 
, 0 
and 0 
_NUM2 0 
normal 0 
controls 0 
following 0 
X-irradiation 0 
with 0 
_NUM1 0 
Gy 0 
in 0 
order 0 
to 0 
evaluate 0 
this 0 
cytogenetic 0 
method 0 
as 0 
a 0 
tool 0 
for 0 
detection 0 
of 0 
ATM 0 
carriers 0 
. 0 

Both 0 
A-T 1
homozygotes 0 
and 0 
heterozygotes 0 
showed 0 
significantly 0 
increased 0 
levels 0 
of 0 
radiation-induced 0 
chromatid 0 
damage 0 
relative 0 
to 0 
that 0 
of 0 
normal 0 
controls 0 
. 0 

These 0 
results 0 
show 0 
that 0 
the 0 
G2-phase 0 
chromosomal 0 
radiosensitivity 0 
assay 0 
can 0 
be 0 
used 0 
for 0 
the 0 
detection 0 
of 0 
A-T 1
heterozygotes 0 
. 0 

In 0 
combination 0 
with 0 
molecular 0 
genetic 0 
analyses 0 
, 0 
this 0 
test 0 
may 0 
be 0 
of 0 
value 0 
in 0 
studies 0 
of 0 
familial 1
and 1
sporadic 1
cancers 1
aimed 0 
at 0 
determination 0 
of 0 
the 0 
potential 0 
involvement 0 
of 0 
ATM 0 
mutations 0 
in 0 
tumor 1
risk 0 
or 0 
development 0 
. 0 
. 0 

The 0 
molecular 0 
basis 0 
of 0 
C6 1
deficiency 1
in 0 
the 0 
western 0 
Cape 0 
, 0 
South 0 
Africa 0 
. 0 

Deficiency 1
of 1
the 1
sixth 1
component 1
of 1
human 1
complement 1
-LRB- 0 
C6 0 
-RRB- 0 
has 0 
been 0 
reported 0 
in 0 
a 0 
number 0 
of 0 
families 0 
from 0 
the 0 
western 0 
Cape 0 
, 0 
South 0 
Africa 0 
. 0 

Meningococcal 1
disease 1
is 0 
endemic 0 
in 0 
the 0 
Cape 0 
and 0 
almost 0 
all 0 
pedigrees 0 
of 0 
total 0 
C6 1
deficiency 1
-LRB- 0 
C6Q0 0 
-RRB- 0 
have 0 
been 0 
ascertained 0 
because 0 
of 0 
recurrent 0 
disease 0 
. 0 

We 0 
have 0 
sequenced 0 
the 0 
expressed 0 
exons 0 
of 0 
the 0 
C6 0 
gene 0 
from 0 
selected 0 
cases 0 
and 0 
have 0 
found 0 
three 0 
molecular 0 
defects 0 
leading 0 
to 0 
total 0 
deficiency 0 
879delG 0 
, 0 
which 0 
is 0 
the 0 
common 0 
defect 0 
in 0 
the 0 
Cape 0 
and 0 
hitherto 0 
unreported 0 
, 0 
and 0 
1195delC 0 
and 0 
1936delG 0 
, 0 
which 0 
have 0 
been 0 
previously 0 
reported 0 
in 0 
African-Americans 0 
. 0 

We 0 
also 0 
show 0 
that 0 
the 0 
879delG 0 
and 0 
1195delC 0 
defects 0 
are 0 
associated 0 
with 0 
characteristic 0 
C6 0 
/ 0 
C7 0 
region 0 
DNA 0 
marker 0 
haplotypes 0 
, 0 
although 0 
small 0 
variations 0 
were 0 
observed 0 
. 0 

The 0 
1936delG 0 
defect 0 
was 0 
observed 0 
only 0 
once 0 
in 0 
the 0 
Cape 0 
, 0 
but 0 
its 0 
associated 0 
haplotype 0 
could 0 
be 0 
deduced 0 
. 0 

The 0 
data 0 
from 0 
the 0 
haplotypes 0 
indicate 0 
that 0 
these 0 
three 0 
molecular 0 
defects 0 
account 0 
for 0 
the 0 
defects 0 
in 0 
all 0 
the 0 
_NUM2 0 
unrelated 0 
C6Q0 0 
individuals 0 
we 0 
have 0 
studied 0 
from 0 
the 0 
Cape 0 
. 0 

We 0 
have 0 
also 0 
observed 0 
the 0 
879delG 0 
defect 0 
in 0 
two 0 
Dutch 0 
C6-deficient 1
kindreds 0 
, 0 
but 0 
the 0 
879delG 0 
defect 0 
in 0 
the 0 
Cape 0 
probably 0 
did 0 
not 0 
come 0 
from 0 
The 0 
Netherlands 0 
. 0 
. 0 

The 0 
R496H 0 
mutation 0 
of 0 
arylsulfatase 0 
A 0 
does 0 
not 0 
cause 0 
metachromatic 1
leukodystrophy 1
. 0 

Deficiency 1
of 1
arylsulfatase 1
A 1
-LRB- 0 
ARSA 0 
-RRB- 0 
enzyme 0 
activity 0 
causes 0 
metachromatic 1
leukodystrophy 1
-LRB- 0 
MLD 1
-RRB- 0 
. 0 

A 0 
number 0 
of 0 
ARSA 0 
gene 0 
mutations 0 
responsible 0 
for 0 
MLD 1
have 0 
been 0 
identified 0 
. 0 

Recently 0 
, 0 
the 0 
R496H 0 
mutation 0 
of 0 
ARSA 0 
was 0 
proposed 0 
to 0 
be 0 
a 0 
cause 0 
of 0 
MLD 1
-LRB- 0 
Draghia 0 
et 0 
al. 0 
, 0 
_NUM4 0 
-RRB- 0 
. 0 

We 0 
have 0 
investigated 0 
the 0 
R496H 0 
mutation 0 
and 0 
found 0 
this 0 
mutation 0 
at 0 
a 0 
relatively 0 
high 0 
frequency 0 
in 0 
an 0 
African 0 
American 0 
population 0 
-LRB- 0 
f 0 
= 0 
_NUM1 0 
. 0 

_NUM2 0 
, 0 
n 0 
= 0 
_NUM2 0 
subjects 0 
-RRB- 0 
. 0 

The 0 
ARSA 0 
enzyme 0 
activity 0 
in 0 
subjects 0 
with 0 
and 0 
without 0 
the 0 
R496H 0 
mutation 0 
was 0 
determined 0 
and 0 
found 0 
to 0 
be 0 
normal 0 
. 0 

It 0 
is 0 
therefore 0 
concluded 0 
that 0 
the 0 
R496H 0 
mutation 0 
of 0 
ARSA 0 
does 0 
not 0 
negatively 0 
influence 0 
the 0 
activity 0 
of 0 
ARSA 0 
and 0 
is 0 
not 0 
a 0 
cause 0 
of 0 
MLD 1
Piebaldism 1
with 0 
deafness 1
: 0 
molecular 0 
evidence 0 
for 0 
an 0 
expanded 0 
syndrome 0 
. 0 

In 0 
a 0 
South 0 
African 0 
girl 0 
of 0 
Xhosa 0 
stock 0 
with 0 
severe 0 
piebaldism 1
and 0 
profound 0 
congenital 0 
sensorineural 1
deafness 1
we 0 
identified 0 
a 0 
novel 0 
missense 0 
substitution 0 
at 0 
a 0 
highly 0 
conserved 0 
residue 0 
in 0 
the 0 
intracellular 0 
kinase 0 
domain 0 
of 0 
the 0 
KIT 0 
proto-oncogene 0 
, 0 
R796G 0 
. 0 

Though 0 
auditory 1
anomalies 1
have 0 
been 0 
observed 0 
in 0 
mice 0 
with 0 
dominant 0 
white 0 
spotting 0 
-LRB- 0 
W 0 
-RRB- 0 
due 0 
to 0 
KIT 0 
mutations 0 
, 0 
deafness 1
is 0 
not 0 
typical 0 
in 0 
human 0 
piebaldism 1
. 0 

Thus 0 
, 0 
the 0 
occurrence 0 
of 0 
sensorineural 1
deafness 1
in 0 
this 0 
patient 0 
extends 0 
considerably 0 
the 0 
phenotypic 0 
range 0 
of 0 
piebaldism 1
due 0 
to 0 
KIT 0 
gene 0 
mutation 0 
in 0 
humans 0 
and 0 
tightens 0 
the 0 
clinical 0 
similarity 0 
between 0 
piebaldism 1
and 0 
the 0 
various 0 
forms 0 
of 0 
Waardenburg 1
syndrome 1
. 0 
. 0 

Genetic 0 
heterogeneity 0 
and 0 
penetrance 0 
analysis 0 
of 0 
the 0 
BRCA1 0 
and 0 
BRCA2 0 
genes 0 
in 0 
breast 1
cancer 1
families 0 
. 0 

The 0 
Breast 1
Cancer 1
Linkage 0 
Consortium 0 
. 0 

The 0 
contribution 0 
of 0 
BRCA1 0 
and 0 
BRCA2 0 
to 0 
inherited 1
breast 1
cancer 1
was 0 
assessed 0 
by 0 
linkage 0 
and 0 
mutation 0 
analysis 0 
in 0 
_NUM3 0 
families 0 
, 0 
each 0 
with 0 
at 0 
least 0 
four 0 
cases 0 
of 0 
breast 1
cancer 1
, 0 
collected 0 
by 0 
the 0 
Breast 1
Cancer 1
Linkage 0 
Consortium 0 
. 0 

Families 0 
were 0 
included 0 
without 0 
regard 0 
to 0 
the 0 
occurrence 0 
of 0 
ovarian 1
or 1
other 1
cancers 1
. 0 

Overall 0 
, 0 
disease 0 
was 0 
linked 0 
to 0 
BRCA1 0 
in 0 
an 0 
estimated 0 
_NUM2 0 
% 0 
of 0 
families 0 
, 0 
to 0 
BRCA2 0 
in 0 
_NUM2 0 
% 0 
of 0 
families 0 
, 0 
and 0 
to 0 
neither 0 
gene 0 
in 0 
_NUM2 0 
% 0 
-LRB- 0 
_NUM2 0 
% 0 
confidence 0 
interval 0 
-LSB- 0 
CI 0 
-RSB- 0 
_NUM1 0 
% 0 
-28 0 
% 0 
-RRB- 0 
, 0 
suggesting 0 
other 0 
predisposition 0 
genes 0 
. 0 

The 0 
majority 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
of 0 
the 0 
breast-ovarian 1
cancer 1
families 0 
were 0 
due 0 
to 0 
BRCA1 0 
, 0 
with 0 
most 0 
others 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
due 0 
to 0 
BRCA2 0 
. 0 

Conversely 0 
, 0 
the 0 
majority 0 
of 0 
families 0 
with 0 
male 1
and 1
female 1
breast 1
cancer 1
were 0 
due 0 
to 0 
BRCA2 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
. 0 

The 0 
largest 0 
proportion 0 
-LRB- 0 
_NUM2 0 
% 0 
-RRB- 0 
of 0 
families 0 
due 0 
to 0 
other 0 
genes 0 
was 0 
found 0 
in 0 
families 0 
with 0 
four 0 
or 0 
five 0 
cases 0 
of 0 
female 0 
breast 1
cancer 1
only 0 
. 0 

These 0 
estimates 0 
were 0 
not 0 
substantially 0 
affected 0 
either 0 
by 0 
changing 0 
the 0 
assumed 0 
penetrance 0 
model 0 
for 0 
BRCA1 0 
or 0 
by 0 
including 0 
or 0 
excluding 0 
BRCA1 0 
mutation 0 
data 0 
. 0 

Among 0 
those 0 
families 0 
with 0 
disease 0 
due 0 
to 0 
BRCA1 0 
that 0 
were 0 
tested 0 
by 0 
one 0 
of 0 
the 0 
standard 0 
screening 0 
methods 0 
, 0 
mutations 0 
were 0 
detected 0 
in 0 
the 0 
coding 0 
sequence 0 
or 0 
splice 0 
sites 0 
in 0 
an 0 
estimated 0 
_NUM2 0 
% 0 
-LRB- 0 
_NUM2 0 
% 0 
CI 0 
_NUM2 0 
% 0 
-77 0 
% 0 
-RRB- 0 
. 0 

The 0 
estimated 0 
sensitivity 0 
was 0 
identical 0 
for 0 
direct 0 
sequencing 0 
and 0 
other 0 
techniques 0 
. 0 

The 0 
penetrance 0 
of 0 
BRCA2 0 
was 0 
estimated 0 
by 0 
maximizing 0 
the 0 
LOD 0 
score 0 
in 0 
BRCA2-mutation 0 
families 0 
, 0 
over 0 
all 0 
possible 0 
penetrance 0 
functions 0 
. 0 

The 0 
estimated 0 
cumulative 0 
risk 0 
of 0 
breast 1
cancer 1
reached 0 
_NUM2 0 
% 0 
-LRB- 0 
_NUM2 0 
% 0 
CI 0 
_NUM1 0 
% 0 
-44 0 
% 0 
-RRB- 0 
by 0 
age 0 
_NUM2 0 
years 0 
and 0 
_NUM2 0 
% 0 
-LRB- 0 
_NUM2 0 
% 0 
CI 0 
_NUM2 0 
% 0 
-95 0 
% 0 
-RRB- 0 
by 0 
age 0 
_NUM2 0 
years 0 
. 0 

The 0 
corresponding 0 
ovarian 1
cancer 1
risks 0 
were 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-LRB- 0 
_NUM2 0 
% 0 
CI 0 
_NUM1 0 
% 0 
-1 0 
% 0 
-RRB- 0 
by 0 
age 0 
_NUM2 0 
years 0 
and 0 
_NUM2 0 
% 0 
-LRB- 0 
_NUM2 0 
% 0 
CI 0 
_NUM1 0 
% 0 
-47 0 
% 0 
-RRB- 0 
by 0 
age 0 
_NUM2 0 
years 0 
. 0 

The 0 
lifetime 0 
risk 0 
of 0 
breast 1
cancer 1
appears 0 
similar 0 
to 0 
the 0 
risk 0 
in 0 
BRCA1 0 
carriers 0 
, 0 
but 0 
there 0 
was 0 
some 0 
suggestion 0 
of 0 
a 0 
lower 0 
risk 0 
in 0 
BRCA2 0 
carriers 0 
< 0 
_NUM2 0 
years 0 
of 0 
age 0 
. 0 

Severe 0 
early-onset 0 
obesity 1
, 0 
adrenal 1
insufficiency 1
and 0 
red 0 
hair 0 
pigmentation 0 
caused 0 
by 0 
POMC 0 
mutations 0 
in 0 
humans 0 
. 0 

Sequential 0 
cleavage 0 
of 0 
the 0 
precursor 0 
protein 0 
pre-pro-opiomelanocortin 0 
-LRB- 0 
POMC 0 
-RRB- 0 
generates 0 
the 0 
melanocortin 0 
peptides 0 
adrenocorticotrophin 0 
-LRB- 0 
ACTH 0
-RRB- 0 
, 0 
melanocyte-stimulating 0 
hormones 0 
-LRB- 0 
MSH 0 
-RRB- 0 
alpha 0 
, 0 
beta 0 
and 0 
gamma 0 
as 0 
well 0 
as 0 
the 0 
opioid-receptor 0 
ligand 0 
beta-endorphin 0 
. 0 

While 0 
a 0 
few 0 
cases 0 
of 0 
isolated 0 
ACTH 1
deficiency 1
have 0 
been 0 
reported 0 
-LRB- 0 
OMIM 0 
_NUM6 0 
-RRB- 0 
, 0 
an 0 
inherited 0 
POMC 0 
defect 0 
has 0 
not 0 
been 0 
described 0 
so 0 
far 0 
. 0 

Recent 0 
studies 0 
in 0 
animal 0 
models 0 
elucidated 0 
a 0 
central 0 
role 0 
of 0 
alpha-MSH 0 
in 0 
the 0 
regulation 0 
of 0 
food 0 
intake 0 
by 0 
activation 0 
of 0 
the 0 
brain 0 
melanocortin-4-receptor 0 
-LRB- 0 
MC4-R 0 
; 0 
refs 0 
3-5 0 
-RRB- 0 
and 0 
the 0 
linkage 0 
of 0 
human 0 
obesity 1
to 0 
chromosome 0 
_NUM1 0 
in 0 
close 0 
proximity 0 
to 0 
the 0 
POMC 0 
locus 0 
, 0 
led 0 
to 0 
the 0 
proposal 0 
of 0 
an 0 
association 0 
of 0 
POMC 0 
with 0 
human 0 
obesity 1
. 0 

The 0 
dual 0 
role 0 
of 0 
alpha-MSH 0 
in 0 
regulating 0 
food 0 
intake 0 
and 0 
influencing 0 
hair 0 
pigmentation 0 
predicts 0 
that 0 
the 0 
phenotype 0 
associated 0 
with 0 
a 0 
defect 0 
in 0 
POMC 0 
function 0 
would 0 
include 0 
obesity 1
, 0 
alteration 0 
in 0 
pigmentation 0 
and 0 
ACTH 1
deficiency 1
. 0 

The 0 
observation 0 
of 0 
these 0 
symptoms 0 
in 0 
two 0 
probands 0 
prompted 0 
us 0 
to 0 
search 0 
for 0 
mutations 0 
within 0 
their 0 
POMC 0 
genes 0 
. 0 

Patient 0 
_NUM1 0 
was 0 
found 0 
to 0 
be 0 
a 0 
compound 0 
heterozygote 0 
for 0 
two 0 
mutations 0 
in 0 
exon 0 
_NUM1 0 
-LRB- 0 
G7013T 0 
, 0 
C7133delta 0 
-RRB- 0 
which 0 
interfere 0 
with 0 
appropriate 0 
synthesis 0 
of 0 
ACTH 0 
and 0 
alpha-MSH 0 
. 0 

Patient 0 
_NUM1 0 
was 0 
homozygous 0 
for 0 
a 0 
mutation 0 
in 0 
exon 0 
_NUM1 0 
-LRB- 0 
C3804A 0 
-RRB- 0 
which 0 
abolishes 0 
POMC 0 
translation 0 
. 0 

These 0 
findings 0 
represent 0 
the 0 
first 0 
examples 0 
of 0 
a 0 
genetic 1
defect 1
within 0 
the 0 
POMC 0 
gene 0 
and 0 
define 0 
a 0 
new 0 
monogenic 1
endocrine 1
disorder 1
resulting 0 
in 0 
early-onset 0 
obesity 1
, 0 
adrenal 1
insufficiency 1
and 0 
red 0 
hair 0 
pigmentation 0 
. 0 
. 0 

The 0 
tumor 1
suppressor 0 
gene 0 
Smad4 0 
/ 0 
Dpc4 0 
is 0 
required 0 
for 0 
gastrulation 0 
and 0 
later 0 
for 0 
anterior 0 
development 0 
of 0 
the 0 
mouse 0 
embryo 0 
. 0 

Mutations 0 
in 0 
the 0 
SMAD4 0 
/ 0 
DPC4 0 
tumor 1
suppressor 0 
gene 0 
, 0 
a 0 
key 0 
signal 0 
transducer 0 
in 0 
most 0 
TGFbeta-related 0 
pathways 0 
, 0 
are 0 
involved 0 
in 0 
_NUM2 0 
% 0 
of 0 
pancreatic 1
cancers 1
. 0 

Homozygous 0 
Smad4 0 
mutant 0 
mice 0 
die 0 
before 0 
day 0 
_NUM1 0 
. 0 

_NUM1 0 
of 0 
embryogenesis 0 
. 0 

Mutant 0 
embryos 0 
have 0 
reduced 0 
size 0 
, 0 
fail 0 
to 0 
gastrulate 0 
or 0 
express 0 
a 0 
mesodermal 0 
marker 0 
, 0 
and 0 
show 0 
abnormal 0 
visceral 0 
endoderm 0 
development 0 
. 0 

Growth 1
retardation 1
of 0 
the 0 
Smad4-deficient 0 
embryos 0 
results 0 
from 0 
reduced 0 
cell 0 
proliferation 0 
rather 0 
than 0 
increased 0 
apoptosis 0 
. 0 

Aggregation 0 
of 0 
mutant 0 
Smad4 0 
ES 0 
cells 0 
with 0 
wild-type 0 
tetraploid 0 
morulae 0 
rescues 0 
the 0 
gastrulation 1
defect 1
. 0 

These 0 
results 0 
indicate 0 
that 0 
Smad4 0 
is 0 
initially 0 
required 0 
for 0 
the 0 
differentiation 0 
of 0 
the 0 
visceral 0 
endoderm 0 
and 0 
that 0 
the 0 
gastrulation 1
defect 1
in 0 
the 0 
epiblast 0 
is 0 
secondary 0 
and 0 
non-cell 0 
autonomous 0 
. 0 

Rescued 0 
embryos 0 
show 0 
severe 0 
anterior 0 
truncations 0 
, 0 
indicating 0 
a 0 
second 0 
important 0 
role 0 
for 0 
Smad4 0 
in 0 
anterior 0 
patterning 0 
during 0 
embryogenesis 0 
. 0 

Coincidence 0 
of 0 
two 0 
novel 0 
arylsulfatase 0 
A 0 
alleles 0 
and 0 
mutation 0 
_NUM3 0 
+1 0 
G 0 
> 0 
A 0 
within 0 
a 0 
family 0 
with 0 
metachromatic 1
leukodystrophy 1
: 0 
molecular 0 
basis 0 
of 0 
phenotypic 0 
heterogeneity 0 
. 0 

In 0 
a 0 
family 0 
with 0 
three 0 
siblings 0 
, 0 
one 0 
developed 0 
classical 0 
late 0 
infantile 0 
metachromatic 1
leukodystrophy 1
-LRB- 0 
MLD 1
-RRB- 0 
, 0 
fatal 0 
at 0 
age 0 
_NUM1 0 
years 0 
, 0 
with 0 
deficient 0 
arylsulfatase 0 
A 0 
-LRB- 0 
ARSA 0 
-RRB- 0 
activity 0 
and 0 
increased 0 
galactosylsulfatide 0 
-LRB- 0 
GS 0 
-RRB- 0 
excretion 0 
. 0 

The 0 
two 0 
other 0 
siblings 0 
, 0 
apparently 0 
healthy 0 
at 0 
_NUM2 0 
-LRB- 0 
1 0 
/ 0 
2 0 
-RRB- 0 
and 0 
_NUM2 0 
years 0 
, 0 
respectively 0 
, 0 
and 0 
their 0 
father 0 
, 0 
apparently 0 
healthy 0 
as 0 
well 0 
, 0 
presented 0 
ARSA 0 
and 0 
GS 0 
values 0 
within 0 
the 0 
range 0 
of 0 
MLD 1
patients 0 
. 0 

Mutation 0 
screening 0 
and 0 
sequence 0 
analysis 0 
disclosed 0 
the 0 
involvement 0 
of 0 
three 0 
different 0 
ARSA 0 
mutations 0 
being 0 
the 0 
molecular 0 
basis 0 
of 0 
intrafamilial 0 
phenotypic 0 
heterogeneity 0 
. 0 

The 0 
late 0 
infantile 0 
patient 0 
inherited 0 
from 0 
his 0 
mother 0 
the 0 
frequent 0 
0-type 0 
mutation 0 
_NUM3 0 
+ 0 
1G 0 
> 0 
A 0 
, 0 
and 0 
from 0 
his 0 
father 0 
a 0 
novel 0 
, 0 
single 0 
basepair 0 
microdeletion 0 
of 0 
guanine 0 
at 0 
nucleotide 0 
_NUM1 0 
in 0 
exon 0 
_NUM1 0 
-LRB- 0 
7delG 0 
-RRB- 0 
. 0 

The 0 
two 0 
clinically 0 
unaffected 0 
siblings 0 
carried 0 
the 0 
maternal 0 
mutation 0 
_NUM3 0 
+ 0 
1G 0 
> 0 
A 0 
and 0 
, 0 
on 0 
their 0 
paternal 0 
allele 0 
, 0 
a 0 
novel 0 
cytosine 0 
to 0 
thymidine 0 
transition 0 
at 0 
nucleotide 0 
_NUM4 0 
in 0 
exon 0 
_NUM1 0 
, 0 
resulting 0 
in 0 
substitution 0 
of 0 
alanine 0 
_NUM3 0 
by 0 
valine 0 
-LRB- 0 
A464V 0 
-RRB- 0 
. 0 

The 0 
fathers 0 
genotype 0 
thus 0 
was 0 
7delG 0 
/ 0 
A464V 0 
. 0 

Mutation 0 
A464V 0 
was 0 
not 0 
found 0 
in 0 
_NUM2 0 
unrelated 0 
MLD 1
patients 0 
and 0 
_NUM2 0 
controls 0 
. 0 

A464V 0 
, 0 
although 0 
clearly 0 
modifying 0 
ARSA 0 
and 0 
GS 0 
levels 0 
, 0 
apparently 0 
bears 0 
little 0 
significance 0 
for 0 
clinical 0 
manifestation 0 
of 0 
MLD 1
, 0 
mimicking 0 
the 0 
frequent 0 
ARSA 0 
pseudodeficiency 0 
allele 0 
. 0 

Our 0 
results 0 
demonstrate 0 
that 0 
in 0 
certain 0 
genetic 0 
conditions 0 
MLD 1
like 0 
ARSA 0 
and 0 
GS 0 
values 0 
need 0 
not 0 
be 0 
paralleled 0 
by 0 
clinical 0 
disease 0 
, 0 
a 0 
finding 0 
with 0 
serious 0 
diagnostic 0 
and 0 
prognostic 0 
implications 0 
. 0 

Moreover 0 
, 0 
further 0 
ARSA 0 
alleles 0 
functionally 0 
similar 0 
to 0 
A464V 0 
might 0 
exist 0 
which 0 
, 0 
together 0 
with 0 
0-type 0 
mutations 0 
, 0 
may 0 
cause 0 
pathological 0 
ARSA 0 
and 0 
GS 0 
levels 0 
, 0 
but 0 
not 0 
clinical 0 
outbreak 0 
of 0 
the 0 
disease 0 
. 0 
. 0 

Low 0 
levels 0 
of 0 
beta 0 
hexosaminidase 0 
A 0 
in 0 
healthy 0 
individuals 0 
with 0 
apparent 0 
deficiency 0 
of 0 
this 0 
enzyme 0 
. 0 

Appreciable 0 
beta 0 
hexosaminidase 0 
A 0 
-LRB- 0 
hex 0 
A 0 
-RRB- 0 
activity 0 
has 0 
been 0 
detected 0 
in 0 
cultured 0 
skin 0 
fibroblasts 0 
and 0 
melanoma 1
tissue 0 
from 0 
healthy 0 
individuals 0 
previously 0 
reported 0 
as 0 
having 0 
deficiency 1
of 1
hex 1
A 1
activity 0 
indistinguishable 0 
from 0 
that 0 
of 0 
patients 0 
with 0 
Tay-Sachs 1
disease 1
-LRB- 0 
TSD 1
-RRB- 0 
. 0 

Identification 0 
and 0 
quantitation 0 
of 0 
hex 0 
A 0 
, 0 
amounting 0 
to 0 
_NUM1 0 
. 0 

_NUM1 0 
% 0 
-6 0 
. 0 

_NUM1 0 
% 0 
of 0 
total 0 
beta 0 
hexosaminidase 0 
activity 0 
, 0 
has 0 
been 0 
obtained 0 
by 0 
cellulose 0 
acetate 0 
gel 0 
electrophoresis 0 
, 0 
DEAE-cellulose 0 
ion-exchange 0 
chromatography 0 
, 0 
radial 0 
immunodiffusion 0 
, 0 
and 0 
radioimmunoassay 0 
. 0 

Previous 0 
family 0 
studies 0 
suggested 0 
that 0 
these 0 
individuals 0 
may 0 
be 0 
compound 0 
heterozygotes 0 
for 0 
the 0 
common 0 
mutant 0 
TSD 1
gene 0 
and 0 
a 0 
rare 0 
-LRB- 0 
allelic 0 
-RRB- 0 
mutant 0 
gene 0 
. 0 

Thus 0 
, 0 
the 0 
postulated 0 
rate 0 
mutant 0 
gene 0 
appears 0 
to 0 
code 0 
for 0 
the 0 
expression 0 
of 0 
low 0 
amounts 0 
of 0 
hex 0 
A. 0 
Heterozygotes 0 
for 0 
the 0 
rare 0 
mutant 0 
may 0 
be 0 
indistinguishable 0 
from 0 
heterozygotes 0 
for 0 
the 0 
common 0 
TSD 1
mutant 0 
. 0 

However 0 
, 0 
direct 0 
visualization 0 
and 0 
quantitation 0 
of 0 
hex 0 
A 0 
by 0 
the 0 
methods 0 
described 0 
may 0 
prevent 0 
false-positive 0 
prenatal 0 
diagnosis 0 
of 0 
TSD 1
in 0 
fetuses 0 
having 0 
the 0 
incomplete 0 
hex 1
A 1
deficiency 1
of 0 
the 0 
type 0 
described 0 
in 0 
the 0 
four 0 
healthy 0 
individuals 0 
A 0 
mouse 0 
model 0 
for 0 
Prader-Willi 1
syndrome 1
imprinting-centre 0 
mutations 0 
. 0 

Imprinting 0 
in 0 
the 0 
15q11-q13 0 
region 0 
involves 0 
an 0 
imprinting 0 
centre 0 
-LRB- 0 
IC 0 
-RRB- 0 
, 0 
mapping 0 
in 0 
part 0 
to 0 
the 0 
promoter 0 
and 0 
first 0 
exon 0 
of 0 
SNRPN 0 
. 0 

Deletion 0 
of 0 
this 0 
IC 0 
abolishes 0 
local 0 
paternally 0 
derived 0 
gene 0 
expression 0 
and 0 
results 0 
in 0 
Prader-Willi 1
syndrome 1
-LRB- 0 
PWS 1
-RRB- 0 
. 0 

We 0 
have 0 
created 0 
two 0 
deletion 0 
mutations 0 
in 0 
mice 0 
to 0 
understand 0 
PWS 1
and 0 
the 0 
mechanism 0 
of 0 
this 0 
IC 0 
. 0 

Mice 0 
harbouring 0 
an 0 
intragenic 0 
deletion 0 
in 0 
Snrpn 0 
are 0 
phenotypically 0 
normal 0 
, 0 
suggesting 0 
that 0 
mutations 0 
of 0 
SNRPN 0 
are 0 
not 0 
sufficient 0 
to 0 
induce 0 
PWS 1
. 0 

Mice 0 
with 0 
a 0 
larger 0 
deletion 0 
involving 0 
both 0 
Snrpn 0 
and 0 
the 0 
putative 0 
PWS-IC 0 
lack 0 
expression 0 
of 0 
the 0 
imprinted 0 
genes 0 
Zfp127 0 
-LRB- 0 
mouse 0 
homologue 0 
of 0 
ZNF127 0 
-RRB- 0 
, 0 
Ndn 0 
and 0 
Ipw 0 
, 0 
and 0 
manifest 0 
several 0 
phenotypes 0 
common 0 
to 0 
PWS 1
infants 0 
. 0 

These 0 
data 0 
demonstrate 0 
that 0 
both 0 
the 0 
position 0 
of 0 
the 0 
IC 0 
and 0 
its 0 
role 0 
in 0 
the 0 
coordinate 0 
expression 0 
of 0 
genes 0 
is 0 
conserved 0 
between 0 
mouse 0 
and 0 
human 0 
, 0 
and 0 
indicate 0 
that 0 
the 0 
mouse 0 
is 0 
a 0 
suitable 0 
model 0 
system 0 
in 0 
which 0 
to 0 
investigate 0 
the 0 
molecular 0 
mechanisms 0 
of 0 
imprinting 0 
in 0 
this 0 
region 0 
of 0 
the 0 
genome 0 
. 0 
. 0 

A 0 
deletion 0 
mutation 0 
in 0 
COL17A1 0 
in 0 
five 0 
Austrian 0 
families 0 
with 0 
generalized 0 
atrophic 1
benign 1
epidermolysis 1
bullosa 1
represents 0 
propagation 0 
of 0 
an 0 
ancestral 0 
allele 0 
. 0 

Patients 0 
with 0 
generalized 0 
atrophic 1
benign 1
epidermolysis 1
bullosa 1
, 0 
a 0 
usually 0 
nonlethal 0 
form 0 
of 0 
junctional 1
epidermolysis 1
bullosa 1
, 0 
have 0 
generalized 0 
blistering 1
, 0 
nail 1
dystrophy 1
, 0 
patchy 1
alopecia 1
, 0 
and 0 
dental 1
abnormalities 1
. 0 

Skin 1
fragility 1
in 0 
most 0 
cases 0 
is 0 
due 0 
to 0 
mutations 0 
in 0 
the 0 
gene 0 
encoding 0 
type 0 
XVII 0 
collagen 0 
-LRB- 0 
COL17A1 0 
-RRB- 0 
. 0 

Recently 0 
, 0 
we 0 
reported 0 
five 0 
Austrian 0 
families 0 
with 0 
generalized 0 
atrophic 1
benign 1
epidermolysis 1
bullosa 1
who 0 
share 0 
the 0 
same 0 
COL17A1 0 
mutation 0 
. 0 

Affected 0 
individuals 0 
in 0 
three 0 
families 0 
are 0 
homozygous 0 
for 0 
4003delTC 0 
, 0 
whereas 0 
those 0 
in 0 
two 0 
others 0 
are 0 
compound 0 
heterozygotes 0 
. 0 

To 0 
determine 0 
if 0 
the 0 
occurrence 0 
of 0 
4003delTC 0 
in 0 
these 0 
unrelated 0 
families 0 
signifies 0 
propagation 0 
of 0 
an 0 
ancestral 0 
allele 0 
or 0 
a 0 
mutational 0 
hot 0 
spot 0 
, 0 
haplotypes 0 
were 0 
determined 0 
for 0 
polymorphisms 0 
both 0 
within 0 
and 0 
flanking 0 
COL17A1 0 
. 0 

Five 0 
intragenic 0 
polymorphisms 0 
were 0 
chosen 0 
based 0 
on 0 
their 0 
informativeness 0 
. 0 

One 0 
of 0 
these 0 
, 0 
not 0 
previously 0 
reported 0 
, 0 
was 0 
_NUM4 0 
A 0 
or 0 
C 0 
that 0 
introduces 0 
a 0 
new 0 
restriction 0 
site 0 
for 0 
Eco0109 0 
I. 0 
All 0 
the 0 
4003delTC 0 
alleles 0 
showed 0 
the 0 
same 0 
haplotype 0 
for 0 
these 0 
five 0 
polymorphic 0 
markers 0 
. 0 

Fourteen 0 
microsatellite 0 
polymorphisms 0 
were 0 
selected 0 
based 0 
on 0 
their 0 
high 0 
heterozygosity 0 
and 0 
their 0 
location 0 
within 0 
10q23-q25 0 
near 0 
COL17A1 0 
. 0 

Three 0 
families 0 
shared 0 
microsatellite 0 
polymorphisms 0 
covering 0 
at 0 
most 0 
_NUM2 0 
cM 0 
, 0 
whereas 0 
the 0 
others 0 
shared 0 
smaller 0 
regions 0 
consistent 0 
with 0 
cross-over 0 
events 0 
during 0 
passage 0 
of 0 
this 0 
mutation 0 
through 0 
several 0 
generations 0 
. 0 

These 0 
results 0 
indicate 0 
that 0 
4003delTC 0 
occurs 0 
on 0 
a 0 
single 0 
ancestral 0 
allele 0 
. 0 
. 0 

Identification 0 
of 0 
a 0 
novel 0 
mutation 0 
of 0 
the 0 
CPO 0 
gene 0 
in 0 
a 0 
Japanese 0 
hereditary 1
coproporphyria 1
family 0 
. 0 

Hereditary 1
coproporphyria 1
-LRB- 0 
HCP 1
-RRB- 0 
is 0 
an 0 
autosomal 1
dominant 1
disease 1
characterized 0 
by 0 
a 0 
deficiency 1
of 1
coproporphyrinogen 1
oxidase 1
-LRB- 0 
CPO 0 
-RRB- 0 
caused 0 
by 0 
a 0 
mutation 0 
in 0 
the 0 
CPO 0 
gene 0 
. 0 

Only 0 
_NUM2 0 
mutations 0 
of 0 
the 0 
gene 0 
have 0 
been 0 
reported 0 
in 0 
HCP 1
patients 0 
. 0 

We 0 
report 0 
another 0 
mutation 0 
in 0 
a 0 
Japanese 0 
family 0 
. 0 

Polymerase 0 
chain 0 
reaction-single 0 
strand 0 
conformational 0 
polymorphism 0 
and 0 
direct 0 
sequence 0 
analyses 0 
demonstrated 0 
a 0 
C 0 
to 0 
T 0 
substitution 0 
in 0 
exon 0 
_NUM1 0 
of 0 
the 0 
CPO 0 
gene 0 
at 0 
nucleotide 0 
position 0 
_NUM2 0 
, 0 
which 0 
lies 0 
in 0 
the 0 
putative 0 
presequence 0 
for 0 
targeting 0 
to 0 
mitochondria 0 
. 0 

This 0 
mutation 0 
changes 0 
the 0 
codon 0 
for 0 
glutamine 0 
to 0 
a 0 
termination 0 
codon 0 
at 0 
amino 0 
acid 0 
position 0 
_NUM2 0 
. 0 

MaeI 0 
restriction 0 
analysis 0 
showed 0 
two 0 
other 0 
carriers 0 
in 0 
the 0 
family 0 
. 0 

The 0 
C-T 0 
mutation 0 
is 0 
located 0 
within 0 
a 0 
recently 0 
proposed 0 
putative 0 
alternative 0 
translation 0 
initiation 0 
codon 0 
-LRB- 0 
TIC-1 0 
-RRB- 0 
, 0 
supporting 0 
that 0 
TIC-1 0 
is 0 
the 0 
real 0 
TIC 0 
rather 0 
than 0 
TIC-2 0 
. 0 
. 0 

The 0 
chromosomal 0 
order 0 
of 0 
genes 0 
controlling 0 
the 0 
major 0 
histocompatibility 0 
complex 0 
, 0 
properdin 0 
factor 0 
B 0 
, 0 
and 0 
deficiency 1
of 1
the 1
second 1
component 1
of 1
complement 1
. 0 

The 0 
relationship 0 
of 0 
the 0 
genes 0 
coding 0 
for 0 
HLA 0 
to 0 
those 0 
coding 0 
for 0 
properdin 0 
Factor 0 
B 0 
allotypes 0 
and 0 
for 0 
deficiency 1
of 1
the 1
second 1
component 1
of 1
complement 1
-LRB- 0 
C2 0
-RRB- 0 
was 0 
studied 0 
in 0 
families 0 
of 0 
patients 0 
with 0 
connective 0 
tissue 0 
disorders 0 
. 0 

Patients 0 
were 0 
selected 0 
because 0 
they 0 
were 0 
heterozygous 0 
or 0 
homozygous 0 
for 0 
C2 1
deficiency 1
. 0 

_NUM2 0 
families 0 
with 0 
_NUM2 0 
matings 0 
informative 0 
for 0 
C2 1
deficiency 1
were 0 
found 0 
. 0 

Of 0 
_NUM2 0 
informative 0 
meioses 0 
, 0 
two 0 
crossovers 0 
were 0 
noted 0 
between 0 
the 0 
C2 1
deficiency 1
gene 0 
and 0 
the 0 
HLA-B 0 
gene 0 
, 0 
with 0 
a 0 
recombinant 0 
fraction 0 
of 0 
_NUM1 0 
. 0 

_NUM3 0 
. 0 

A 0 
lod 0 
score 0 
of 0 
_NUM2 0 
was 0 
calculated 0 
for 0 
linkage 0 
between 0 
C2 1
deficiency 1
and 0 
HLA-B 0 
at 0 
a 0 
maximum 0 
likelihood 0 
value 0 
of 0 
the 0 
recombinant 0 
fraction 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
. 0 

_NUM2 0 
families 0 
with 0 
_NUM2 0 
informative 0 
matings 0 
for 0 
both 0 
properdin 0 
Factor 0 
B 0 
allotype 0 
and 0 
HLA-B 0 
were 0 
found 0 
. 0 

Of 0 
_NUM2 0 
informative 0 
meioses 0 
, 0 
three 0 
recombinants 0 
were 0 
found 0 
, 0 
giving 0 
a 0 
recombinant 0 
fraction 0 
of 0 
_NUM1 0 
. 0 

_NUM3 0 
. 0 

A 0 
lod 0 
score 0 
of 0 
_NUM2 0 
between 0 
HLA-B 0 
and 0 
Factor 0 
B 0 
allotypes 0 
was 0 
calculated 0 
at 0 
a 0 
maximum 0 
likelihood 0 
value 0 
of 0 
the 0 
recombinant 0 
fraction 0 
of 0 
_NUM1 0 
. 0 

_NUM2 0 
. 0 

A 0 
crossover 0 
was 0 
shown 0 
to 0 
have 0 
occurred 0 
between 0 
genes 0 
for 0 
Factor 0 
B 0 
and 0 
HLA-D 0 
, 0 
in 0 
which 0 
HLA-D 0 
segregared 0 
with 0 
HLA-A 0 
and 0 
B 0 
. 0 

These 0 
studies 0 
suggest 0 
that 0 
the 0 
genes 0 
for 0 
Factor 0 
B 0 
and 0 
C2 1
deficiency 1
are 0 
located 0 
outside 0 
those 0 
for 0 
HLA 0 
, 0 
that 0 
the 0 
order 0 
of 0 
genese 0 
is 0 
HLA-A 0 
, 0 
- 0 
B 0 
, 0 
- 0 
D 0 
, 0 
Factor 0 
B 0 
allotype 0 
, 0 
C2 1
deficiency 1
, 0 
that 0 
the 0 
genes 0 
coding 0 
for 0 
C2 1
deficiency 1
and 0 
Factor 0 
B 0 
allotypes 0 
are 0 
approximately 0 
_NUM1 0 
-- 0 
_NUM1 0 
centimorgans 0 
from 0 
the 0 
HLA-A 0 
and 0 
HLA-B 0 
loci 0 
, 0 
and 0 
that 0 
the 0 
apparent 0 
lack 0 
of 0 
recombinants 0 
between 0 
the 0 
Factor 0 
B 0 
gene 0 
and 0 
C2 1
deficiency 1
gene 0 
suggests 0 
that 0 
these 0 
two 0 
genes 0 
lie 0 
in 0 
close 0 
proximity 0 
to 0 
one 0 
another 0 
. 0 

A 0 
novel 0 
missense 0 
mutation 0 
in 0 
patients 0 
from 0 
a 0 
retinoblastoma 1
pedigree 0 
showing 0 
only 0 
mild 0 
expression 0 
of 0 
the 0 
tumor 1
phenotype 0 
. 0 

We 0 
have 0 
used 0 
single 0 
strand 0 
conformation 0 
polymorphism 0 
analysis 0 
to 0 
study 0 
the 0 
_NUM2 0 
exons 0 
of 0 
the 0 
RB1 0 
gene 0 
in 0 
individuals 0 
from 0 
a 0 
family 0 
showing 0 
mild 0 
expression 0 
of 0 
the 0 
retinoblastoma 1
phenotype 0 
. 0 

In 0 
this 0 
family 0 
affected 0 
individuals 0 
developed 0 
unilateral 1
tumors 1
and 0 
, 0 
as 0 
a 0 
result 0 
of 0 
linkage 0 
analysis 0 
, 0 
unaffected 0 
mutation 0 
carriers 0 
were 0 
also 0 
identified 0 
within 0 
the 0 
pedigree 0 
. 0 

A 0 
single 0 
band 0 
shift 0 
using 0 
SSCP 0 
was 0 
identified 0 
in 0 
exon 0 
_NUM2 0 
which 0 
resulted 0 
in 0 
a 0 
missense 0 
mutation 0 
converting 0 
a 0 
cys 0 
-- 0 
> 0 
arg 0 
at 0 
nucleotide 0 
position 0 
_NUM2 0 
in 0 
the 0 
exon 0 
. 0 

The 0 
mutation 0 
destroyed 0 
an 0 
NdeI 0 
restriction 0 
enzyme 0 
site 0 
. 0 

Analysis 0 
of 0 
all 0 
family 0 
members 0 
demonstrated 0 
that 0 
the 0 
missense 0 
mutation 0 
co-segregated 0 
with 0 
patients 0 
with 0 
tumors 1
or 0 
who 0 
, 0 
as 0 
a 0 
result 0 
of 0 
linkage 0 
analysis 0 
had 0 
been 0 
predicted 0 
to 0 
carry 0 
the 0 
predisposing 0 
mutation 0 
. 0 

These 0 
observations 0 
point 0 
to 0 
another 0 
region 0 
of 0 
the 0 
RB1 0 
gene 0 
where 0 
mutations 0 
only 0 
modify 0 
the 0 
function 0 
of 0 
the 0 
gene 0 
and 0 
raise 0 
important 0 
questions 0 
for 0 
genetic 0 
counseling 0 
in 0 
families 0 
with 0 
these 0 
distinctive 0 
phenotypes 0 
. 0 
. 0 

Complement 1
C7 1
deficiency 1
: 0 
seven 0 
further 0 
molecular 0 
defects 0 
and 0 
their 0 
associated 0 
marker 0 
haplotypes 0 
. 0 

Seven 0 
further 0 
molecular 0 
bases 0 
of 0 
C7 1
deficiency 1
are 0 
described 0 
. 0 

All 0 
these 0 
new 0 
molecular 0 
defects 0 
involve 0 
single-nucleotide 0 
events 0 
, 0 
deletions 0 
and 0 
substitutions 0 
, 0 
some 0 
of 0 
which 0 
alter 0 
splice 0 
sites 0 
, 0 
and 0 
others 0 
codons 0 
. 0 

They 0 
are 0 
distributed 0 
along 0 
the 0 
C7 0
gene 0 
, 0 
but 0 
predominantly 0 
towards 0 
the 0 
_NUM1 0 
end 0 
. 0 

All 0 
were 0 
found 0 
in 0 
compound 0 
heterozygous 0 
individuals 0 
. 0 

The 0 
C6 0 
/ 0 
C7 0
marker 0 
haplotypes 0 
associated 0 
with 0 
most 0 
C7 1
defects 1
are 0 
tabulated 0 
. 0 
. 0 

Identification 0 
of 0 
constitutional 0 
WT1 0 
mutations 0 
, 0 
in 0 
patients 0 
with 0 
isolated 0 
diffuse 1
mesangial 1
sclerosis 1
, 0 
and 0 
analysis 0 
of 0 
genotype 0 
/ 0 
phenotype 0 
correlations 0 
by 0 
use 0 
of 0 
a 0 
computerized 0 
mutation 0 
database 0 
. 0 

Constitutional 0 
mutations 0 
of 0 
the 0 
WT1 0 
gene 0 
, 0 
encoding 0 
a 0 
zinc-finger 0 
transcription 0 
factor 0 
involved 0 
in 0 
renal 0 
and 0 
gonadal 0 
development 0 
, 0 
are 0 
found 0 
in 0 
most 0 
patients 0 
with 0 
Denys-Drash 1
syndrome 1
-LRB- 0 
DDS 1
-RRB- 0 
, 0 
or 0 
diffuse 1
mesangial 1
sclerosis 1
-LRB- 0 
DMS 1
-RRB- 0 
associated 0 
with 0 
pseudohermaphroditism 1
and 0 
/ 0 
or 0 
Wilms 1
tumor 1
-LRB- 0 
WT 1
-RRB- 0 
. 0 

Most 0 
mutations 0 
in 0 
DDS 1
patients 0 
lie 0 
in 0 
exon 0 
_NUM1 0 
or 0 
exon 0 
_NUM1 0 
, 0 
encoding 0 
zinc 0 
finger 0 
_NUM1 0 
or 0 
zinc 0 
finger 0 
_NUM1 0 
, 0 
respectively 0 
, 0 
with 0 
a 0 
hot 0 
spot 0 
-LRB- 0 
R394W 0 
-RRB- 0 
in 0 
exon 0 
_NUM1 0 
. 0 

We 0 
analyzed 0 
a 0 
series 0 
of 0 
_NUM2 0 
patients 0 
, 0 
_NUM2 0 
with 0 
isolated 1
DMS 1
-LRB- 0 
IDMS 1
-RRB- 0 
, 0 
_NUM2 0 
with 0 
DDS 1
, 0 
and 0 
_NUM1 0 
with 0 
urogenital 1
abnormalities 1
and 0 
/ 0 
or 0 
WT 1
. 0 

We 0 
report 0 
WT1 0 
heterozygous 0 
mutations 0 
in 0 
_NUM2 0 
patients 0 
, 0 
_NUM1 0 
of 0 
whom 0 
presented 0 
with 0 
IDMS 1
. 0 

One 0 
male 0 
and 0 
two 0 
female 0 
IDMS 1
patients 0 
with 0 
WT1 0 
mutations 0 
underwent 0 
normal 0 
puberty 0 
. 0 

Two 0 
mutations 0 
associated 0 
with 0 
IDMS 1
are 0 
different 0 
from 0 
those 0 
described 0 
in 0 
DDS 1
patients 0 
. 0 

No 0 
WT1 0 
mutations 0 
were 0 
detected 0 
in 0 
the 0 
six 0 
other 0 
IDMS 1
patients 0 
, 0 
suggesting 0 
genetic 0 
heterogeneity 0 
of 0 
this 0 
disease 0 
. 0 

We 0 
analyzed 0 
genotype 0 
/ 0 
phenotype 0 
correlations 0 
, 0 
on 0 
the 0 
basis 0 
of 0 
the 0 
constitution 0 
of 0 
a 0 
WT1 0 
mutation 0 
database 0 
of 0 
_NUM2 0 
germ-line 0 
mutations 0 
, 0 
to 0 
compare 0 
the 0 
distribution 0 
and 0 
type 0 
of 0 
mutations 0 
, 0 
according 0 
to 0 
the 0 
different 0 
symptoms 0 
. 0 

This 0 
demonstrated 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
the 0 
association 0 
between 0 
mutations 0 
in 0 
exons 0 
_NUM1 0 
and 0 
_NUM1 0 
and 0 
DMS 1
; 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
among 0 
patients 0 
with 0 
DMS 1
, 0 
a 0 
higher 0 
frequency 0 
of 0 
exon 0 
_NUM1 0 
mutations 0 
among 0 
_NUM2 0 
, 0 
XY 0 
patients 0 
with 0 
female 0 
phenotype 0 
than 0 
among 0 
_NUM2 0 
, 0 
XY 0 
patients 0 
with 0 
sexual 0 
ambiguity 0 
or 0 
male 0 
phenotype 0 
; 0 
and 0 
-LRB- 0 
_NUM1 0 
-RRB- 0 
statistically 0 
significant 0 
evidence 0 
that 0 
mutations 0 
in 0 
exons 0 
_NUM1 0 
and 0 
_NUM1 0 
preferentially 0 
affect 0 
amino 0 
acids 0 
with 0 
different 0 
functions 0 
. 0 
. 0 

Paternal 0 
transmission 0 
of 0 
congenital 1
myotonic 1
dystrophy 1
. 0 

We 0 
report 0 
a 0 
rare 0 
case 0 
of 0 
paternally 0 
transmitted 0 
congenital 1
myotonic 1
dystrophy 1
-LRB- 0 
DM 1
-RRB- 0 
. 0 

The 0 
proband 0 
is 0 
a 0 
_NUM2 0 
year 0 
old 0 
, 0 
mentally 1
retarded 1
male 0 
who 0 
suffers 0 
severe 0 
muscular 1
weakness 1
. 0 

He 0 
presented 0 
with 0 
respiratory 0 
and 0 
feeding 0 
difficulties 0 
at 0 
birth 0 
. 0 

His 0 
two 0 
sibs 0 
suffer 0 
from 0 
childhood 0 
onset 0 
DM 1
. 0 

Their 0 
late 0 
father 0 
had 0 
the 0 
adult 0 
type 0 
of 0 
DM 1
, 0 
with 0 
onset 0 
around 0 
_NUM2 0 
years 0 
. 0 

Only 0 
six 0 
other 0 
cases 0 
of 0 
paternal 0 
transmission 0 
of 0 
congenital 1
DM 1
have 0 
been 0 
reported 0 
recently 0 
. 0 

We 0 
review 0 
the 0 
sex 0 
related 0 
effects 0 
on 0 
transmission 0 
of 0 
congenital 1
DM 1
. 0 

Decreased 0 
fertility 0 
of 0 
males 0 
with 0 
adult 0 
onset 0 
DM 1
and 0 
contraction 0 
of 0 
the 0 
repeat 0 
upon 0 
male 0 
transmission 0 
contribute 0 
to 0 
the 0 
almost 0 
absent 0 
occurrence 0 
of 0 
paternal 0 
transmission 0 
of 0 
congenital 1
DM 1
. 0 

Also 0 
the 0 
fathers 0 
of 0 
the 0 
reported 0 
congenitally 0 
affected 0 
children 0 
showed 0 
, 0 
on 0 
average 0 
, 0 
shorter 0 
_DS 0 
repeat 0 
lengths 0 
and 0 
hence 0 
less 0 
severe 0 
clinical 0 
symptoms 0 
than 0 
the 0 
mothers 0 
of 0 
children 0 
with 0 
congenital 1
DM 1
. 0 

We 0 
conclude 0 
that 0 
paternal 0 
transmission 0 
of 0 
congenital 1
DM 1
is 0 
rare 0 
and 0 
preferentially 0 
occurs 0 
with 0 
onset 0 
of 0 
DM 1
past 0 
_NUM2 0 
years 0 
in 0 
the 0 
father 0 
. 0 
. 0 

Genomic 0 
organization 0 
of 0 
the 0 
UBE3A 0 
/ 0 
E6-AP 0 
gene 0 
and 0 
related 0 
pseudogenes 0 
. 0 

The 0 
UBE3A 0 
gene 0 
encodes 0 
the 0 
E6-AP 0 
ubiquitin-protein 0 
ligase 0 
and 0 
has 0 
recently 0 
been 0 
shown 0 
to 0 
be 0 
mutated 0 
in 0 
Angelman 1
syndrome 1
patients 0 
who 0 
lack 0 
15q11-q13 0 
deletions 0 
or 0 
chromosome 0 
_NUM2 0 
paternal 0 
uniparental 1
disomy 1
. 0 

Previous 0 
UBE3A 0 
cDNA 0 
analysis 0 
has 0 
shown 0 
a 0 
coding 0 
region 0 
of 0 
approximately 0 
_NUM1 0 
. 0 

_NUM1 0 
kb 0 
and 0 
a 0 
3-untranslated 0 
region 0 
-LRB- 0 
UTR 0 
-RRB- 0 
of 0 
< 0 
_NUM2 0 
bp 0 
, 0 
whereas 0 
Northern 0 
analysis 0 
has 0 
indicated 0 
mRNA 0 
sizes 0 
of 0 
5-8 0 
kb 0 
. 0 

We 0 
have 0 
analyzed 0 
additional 0 
cDNA 0 
clones 0 
and 0 
provide 0 
evidence 0 
for 0 
an 0 
additional 0 
_NUM1 0 
. 0 

_NUM1 0 
kb 0 
of 0 
5-UTR 0 
and 0 
> 0 
_NUM1 0 
kb 0 
of 0 
3-UTR 0 
. 0 

We 0 
have 0 
established 0 
the 0 
genomic 0 
organization 0 
of 0 
UBE3A 0 
and 0 
the 0 
sequence 0 
of 0 
intron-exon 0 
borders 0 
. 0 

We 0 
have 0 
also 0 
mapped 0 
two 0 
highly 0 
homologous 0 
processed 0 
pseudogenes 0 
, 0 
UBE3AP1 0 
and 0 
UBE3AP2 0 
, 0 
to 0 
chromosomes 0 
_NUM1 0 
and 0 
_NUM2 0 
, 0 
respectively 0 
, 0 
and 0 
determined 0 
their 0 
genomic 0 
organization 0 
. 0 

These 0 
results 0 
will 0 
form 0 
the 0 
basis 0 
for 0 
studies 0 
of 0 
mutation 0 
and 0 
imprinting 0 
of 0 
UBE3A 0 
. 0 

Distribution 0 
of 0 
emerin 0 
and 0 
lamins 0 
in 0 
the 0 
heart 0 
and 0 
implications 0 
for 0 
Emery-Dreifuss 1
muscular 1
dystrophy 1
. 0 

Emerin 0 
is 0 
a 0 
nuclear 0 
membrane 0 
protein 0 
which 0 
is 0 
missing 0 
or 0 
defective 0 
in 0 
Emery-Dreifuss 1
muscular 1
dystrophy 1
-LRB- 0 
EDMD 1
-RRB- 0 
. 0 

It 0 
is 0 
one 0 
member 0 
of 0 
a 0 
family 0 
of 0 
lamina-associated 0 
proteins 0 
which 0 
includes 0 
LAP1 0 
, 0 
LAP2 0 
and 0 
lamin 0 
B 0 
receptor 0 
-LRB- 0 
LBR 0 
-RRB- 0 
. 0 

A 0 
panel 0 
of 0 
_NUM2 0 
monoclonal 0 
antibodies 0 
-LRB- 0 
mAbs 0 
-RRB- 0 
has 0 
been 0 
mapped 0 
to 0 
six 0 
specific 0 
sites 0 
throughout 0 
the 0 
emerin 0 
molecule 0 
using 0 
phage-displayed 0 
peptide 0 
libraries 0 
and 0 
has 0 
been 0 
used 0 
to 0 
localize 0 
emerin 0 
in 0 
human 0 
and 0 
rabbit 0 
heart 0 
. 0 

Several 0 
mAbs 0 
against 0 
different 0 
emerin 0 
epitopes 0 
did 0 
not 0 
recognize 0 
intercalated 0 
discs 0 
in 0 
the 0 
heart 0 
, 0 
though 0 
they 0 
recognized 0 
cardiomyocyte 0 
nuclei 0 
strongly 0 
, 0 
both 0 
at 0 
the 0 
rim 0 
and 0 
in 0 
intranuclear 0 
spots 0 
or 0 
channels 0 
. 0 

A 0 
polyclonal 0 
rabbit 0 
antiserum 0 
against 0 
emerin 0 
did 0 
recognize 0 
both 0 
nuclear 0 
membrane 0 
and 0 
intercalated 0 
discs 0 
but 0 
, 0 
after 0 
affinity 0 
purification 0 
against 0 
a 0 
pure-emerin 0 
band 0 
on 0 
a 0 
western 0 
blot 0 
, 0 
it 0 
stained 0 
only 0 
the 0 
nuclear 0 
membrane 0 
. 0 

These 0 
results 0 
would 0 
not 0 
be 0 
expected 0 
if 0 
immunostaining 0 
at 0 
intercalated 0 
discs 0 
were 0 
due 0 
to 0 
a 0 
product 0 
of 0 
the 0 
emerin 0 
gene 0 
and 0 
, 0 
therefore 0 
, 0 
cast 0 
some 0 
doubt 0 
upon 0 
the 0 
hypothesis 0 
that 0 
cardiac 1
defects 1
in 0 
EDMD 1
are 0 
caused 0 
by 0 
absence 0 
of 0 
emerin 0 
from 0 
intercalated 0 
discs 0 
. 0 

Although 0 
emerin 0 
was 0 
abundant 0 
in 0 
the 0 
membranes 0 
of 0 
cardiomyocyte 0 
nuclei 0 
, 0 
it 0 
was 0 
absent 0 
from 0 
many 0 
non-myocyte 0 
cells 0 
in 0 
the 0 
heart 0 
. 0 

This 0 
distribution 0 
of 0 
emerin 0 
was 0 
similar 0 
to 0 
that 0 
of 0 
lamin 0 
A 0 
, 0 
a 0 
candidate 0 
gene 0 
for 0 
an 0 
autosomal 0 
form 0 
of 0 
EDMD 1
. 0 

In 0 
contrast 0 
, 0 
lamin 0 
B1 0 
was 0 
absent 0 
from 0 
cardiomyocyte 0 
nuclei 0 
, 0 
showing 0 
that 0 
lamin 0 
B1 0 
is 0 
not 0 
essential 0 
for 0 
localization 0 
of 0 
emerin 0 
to 0 
the 0 
nuclear 0 
lamina 0 
. 0 

Lamin 0 
B1 0 
is 0 
also 0 
almost 0 
completely 0 
absent 0 
from 0 
skeletal 0 
muscle 0 
nuclei 0 
. 0 

In 0 
EDMD 1
, 0 
the 0 
additional 0 
absence 0 
of 0 
lamin 0 
B1 0 
from 0 
heart 0 
and 0 
skeletal 0 
muscle 0 
nuclei 0 
which 0 
already 0 
lack 0 
emerin 0 
may 0 
offer 0 
an 0 
alternative 0 
explanation 0 
of 0 
why 0 
these 0 
tissues 0 
are 0 
particularly 0 
affected 0 
. 0 
. 0 

Localization 0 
of 0 
human 0 
BRCA1 0 
and 0 
its 0 
loss 0 
in 0 
high-grade 0 
, 0 
non-inherited 1
breast 1
carcinomas 1
. 0 

Although 0 
the 0 
link 0 
between 0 
the 0 
BRCA1 0 
tumour 1
suppressor 0 
gene 0 
and 0 
hereditary 1
breast 1
and 1
ovarian 1
cancer 1
is 0 
established 0 
, 0 
the 0 
role 0 
, 0 
if 0 
any 0 
, 0 
of 0 
BRCA1 0 
in 0 
non-familial 1
cancers 1
is 0 
unclear 0 
. 0 

BRCA1 0 
mutations 0 
are 0 
rare 0 
in 0 
sporadic 1
cancers 1
, 0 
but 0 
loss 0 
of 0 
BRCA1 0 
resulting 0 
from 0 
reduced 0 
expression 0 
or 0 
incorrect 0 
subcellular 0 
localization 0 
is 0 
postulated 0 
to 0 
be 0 
important 0 
in 0 
non-familial 1
breast 1
and 1
ovarian 1
cancers 1
. 0 

Epigenetic 0 
loss 0 
, 0 
however 0 
, 0 
has 0 
not 0 
received 0 
general 0 
acceptance 0 
due 0 
to 0 
controversy 0 
regarding 0 
the 0 
subcellular 0 
localization 0 
of 0 
BRCA1 0 
proteins 0 
, 0 
reports 0 
of 0 
which 0 
have 0 
ranged 0 
from 0 
exclusively 0 
nuclear 0 
, 0 
to 0 
conditionally 0 
nuclear 0 
, 0 
to 0 
the 0 
ER 0 
/ 0 
golgi 0 
, 0 
to 0 
cytoplasmic 0 
invaginations 0 
into 0 
the 0 
nucleus 0 
. 0 

In 0 
an 0 
attempt 0 
to 0 
resolve 0 
this 0 
issue 0 
, 0 
we 0 
have 0 
comprehensively 0 
characterized 0 
_NUM2 0 
anti-BRCA1 0 
antibodies 0 
. 0 

These 0 
reagents 0 
detect 0 
a 0 
220-kD 0 
protein 0 
localized 0 
in 0 
discrete 0 
nuclear 0 
foci 0 
in 0 
all 0 
epithelial 0 
cell 0 
lines 0 
, 0 
including 0 
those 0 
derived 0 
from 0 
breast 1
malignancies 1
. 0 

Immunohistochemical 0 
staining 0 
of 0 
human 0 
breast 0 
specimens 0 
also 0 
revealed 0 
BRCA1 0 
nuclear 0 
foci 0 
in 0 
benign 0 
breast 0 
, 0 
invasive 1
lobular 1
cancers 1
and 0 
low-grade 1
ductal 1
carcinomas 1
. 0 

Conversely 0 
, 0 
BRCA1 0 
expression 0 
was 0 
reduced 0 
or 0 
undetectable 0 
in 0 
the 0 
majority 0 
of 0 
high-grade 0 
, 0 
ductal 1
carcinomas 1
, 0 
suggesting 0 
that 0 
absence 0 
of 0 
BRCA1 0 
may 0 
contribute 0 
to 0 
the 0 
pathogenesis 0 
of 0 
a 0 
significant 0 
percentage 0 
of 0 
sporadic 1
breast 1
cancers 1
. 0 
. 0 

